|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression decreases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of ABCA1 mRNA Atorvastatin results in decreased expression of ABCA1 mRNA; Atorvastatin results in decreased expression of ABCA1 protein [Rosiglitazone co-treated with Atorvastatin] results in increased expression of ABCA1 protein |
CTD |
PMID:15183127 PMID:16386711 PMID:25278499 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Atorvastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid]; Atorvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atorvastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:15901796 PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression decreases activity increases transport |
ISO EXP |
ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Atorvastatin]; Atorvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Atorvastatin results in decreased expression of ABCB1A mRNA Atorvastatin analog results in decreased activity of ABCB1 protein ABCB1 protein results in increased transport of Atorvastatin; ABCB1 protein results in increased transport of Atorvastatin analog |
CTD |
PMID:10751037 PMID:15616150 PMID:19802823 PMID:24502637 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCB4 mRNA; Atorvastatin results in increased expression of ABCB4 protein |
CTD |
PMID:15986414 PMID:25278499 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Atorvastatin analog; Atorvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Atorvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Atorvastatin results in increased expression of ABCC2 mRNA |
CTD |
PMID:15616150 PMID:23562342 PMID:25278499 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCC3 mRNA; Atorvastatin results in increased expression of ABCC3 protein |
CTD |
PMID:15986414 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCG2 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Atorvastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of ACACB mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of ACACB mRNA] |
CTD |
PMID:12056585 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases expression |
EXP |
Atorvastatin results in decreased expression of ACE mRNA |
CTD |
PMID:23390189 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression |
EXP |
Atorvastatin results in increased expression of ACE2 mRNA |
CTD |
PMID:23390189 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of ACTA2 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ADAM12 protein |
CTD |
PMID:18360054 |
|
NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:188,686,989...189,020,667
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ADAM17 protein |
CTD |
PMID:18360054 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ADGRE1 protein] |
CTD |
PMID:37023836 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression increases expression |
ISO |
Atorvastatin results in decreased expression of ADIPOQ protein Atorvastatin results in increased expression of ADIPOQ protein |
CTD |
PMID:19651449 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [AGT protein results in decreased expression of SOD1 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased abundance of Malondialdehyde]; Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK1 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK3 protein]; Atorvastatin inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of AKT1 protein] [Atorvastatin co-treated with Celecoxib] results in decreased phosphorylation of AKT1 protein; Atorvastatin results in decreased expression of and results in decreased phosphorylation of AKT1 protein Atorvastatin results in decreased phosphorylation of AKT1 protein Atorvastatin results in increased phosphorylation of AKT1 protein [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of AKT1 protein]; coenzyme Q10 inhibits the reaction [Atorvastatin results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:18172863 PMID:19526287 PMID:20305681 PMID:27345130 PMID:27815113 PMID:29630879 PMID:32259528 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt2 |
angiopoietin 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of ANGPT2 mRNA |
CTD |
PMID:16410222 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases secretion decreases expression |
ISO EXP |
Atorvastatin results in decreased expression of and results in decreased secretion of APOB protein Atorvastatin inhibits the reaction [Fructose results in increased expression of APOB protein] Atorvastatin results in decreased secretion of APOB protein Atorvastatin results in decreased expression of APOB protein |
CTD |
PMID:9512650 PMID:10357840 PMID:11728391 PMID:12065722 PMID:12172771 PMID:12612140 PMID:12633795 PMID:18702965 More...
|
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
decreases expression multiple interactions |
ISO |
Atorvastatin results in decreased expression of APOE mRNA; Atorvastatin results in decreased expression of APOE protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the activity of GPT protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BAX protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BCL2 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CASP3 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of FTH1 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of GPX4 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMOX1 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of NFE2L2 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of RELA protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TFRC protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TRP53 protein] [Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein |
CTD |
PMID:16386711 PMID:19603250 PMID:32976958 PMID:37121058 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A2 protein]; Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A3 protein] |
CTD |
PMID:20816828 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of ATF6 protein] |
CTD |
PMID:34939712 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases response to substance |
ISO |
ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein] ATG5 results in increased susceptibility to Atorvastatin |
CTD |
PMID:20876807 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of BAK1 protein |
CTD |
PMID:19935899 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of BAX protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BAX protein] |
CTD |
PMID:19935899 PMID:37121058 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of BCL2 mRNA; Atorvastatin results in decreased expression of BCL2 protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of BCL2 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of BCL2 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:16470222 PMID:31423616 PMID:32259528 PMID:37121058 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of BECN1 protein |
CTD |
PMID:20876807 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Atorvastatin results in increased expression of BGLAP mRNA |
CTD |
PMID:17252541 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
EXP |
Atorvastatin results in decreased expression of and results in increased cleavage of BID protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of and results in increased cleavage of BID protein]; U 0126 inhibits the reaction [Atorvastatin results in decreased expression of and results in increased cleavage of BID protein] |
CTD |
PMID:18339080 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of BIRC5 mRNA; Atorvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17372815 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression increases secretion |
ISO |
Atorvastatin results in increased expression of BMP2 mRNA Atorvastatin results in increased secretion of BMP2 protein |
CTD |
PMID:16470222 PMID:17252541 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
C3 |
complement C3 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of C3 protein modified form] |
CTD |
PMID:20946910 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CASP1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases activity decreases activity multiple interactions increases cleavage |
ISO EXP |
Atorvastatin results in increased activity of CASP3 protein Atorvastatin results in decreased activity of CASP3 protein [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] Atorvastatin results in increased cleavage of CASP3 protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the cleavage of CASP3 protein; ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of CASP3 protein]; Atorvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; [Atorvastatin co-treated with Celecoxib] results in increased cleavage of and results in increased activity of CASP3 protein; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein]; RHOA protein inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] |
CTD |
PMID:16470222 PMID:18172863 PMID:18339080 PMID:19429019 PMID:20305681 PMID:20876807 PMID:20946910 PMID:30511338 PMID:31423616 PMID:37121058 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO EXP |
[Atorvastatin co-treated with Celecoxib] results in increased cleavage of CASP8 protein [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased activity of CASP8 protein]; [Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased expression of CASP8 protein] Atorvastatin results in increased activity of CASP8 protein |
CTD |
PMID:15705602 PMID:18172863 PMID:20946910 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
[Atorvastatin co-treated with Celecoxib] results in increased cleavage of CASP9 protein Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of CASP9 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:15705602 PMID:16470222 PMID:18172863 PMID:18339080 PMID:29630879 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] Atorvastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 PMID:25218292 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO EXP |
Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Atorvastatin results in decreased expression of and results in decreased secretion of CCL2 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of CCL2 mRNA] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of CCL2 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CCL2 protein] |
CTD |
PMID:12117737 PMID:25058445 PMID:34939712 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD14 protein |
CTD |
PMID:18333374 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Rosiglitazone results in increased expression of CD36 mRNA]; Atorvastatin inhibits the reaction [Rosiglitazone results in increased expression of CD36 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of CD36 protein] |
CTD |
PMID:15183127 PMID:16386711 PMID:32259528 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD40 protein |
CTD |
PMID:16387846 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD40LG protein |
CTD |
PMID:16368305 PMID:19171469 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of CDC42 mRNA |
CTD |
PMID:34696514 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of CDH1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of CDKN1A protein; CDKN1A protein mutant form inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] Atorvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:18172863 PMID:20876807 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of CDKN1B protein Atorvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:16470222 PMID:18172863 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19800637 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Clcn1 |
chloride voltage-gated channel 1 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of CLCN1 protein |
CTD |
PMID:27377005 |
|
NCBI chr 4:71,171,949...71,201,483
Ensembl chr 4:71,172,547...71,199,984
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Atorvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:17252541 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of CPT1A mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased expression of CPT1A mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Crp |
C-reactive protein |
multiple interactions decreases expression |
ISO EXP |
[Atorvastatin co-treated with Amlodipine] results in decreased expression of CRP protein; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP mRNA]; Atorvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CRP protein] Atorvastatin results in decreased expression of CRP protein |
CTD |
PMID:16025360 PMID:16360360 PMID:17673219 PMID:18389332 PMID:21584495 PMID:25058445 More...
|
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cs |
citrate synthase |
increases expression multiple interactions |
EXP |
Atorvastatin results in increased expression of CS mRNA Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of CS mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CSF2 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of CSF2 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CSF2 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of CSF2 protein] |
CTD |
PMID:19482827 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
decreases expression |
EXP |
Atorvastatin results in decreased expression of CXCL10 |
CTD |
PMID:15831368 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of CYBA mRNA] |
CTD |
PMID:25218292 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
EXP ISO |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of CYCS protein] Atorvastatin affects the localization of CYCS protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the localization of CYCS protein] |
CTD |
PMID:31423616 PMID:32259528 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression |
EXP |
Atorvastatin affects the expression of CYP11A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP17A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP19A1 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression increases expression |
ISO |
Atorvastatin results in decreased expression of CYP27A1 mRNA; Atorvastatin results in decreased expression of CYP27A1 protein Atorvastatin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:16386711 PMID:25278499 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Atorvastatin results in increased expression of CYP2B6 mRNA Atorvastatin results in increased expression of CYP2B10 mRNA; Atorvastatin results in increased expression of CYP2B10 protein |
CTD |
PMID:15802384 PMID:15986414 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of CYP39A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression affects response to substance increases metabolic processing multiple interactions affects metabolic processing decreases activity increases expression |
EXP ISO |
Atorvastatin results in decreased expression of CYP3A4 mRNA; Atorvastatin results in decreased expression of CYP3A4 protein CYP3A4 polymorphism affects the susceptibility to Atorvastatin CYP3A4 protein results in increased metabolism of Atorvastatin ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Atorvastatin]; Atorvastatin inhibits the reaction [CYP3A4 protein affects the metabolism of Midazolam] CYP3A4 protein affects the metabolism of Atorvastatin Atorvastatin results in decreased activity of CYP3A4 protein Atorvastatin results in increased expression of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein] |
CTD |
PMID:15963098 PMID:16011971 PMID:16029222 PMID:18528690 PMID:18846481 PMID:19802823 PMID:26616219 PMID:30086269 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[Dietary Fats co-treated with Atorvastatin] results in increased expression of CYP3A23-3A1 protein |
CTD |
PMID:26616219 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of CYP7A1 mRNA Atorvastatin inhibits the reaction [Dietary Fats results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:25278499 PMID:32048413 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dcx |
doublecortin |
increases expression |
EXP |
Atorvastatin results in increased expression of DCX protein |
CTD |
PMID:15255259 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression multiple interactions increases activity |
EXP |
Atorvastatin results in increased expression of DGAT1 mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of DGAT1 protein] |
CTD |
PMID:12056585 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dscc1 |
DNA replication and sister chromatid cohesion 1 |
affects response to substance |
ISO |
DSCC1 protein affects the susceptibility to Atorvastatin |
CTD |
PMID:35926565 |
|
NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of EDN1 protein |
CTD |
PMID:16360360 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions decreases expression |
EXP |
Atorvastatin promotes the reaction [Losartan results in decreased expression of EDNRA mRNA]; Losartan promotes the reaction [Atorvastatin results in decreased expression of EDNRA mRNA] |
CTD |
PMID:23091284 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Phenylephrine results in increased expression of and results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:18360054 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases response to substance |
ISO |
EIF2AK3 mutant form inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein] EIF2AK3 results in increased susceptibility to Atorvastatin |
CTD |
PMID:20876807 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
4-phenylbutyric acid inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Atorvastatin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:20876807 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Epb41 |
erythrocyte membrane protein band 4.1 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in decreased expression of EPB41 protein] |
CTD |
PMID:20946910 |
|
NCBI chr 5:144,110,010...144,264,037
Ensembl chr 5:144,111,906...144,237,821
|
|
G |
F2 |
coagulation factor II, thrombin |
decreases activity |
ISO |
Atorvastatin results in decreased activity of F2 protein |
CTD |
PMID:16907931 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
decreases activity |
ISO |
Atorvastatin results in decreased activity of F5 protein |
CTD |
PMID:16907931 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite results in increased expression of FADD protein] |
CTD |
PMID:20946910 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
affects expression |
EXP |
Atorvastatin affects the expression of FAS mRNA; Atorvastatin affects the expression of FAS protein |
CTD |
PMID:17372815 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
EXP ISO |
[Atorvastatin co-treated with Acetylcysteine] inhibits the reaction [sodium arsenite results in increased expression of FASLG protein] Atorvastatin results in increased expression of FASLG protein modified form Atorvastatin inhibits the reaction [TNF protein results in decreased expression of and results in decreased secretion of FASLG protein modified form] |
CTD |
PMID:15063428 PMID:20946910 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of FASN mRNA [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of FASN protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of FASN protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of FASN mRNA] |
CTD |
PMID:11728391 PMID:12056585 PMID:32259528 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression |
EXP |
Atorvastatin results in increased expression of FBXO32 mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of FGF15 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
Atorvastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of FTH1 protein] |
CTD |
PMID:32976958 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gck |
glucokinase |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of GCK protein NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of GCK protein] |
CTD |
PMID:26616219 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
Atorvastatin promotes the reaction [dapagliflozin inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of GJA1 protein]] |
CTD |
PMID:34939712 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gng3 |
G protein subunit gamma 3 |
multiple interactions affects localization |
EXP |
[Isoproterenol co-treated with Atorvastatin] affects the localization of GNG3 protein Atorvastatin affects the localization of GNG3 protein |
CTD |
PMID:19136528 |
|
NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Streptozocin results in increased secretion of GOT1 protein] |
CTD |
PMID:30657622 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of GPAM mRNA] |
CTD |
PMID:19053045 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the activity of GPT protein]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]; Buthionine Sulfoximine promotes the reaction [[Atorvastatin co-treated with Ciprofloxacin] results in increased expression of GPT protein] [Atorvastatin co-treated with triptolide] results in increased expression of GPT protein; [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of GPT protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased secretion of GPT protein] |
CTD |
PMID:29679711 PMID:30657622 PMID:32259528 PMID:32976958 PMID:33600922 PMID:37023836 More...
|
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of GPX4 protein] |
CTD |
PMID:32976958 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
decreases expression |
ISO |
Atorvastatin results in decreased expression of HBEGF protein |
CTD |
PMID:18360054 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions affects binding increases expression increases activity |
ISO EXP |
Atorvastatin results in increased expression of and results in increased activity of HMGCR protein Atorvastatin binds to HMGCR protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of HMGCR mRNA]; Atorvastatin results in increased expression of and results in increased activity of HMGCR protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of HMGCR mRNA] |
CTD |
PMID:9512650 PMID:10357840 PMID:12056585 PMID:12065722 PMID:12612140 PMID:30273964 PMID:32048413 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of HMOX1 mRNA Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of HMOX1 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of HMOX1 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of HMOX1 protein] |
CTD |
PMID:16410222 PMID:32259528 PMID:32976958 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] |
CTD |
PMID:30273964 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO EXP |
Atorvastatin inhibits the reaction [TNF results in increased expression of ICAM1] Atorvastatin results in increased expression of ICAM1 protein Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of ICAM1 protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of ICAM1 mRNA]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of ICAM1 protein] |
CTD |
PMID:12615677 PMID:17589825 PMID:19171469 PMID:25058445 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:19800637 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il12a |
interleukin 12A |
decreases expression |
ISO |
Atorvastatin results in decreased expression of IL12A mRNA |
CTD |
PMID:12492458 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL18 protein] |
CTD |
PMID:37023836 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL1B protein] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL1B mRNA]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL1B protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of IL1B protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of IL1B protein] |
CTD |
PMID:17589825 PMID:19482827 PMID:25058445 PMID:32048413 PMID:34939712 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
affects expression |
ISO |
Atorvastatin affects the expression of IL2RA protein |
CTD |
PMID:16387846 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Atorvastatin results in decreased expression of and results in decreased secretion of IL6 protein; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased expression of IL6 mRNA] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of IL6 protein] Atorvastatin results in decreased expression of IL6 mRNA; Atorvastatin results in decreased expression of IL6 protein Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [Dietary Fats results in increased expression of IL6 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of IL6 protein] Atorvastatin results in decreased secretion of IL6 protein |
CTD |
PMID:12117737 PMID:16387846 PMID:17521631 PMID:19171469 PMID:19482827 PMID:19800637 PMID:25058445 PMID:25834641 PMID:32048413 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of INS1 protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of INS1 protein] |
CTD |
PMID:19800637 PMID:34939712 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of INS protein |
CTD |
PMID:19651449 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of IRAK1 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO EXP |
Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]; geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]] |
CTD |
PMID:12500026 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ITGAL] |
CTD |
PMID:12615677 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgam |
integrin subunit alpha M |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ITGAM protein |
CTD |
PMID:18333374 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgax |
integrin subunit alpha X |
decreases expression |
ISO |
Atorvastatin results in decreased expression of ITGAX protein |
CTD |
PMID:18333374 |
|
NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions increases expression |
ISO EXP |
Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]; geranylgeraniol inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of ITGB1 mRNA] |
CTD |
PMID:12500026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [TNF results in increased expression of ITGB2] |
CTD |
PMID:12615677 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in increased expression of JUN protein; Atorvastatin results in increased phosphorylation of and results in increased activity of JUN protein; Celecoxib promotes the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of JUN protein] |
CTD |
PMID:18172863 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Atorvastatin results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Khk |
ketohexokinase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of KHK protein] |
CTD |
PMID:21122807 |
|
NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Kif6 |
kinesin family member 6 |
increases response to substance |
ISO |
KIF6 polymorphism results in increased susceptibility to Atorvastatin |
CTD |
PMID:21943003 |
|
NCBI chr 9:11,076,203...11,373,205
Ensembl chr 9:11,072,824...11,373,006
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
affects localization multiple interactions |
ISO |
Atorvastatin affects the localization of KPNA2 protein [Ivermectin co-treated with Atorvastatin] affects the localization of KPNA2 protein |
CTD |
PMID:34696514 |
|
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
|
|
G |
Kpna7 |
karyopherin subunit alpha 7 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Poly I-C results in increased expression of KPNA7 mRNA] |
CTD |
PMID:34696514 |
|
NCBI chr12:9,576,378...9,635,247
Ensembl chr12:9,576,378...9,612,833
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] |
CTD |
PMID:30273964 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO EXP |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of LCN2 mRNA [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of LCN2 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of LCN2 protein] |
CTD |
PMID:29679711 PMID:32259528 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin results in increased activity of LDLR protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Atorvastatin inhibits the reaction [Dietary Fats results in decreased expression of LDLR mRNA] Atorvastatin results in increased expression of LDLR mRNA |
CTD |
PMID:10357840 PMID:11728391 PMID:12612140 PMID:24502637 PMID:30273964 PMID:32048413 More...
|
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
Atorvastatin affects the reaction [Fructose results in increased expression of LEP protein] |
CTD |
PMID:21122807 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] |
CTD |
PMID:30273964 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:34939712 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases phosphorylation |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein] Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK1 protein] Atorvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:16470222 PMID:18339080 PMID:18360054 PMID:19451411 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO EXP |
Atorvastatin inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein] Atorvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:17589825 PMID:19767766 PMID:20018284 PMID:20305681 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein] Atorvastatin inhibits the reaction [AGT protein results in increased activity of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Atorvastatin results in increased phosphorylation of MAPK3 protein] Atorvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:16470222 PMID:18339080 PMID:18360054 PMID:19451411 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mb |
myoglobin |
increases expression multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of MB protein [Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased secretion of MB protein |
CTD |
PMID:27815113 PMID:29679711 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MCL1 protein |
CTD |
PMID:16470222 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Atorvastatin results in increased expression of MDM2 protein |
CTD |
PMID:29630879 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
increases expression |
EXP |
Atorvastatin results in increased expression of MEF2D mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased expression of MFN2 protein] |
CTD |
PMID:24721408 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR133B mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir145 |
microRNA 145 |
increases expression |
ISO |
Atorvastatin results in increased expression of MIR145 mRNA |
CTD |
PMID:29630879 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146A; [Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146A |
CTD |
PMID:20524934 |
|
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir146b |
microRNA 146b |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146B; [Atorvastatin co-treated with Telmisartan] results in decreased expression of MIR146B |
CTD |
PMID:20524934 |
|
NCBI chr 1:245,203,438...245,203,525
Ensembl chr 1:245,203,438...245,203,525
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of MIR206 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mir221 |
microRNA 221 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MIR221 |
CTD |
PMID:25517390 |
|
NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573
|
|
G |
Mir222 |
microRNA 222 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MIR222 |
CTD |
PMID:25517390 |
|
NCBI chr X:3,428,904...3,429,006
Ensembl chr X:3,428,904...3,429,006
|
|
G |
Mlxipl |
MLX interacting protein-like |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose affects the localization of and results in increased activity of MLXIPL protein]; Atorvastatin inhibits the reaction [Fructose results in increased expression of MLXIPL protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin inhibits the reaction [Fructose results in increased activity of MLXIPL protein]] |
CTD |
PMID:19053045 PMID:21122807 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression increases activity |
ISO EXP |
Atorvastatin results in decreased expression of MMP2 protein Atorvastatin results in increased activity of MMP2 protein |
CTD |
PMID:18360054 PMID:23831763 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity |
ISO EXP |
Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Sildenafil Citrate promotes the reaction [Atorvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]] Atorvastatin results in increased activity of MMP9 protein |
CTD |
PMID:15728660 PMID:23831763 PMID:26614570 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Paraquat results in increased activity of MPO protein] |
CTD |
PMID:27883937 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msr1 |
macrophage scavenger receptor 1 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with Atorvastatin] results in increased expression of MSR1 mRNA |
CTD |
PMID:15183127 |
|
NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Atorvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Mt-co1 |
mitochondrially encoded cytochrome c oxidase I |
affects expression multiple interactions |
EXP |
Atorvastatin affects the expression of COX1 mRNA Quercetin inhibits the reaction [Atorvastatin affects the expression of COX1 mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867 NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867
|
|
G |
Mt1-ps2 |
metallothionein 1, pseudogene 2 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of MT1-PS2 mRNA] |
CTD |
PMID:21122807 |
|
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of MT2A mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of and results in increased phosphorylation of MTOR protein] |
CTD |
PMID:34939712 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression multiple interactions decreases expression |
EXP ISO |
Atorvastatin results in increased expression of MTTP mRNA Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of MTTP mRNA] Atorvastatin results in decreased expression of MTTP mRNA |
CTD |
PMID:10357840 PMID:12056585 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Atorvastatin results in decreased expression of MYC mRNA |
CTD |
PMID:29630879 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of MYD88 mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of MYD88 protein] |
CTD |
PMID:38213245 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh2 |
myosin heavy chain 2 |
multiple interactions affects expression |
ISO |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of MYH2 protein Atorvastatin affects the expression of MYH2 protein |
CTD |
PMID:30511338 |
|
NCBI chr10:51,856,738...51,883,236
Ensembl chr10:51,856,738...51,883,236
|
|
G |
Nfe2l1 |
NFE2 like bZIP transcription factor 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of NFE2L1 mRNA |
CTD |
PMID:30511338 |
|
NCBI chr10:81,796,055...81,812,926
Ensembl chr10:81,800,366...81,832,318
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression increases expression |
ISO EXP |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of NFE2L2 mRNA; Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of NFE2L2 protein] Atorvastatin results in decreased expression of NFE2L2 protein 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in decreased expression of NFE2L2 protein] [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of NFE2L2 protein]; Atorvastatin inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of NFE2L2 protein] Atorvastatin results in increased expression of NFE2L2 mRNA |
CTD |
PMID:30511338 PMID:31423616 PMID:32259528 PMID:32976958 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Ivermectin co-treated with Atorvastatin] inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA]; Atorvastatin inhibits the reaction [Poly I-C results in increased expression of NFKB1 mRNA] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:34696514 PMID:37023836 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of NLRP3 protein] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of NLRP3 mRNA] |
CTD |
PMID:34939712 PMID:37023836 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression |
ISO |
Atorvastatin results in increased expression of NNMT protein |
CTD |
PMID:33073877 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS2 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS2 protein] Atorvastatin results in decreased expression of NOS2 mRNA; Atorvastatin results in decreased expression of NOS2 protein |
CTD |
PMID:15166393 PMID:25058445 PMID:25218292 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases expression affects response to substance |
ISO EXP |
Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]; Melatonin promotes the reaction [Atorvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of NOS3 protein]] Atorvastatin results in increased expression of NOS3 mRNA; Atorvastatin results in increased expression of NOS3 protein [Dexamethasone co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; [Losartan co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; Atorvastatin inhibits the reaction [Dexamethasone results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in decreased expression of and results in decreased phosphorylation of NOS3 protein]; Atorvastatin inhibits the reaction [sodium arsenite results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOS3 protein]; Atorvastatin inhibits the reaction [Streptozocin results in decreased expression of NOS3 protein] Atorvastatin inhibits the reaction [Homocysteine results in decreased expression of NOS3 mRNA]; Atorvastatin inhibits the reaction [Homocysteine results in decreased phosphorylation of NOS3 protein] NOS3 promoter SNP affects the susceptibility to Atorvastatin |
CTD |
PMID:12490971 PMID:15166393 PMID:16410222 PMID:16962929 PMID:17042910 PMID:17589825 PMID:20305681 PMID:21585521 PMID:23091284 PMID:25058445 PMID:25218292 PMID:25517390 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP ISO |
Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of NOX4 mRNA] Atorvastatin inhibits the reaction [Homocysteine results in increased expression of NOX4 mRNA] |
CTD |
PMID:20018284 PMID:25218292 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Isoproterenol results in increased expression of NPPA mRNA] |
CTD |
PMID:19136528 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
ISO |
Atorvastatin results in decreased expression of NPPB protein |
CTD |
PMID:18360054 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases expression |
ISO EXP |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Atorvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of SLC2A2 protein] Atorvastatin promotes the reaction [Dietary Fats results in increased expression of NR1I2 protein] Atorvastatin binds to and results in increased activity of NR1I2 protein Atorvastatin results in increased expression of NR1I2 protein |
CTD |
PMID:15986414 PMID:24204015 PMID:26616219 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO EXP |
Atorvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions affects expression increases expression |
EXP |
Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of NRF1 mRNA]; Quercetin inhibits the reaction [Atorvastatin affects the expression of NRF1 mRNA] |
CTD |
PMID:21775390 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
2-tert-butylhydroquinone inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; [Atorvastatin co-treated with Celecoxib] results in increased cleavage of PARP1 protein; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; CDKN1A protein mutant form inhibits the reaction [Atorvastatin results in increased cleavage of PARP1 protein] ATG5 mutant form promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16470222 PMID:18172863 PMID:20876807 PMID:31423616 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcyt1a |
phosphate cytidylyltransferase 1A, choline |
increases activity |
EXP |
Atorvastatin results in increased activity of PCYT1A protein |
CTD |
PMID:12056585 |
|
NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]] |
CTD |
PMID:22343369 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in decreased phosphorylation of and results in decreased expression of PDPK1 protein |
CTD |
PMID:18172863 |
|
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
decreases expression |
ISO |
Atorvastatin results in decreased expression of PIK3CA mRNA |
CTD |
PMID:29630879 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of PKLR mRNA] |
CTD |
PMID:19053045 PMID:21122807 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
EXP |
Atorvastatin results in increased expression of PKM mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
Atorvastatin results in decreased expression of PLAU protein |
CTD |
PMID:16410222 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plin2 |
perilipin 2 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of PLIN2 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pomc |
proopiomelanocortin |
increases expression |
EXP |
Atorvastatin results in increased expression of POMC protein |
CTD |
PMID:29574565 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity multiple interactions increases expression |
ISO EXP |
Atorvastatin results in increased activity of PON1 protein Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein] PON1 gene polymorphism affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Atorvastatin results in increased abundance of Cholesterol, HDL] Atorvastatin results in increased expression of PON1 mRNA |
CTD |
PMID:15324535 PMID:15690306 PMID:15969877 PMID:16238680 PMID:30273964 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
increases activity increases expression |
ISO |
Atorvastatin results in increased activity of PON2 protein Atorvastatin results in increased expression of PON2 mRNA |
CTD |
PMID:14592851 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of PPARA mRNA Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PPARA protein]; Atorvastatin inhibits the reaction [Fructose results in increased expression of PPARA protein] |
CTD |
PMID:12065722 PMID:18812576 PMID:21554872 PMID:32259528 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression affects expression multiple interactions increases expression |
EXP ISO |
Atorvastatin results in decreased expression of PPARGC1A mRNA Atorvastatin affects the expression of PPARGC1A mRNA Atorvastatin results in decreased expression of PPARGC1A protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1A mRNA Atorvastatin results in increased expression of PPARGC1A mRNA [Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PPARGC1A protein]; Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of PPARGC1A mRNA]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]; Farnesol inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]] |
CTD |
PMID:21775390 PMID:22343369 PMID:30511338 PMID:32259528 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
affects expression decreases expression affects response to substance multiple interactions |
EXP ISO |
Atorvastatin affects the expression of PPARGC1B mRNA Atorvastatin results in decreased expression of PPARGC1B mRNA PPARGC1B protein affects the susceptibility to Atorvastatin Atorvastatin affects the expression of PPARGC1B protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the cleavage of CASP3 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of MYH2 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of NFE2L2 mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1A mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of PPARGC1B mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of SOD2 protein; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TFAM mRNA; [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TOMM20 protein Quercetin inhibits the reaction [Atorvastatin affects the expression of PPARGC1B mRNA] |
CTD |
PMID:21775390 PMID:30511338 |
|
NCBI chr18:54,758,891...54,861,103
Ensembl chr18:54,758,902...54,861,194
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
EXP |
Atorvastatin results in increased expression of PPP3CA mRNA |
CTD |
PMID:27377005 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases activity |
ISO |
Atorvastatin results in increased activity of PRKAA1 protein |
CTD |
PMID:33073877 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Atorvastatin results in increased phosphorylation of and results in increased activity of PRKACA protein] |
CTD |
PMID:19053045 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of and results in increased phosphorylation of PRKCA protein] |
CTD |
PMID:32259528 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcq |
protein kinase C, theta |
increases expression |
EXP |
Atorvastatin results in increased expression of PRKCQ mRNA; Atorvastatin results in increased expression of PRKCQ protein |
CTD |
PMID:27377005 |
|
NCBI chr17:67,246,394...67,379,049
Ensembl chr17:67,246,394...67,378,704
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
EXP |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in decreased expression of PRKCZ protein] |
CTD |
PMID:32259528 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
EXP |
Atorvastatin results in increased expression of PTEN protein |
CTD |
PMID:15837263 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
EXP |
[Atorvastatin co-treated with Pioglitazone] results in increased expression of PTGS2 protein; [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of PTGS2 protein] Atorvastatin results in increased expression of PTGS2 protein |
CTD |
PMID:16908763 PMID:34939712 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
ISO EXP |
[Poly I-C co-treated with Atorvastatin] results in decreased expression of RAC1 mRNA; Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin inhibits the reaction [Glucose results in increased localization of RAC1 protein]] Atorvastatin inhibits the reaction [Streptozocin results in increased activity of RAC1 protein] Atorvastatin inhibits the reaction [Streptozocin results in increased activity of and results in increased localization of RAC1 protein] |
CTD |
PMID:17279352 PMID:17589825 PMID:34696514 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Celecoxib] results in decreased expression of RB1 protein modified form; [Atorvastatin co-treated with Celecoxib] results in increased expression of RB1 protein |
CTD |
PMID:18172863 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of RELA protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of RELA mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of RELA protein]; Atorvastatin inhibits the reaction [Nitroglycerin results in increased localization of RELA protein] Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of RELA protein] |
CTD |
PMID:19733216 PMID:34939712 PMID:37121058 PMID:38213245 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
increases expression decreases activity multiple interactions decreases localization |
ISO EXP |
Atorvastatin results in increased expression of RHOA protein Atorvastatin results in decreased activity of RHOA protein Atorvastatin inhibits the reaction [Streptozocin results in increased activity of RHOA protein] [Poly I-C co-treated with Atorvastatin co-treated with Ivermectin] results in increased expression of RHOA mRNA; [Poly I-C co-treated with Atorvastatin] results in increased expression of RHOA mRNA; Atorvastatin results in increased localization of and results in decreased prenylation of RHOA protein; Celecoxib promotes the reaction [Atorvastatin results in decreased localization of RHOA protein]; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Atorvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased localization of RHOA protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased expression of BCL2 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK1 protein]; RHOA mutant form inhibits the reaction [Atorvastatin results in decreased phosphorylation of MAPK3 protein]; RHOA protein inhibits the reaction [Atorvastatin results in increased activity of CASP3 protein] |
CTD |
PMID:16470222 PMID:17589825 PMID:18172863 PMID:34696514 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
increases localization increases expression multiple interactions |
ISO |
Atorvastatin results in increased localization of RHOB protein Atorvastatin results in increased expression of RHOB protein [Atorvastatin co-treated with Celecoxib] results in increased localization of RHOB protein; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOB protein] |
CTD |
PMID:18172863 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rhoc |
ras homolog family member C |
decreases localization multiple interactions increases expression |
ISO |
Atorvastatin results in decreased localization of RHOC protein Celecoxib promotes the reaction [Atorvastatin results in decreased localization of RHOC protein]; Celecoxib promotes the reaction [Atorvastatin results in increased expression of RHOC protein] |
CTD |
PMID:18172863 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rpl36a |
ribosomal protein L36A |
increases expression |
EXP |
Atorvastatin results in increased expression of CYP21A2 mRNA |
CTD |
PMID:29574565 |
|
NCBI chr X:97,766,179...97,768,892
Ensembl chr X:97,766,179...97,768,892
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
[Rosiglitazone co-treated with Atorvastatin] results in increased expression of SCARB1 protein |
CTD |
PMID:15183127 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of SCD1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sele |
selectin E |
increases expression |
ISO |
Atorvastatin results in increased expression of SELE protein |
CTD |
PMID:19171469 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Fructose results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:21122807 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
[Atorvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions increases phosphorylation |
EXP ISO |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of SIRT1 protein] Atorvastatin results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:33073877 PMID:34939712 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of SLC10A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of SLC10A2 mRNA; Atorvastatin results in increased expression of SLC10A2 protein |
CTD |
PMID:15986414 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A2 protein] |
CTD |
PMID:20816828 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [APP protein results in decreased expression of SLC1A3 protein] |
CTD |
PMID:20816828 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions increases expression |
ISO |
Atorvastatin inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] Atorvastatin results in increased expression of SLC22A1 mRNA |
CTD |
PMID:21641380 PMID:25278499 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [SLC22A5 protein results in increased uptake of Carnitine] |
CTD |
PMID:21641380 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
increases expression |
ISO |
Atorvastatin results in increased expression of SLC29A1 mRNA |
CTD |
PMID:25278499 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
decreases expression multiple interactions |
EXP ISO |
Atorvastatin results in decreased expression of SLC2A2 protein NR1I2 protein promotes the reaction [Atorvastatin results in decreased expression of SLC2A2 protein] |
CTD |
PMID:26616219 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Atorvastatin inhibits the reaction [Sodium Glutamate results in decreased expression of SLC2A4 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in decreased expression of SLC2A4 protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of SLC2A4 mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of SLC2A4 protein] |
CTD |
PMID:19800637 PMID:25834641 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc4a1 |
solute carrier family 4 member 1 (Diego blood group) |
multiple interactions |
EXP |
[Acetylcysteine co-treated with Atorvastatin] inhibits the reaction [sodium arsenite affects the localization of SLC4A1 protein] |
CTD |
PMID:20946910 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [Monocrotaline results in increased expression of SLC6A4 protein] |
CTD |
PMID:17575010 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression decreases expression |
ISO EXP |
Atorvastatin results in increased expression of SLCO1A4 mRNA; Atorvastatin results in increased expression of SLCO1A4 protein Atorvastatin results in decreased expression of SLCO1A4 protein |
CTD |
PMID:15986414 PMID:24909372 PMID:25278499 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression increases uptake multiple interactions |
ISO |
Atorvastatin results in increased expression of SLCO1B2 mRNA SLCO1B3 protein results in increased uptake of Atorvastatin glimepiride affects the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Glyburide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; repaglinide inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Rosiglitazone inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin]; Sulfobromophthalein inhibits the reaction [SLCO1B3 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 PMID:25106415 PMID:25278499 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases uptake multiple interactions |
ISO |
SLCO2B1 protein results in increased uptake of Atorvastatin glimepiride inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Glyburide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Nateglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; repaglinide inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Rosiglitazone inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin]; Sulfobromophthalein inhibits the reaction [SLCO2B1 protein results in increased uptake of Atorvastatin] |
CTD |
PMID:23121773 PMID:25106415 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Atorvastatin inhibits the reaction [AGT protein results in decreased expression of SOD1 protein] |
CTD |
PMID:19451411 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions affects expression decreases expression increases expression |
EXP ISO |
Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of SOD2 mRNA]; Quercetin affects the reaction [Atorvastatin affects the expression of SOD2 mRNA] 2-tert-butylhydroquinone inhibits the reaction [Atorvastatin affects the expression of SOD2 protein] [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of SOD2 protein Atorvastatin results in decreased expression of SOD2 protein |
CTD |
PMID:21775390 PMID:30511338 PMID:31423616 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
increases expression |
EXP |
Atorvastatin results in increased expression of SOD3 protein |
CTD |
PMID:19451411 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of SQSTM1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Atorvastatin co-treated with dapagliflozin] inhibits the reaction [[Fructose co-treated with Dietary Fats] results in increased expression of SREBF1 protein]; Atorvastatin inhibits the reaction [Fructose results in increased activity of SREBF1 protein] |
CTD |
PMID:19053045 PMID:32259528 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression increases localization |
EXP ISO |
Atorvastatin results in increased activity of and results in increased localization of SREBF2 protein; Mevalonic Acid inhibits the reaction [Atorvastatin results in increased expression of SREBF2 mRNA] Atorvastatin results in increased localization of SREBF2 protein |
CTD |
PMID:11728391 PMID:12056585 PMID:12065722 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects expression |
EXP |
Atorvastatin affects the expression of STAR mRNA |
CTD |
PMID:29574565 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Syp |
synaptophysin |
increases expression |
EXP |
Atorvastatin results in increased expression of SYP protein |
CTD |
PMID:15255259 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression decreases expression multiple interactions |
EXP ISO |
Atorvastatin results in increased expression of TFAM mRNA Atorvastatin results in decreased expression of TFAM protein [PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TFAM mRNA Acetylcysteine inhibits the reaction [Atorvastatin results in increased expression of TFAM mRNA] |
CTD |
PMID:21775390 PMID:30511338 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tfrc |
transferrin receptor |
affects expression multiple interactions |
ISO |
Atorvastatin affects the expression of TFRC protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TFRC protein] |
CTD |
PMID:16387846 PMID:32976958 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Atorvastatin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24161914 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
ISO |
Atorvastatin results in decreased expression of THBS1 mRNA |
CTD |
PMID:16410222 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
Atorvastatin results in increased expression of TLR2 protein |
CTD |
PMID:16387846 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions decreases expression increases expression |
ISO EXP |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 protein; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TLR4 protein Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TLR4 mRNA]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TLR4 protein]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TLR4 mRNA]; Atorvastatin inhibits the reaction [Paraquat results in increased expression of TLR4 protein] Atorvastatin results in decreased expression of TLR4 mRNA; Atorvastatin results in decreased expression of TLR4 protein Atorvastatin results in increased expression of TLR4 protein |
CTD |
PMID:16387846 PMID:20524934 PMID:27883937 PMID:38213245 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Air Pollutants results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Particulate Matter results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of and results in decreased secretion of FASLG protein modified form]; Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Atorvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Atorvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Atorvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]] Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of TNF mRNA]; Atorvastatin inhibits the reaction [Sodium Glutamate results in increased expression of TNF protein] [dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [[Dietary Fats co-treated with Ergocalciferols] results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]; Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]; Atorvastatin inhibits the reaction [TNF protein results in increased oxidation of Glucose]; Farnesol inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PPARGC1A protein]]; Mevalonic Acid inhibits the reaction [Atorvastatin inhibits the reaction [TNF protein results in decreased expression of PDK4 protein]] Atorvastatin results in decreased expression of TNF mRNA Atorvastatin results in decreased secretion of TNF protein Atorvastatin results in decreased expression of TNF protein |
CTD |
PMID:12117737 PMID:12615677 PMID:15063428 PMID:16387846 PMID:17521631 PMID:17589825 PMID:19171469 PMID:19482827 PMID:19800637 PMID:22343369 PMID:29630879 PMID:34939712 PMID:37023836 PMID:38213245 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
decreases expression |
ISO |
Atorvastatin results in decreased expression of TNFRSF1A protein |
CTD |
PMID:16360360 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
TNFSF10 protein results in increased susceptibility to Atorvastatin |
CTD |
PMID:21910007 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions increases expression |
ISO |
[PPARGC1B protein affects the susceptibility to Atorvastatin] which affects the expression of TOMM20 protein Atorvastatin results in increased expression of TOMM20 protein |
CTD |
PMID:30511338 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Atorvastatin results in increased expression of TP53 protein Atorvastatin inhibits the reaction [[APOE protein affects the susceptibility to Dietary Fats] which affects the expression of TRP53 protein] |
CTD |
PMID:29630879 PMID:37121058 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TRAF6 mRNA; [Atorvastatin co-treated with Telmisartan] results in decreased expression of TRAF6 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
increases expression |
EXP |
Atorvastatin results in increased expression of TUBB3 protein |
CTD |
PMID:15255259 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression multiple interactions |
ISO EXP |
Atorvastatin results in decreased expression of VCAM1 mRNA; Atorvastatin results in decreased expression of VCAM1 protein Atorvastatin inhibits the reaction [sodium arsenite results in increased expression of VCAM1 protein]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of VCAM1 mRNA]; Atorvastatin inhibits the reaction [Streptozocin results in increased expression of VCAM1 protein] |
CTD |
PMID:17589825 PMID:17673219 PMID:22245985 PMID:25058445 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfd |
vascular endothelial growth factor D |
affects expression |
ISO |
Atorvastatin affects the expression of VEGFD mRNA |
CTD |
PMID:16410222 |
|
NCBI chr X:30,073,122...30,108,413
Ensembl chr X:30,074,163...30,108,295
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in increased expression of VIM protein] |
CTD |
PMID:34939712 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
ISO |
Atorvastatin results in increased expression of VWF protein |
CTD |
PMID:19171469 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[dapagliflozin co-treated with Atorvastatin] inhibits the reaction [[Dietary Fats co-treated with Fructose] results in decreased expression of WT1 protein] |
CTD |
PMID:34939712 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
G |
Xirp1 |
xin actin-binding repeat containing 1 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Atorvastatin co-treated with Ciprofloxacin] results in increased expression of XIRP1 mRNA |
CTD |
PMID:29679711 |
|
NCBI chr 8:119,744,778...119,757,547
Ensembl chr 8:119,747,419...119,757,349
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[barium chloride results in increased abundance of Barium] which results in decreased activity of ACHE protein |
CTD |
PMID:31407482 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Alb |
albumin |
multiple interactions increases secretion |
EXP |
Plant Extracts inhibits the reaction [barium chloride results in increased secretion of ALB protein] |
CTD |
PMID:26732703 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[[Sodium Selenite results in increased abundance of Selenium] which co-treated with Ascorbic Acid] inhibits the reaction [barium chloride results in decreased activity of CAT protein]; [barium chloride results in increased abundance of Barium] which results in decreased activity of CAT protein; [Sodium Selenite results in increased abundance of Selenium] inhibits the reaction [barium chloride results in decreased activity of CAT protein]; Ascorbic Acid inhibits the reaction [barium chloride results in decreased activity of CAT protein]; Plant Extracts inhibits the reaction [barium chloride results in decreased activity of CAT protein] |
CTD |
PMID:26732703 PMID:27941167 PMID:28683652 PMID:31407482 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
barium chloride inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; barium chloride inhibits the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:23305835 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases activity |
EXP |
barium chloride results in increased activity of GGT1 protein |
CTD |
PMID:28683652 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
increases activity |
EXP |
barium chloride results in increased activity of GOT1 protein |
CTD |
PMID:28683652 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases activity |
EXP |
barium chloride results in increased activity of GPT protein |
CTD |
PMID:28683652 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases activity |
EXP |
barium chloride results in decreased activity of GPX1 protein |
CTD |
PMID:28683652 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of IL1B mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of IL1B mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of IL6 mRNA [barium chloride results in increased abundance of Barium] which results in increased expression of IL6 protein; Plant Extracts inhibits the reaction [barium chloride results in increased expression of IL6 mRNA] |
CTD |
PMID:26732703 PMID:31407482 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
barium chloride results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
multiple interactions |
EXP |
barium chloride inhibits the reaction [KCNJ2 protein results in increased transport of Potassium] |
CTD |
PMID:11087224 |
|
NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnk3 |
potassium two pore domain channel subfamily K member 3 |
decreases activity |
EXP |
barium chloride results in decreased activity of KCNK3 protein |
CTD |
PMID:16020457 |
|
NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
ISO |
barium chloride results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Ldha |
lactate dehydrogenase A |
increases activity |
EXP |
barium chloride results in increased activity of LDHA protein |
CTD |
PMID:28683652 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mt2A |
metallothionein 2A |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of MT2A mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of MT2A mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Serpine1 |
serpin family E member 1 |
increases secretion |
EXP |
barium chloride results in increased secretion of SERPINE1 protein |
CTD |
PMID:21596853 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
barium chloride results in decreased expression of SOD2 mRNA Plant Extracts inhibits the reaction [barium chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stx1a |
syntaxin 1A |
multiple interactions affects localization |
EXP |
Propofol inhibits the reaction [barium chloride affects the localization of STX1A protein]; STX1A protein modified form inhibits the reaction [Propofol inhibits the reaction [barium chloride affects the localization of STX1A protein]] |
CTD |
PMID:29320738 |
|
NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP ISO |
Plant Extracts inhibits the reaction [barium chloride results in increased expression of TNF mRNA] barium chloride inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; barium chloride inhibits the reaction [TNF protein results in increased expression of F3 protein] |
CTD |
PMID:23305835 PMID:26732703 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
ISO |
[barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA] |
CTD |
PMID:29957541 |
|
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
|
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
decreases activity |
EXP |
Barium ion decreases activity of purified Hmbs protein |
RGD |
PMID:6732900 |
RGD:25394584 |
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
|
|
|
G |
Alb |
albumin |
increases expression |
EXP |
Barium Sulfate results in increased expression of ALB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
EXP |
Barium Sulfate results in increased expression of BIRC5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CCL11 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion increases expression |
EXP |
Barium Sulfate results in increased secretion of CCL2 protein Barium Sulfate results in increased expression of CCL2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
affects expression |
EXP |
Barium Sulfate affects the expression of CCL20 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CCL22 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CCL24 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of CCL4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CCL7 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CCR2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of CD40LG mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CXCL9 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CXCR3 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CYP4A1 mRNA |
CTD |
PMID:11124224 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CYP4A2 mRNA |
CTD |
PMID:11124224 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CYP4A3 mRNA |
CTD |
PMID:11124224 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CYP4F1 mRNA |
CTD |
PMID:14644421 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CYP4F4 mRNA |
CTD |
PMID:14644421 |
|
NCBI chr 7:11,717,208...11,733,507
Ensembl chr 7:11,717,208...11,733,506
|
|
G |
Cyp4f6 |
cytochrome P450, family 4, subfamily f, polypeptide 6 |
increases expression |
EXP |
Barium Sulfate results in increased expression of CYP4F6 mRNA |
CTD |
PMID:14644421 |
|
NCBI chr 7:12,030,276...12,058,020
Ensembl chr 7:12,030,301...12,057,782
|
|
G |
Exo1 |
exonuclease 1 |
affects expression |
EXP |
Barium Sulfate affects the expression of EXO1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of FABP4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of HBA1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Il2rb |
interleukin 2 receptor subunit beta |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of IL2RB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Barium Sulfate results in increased expression of IL6 protein |
CTD |
PMID:11403239 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Krt1 |
keratin 1 |
increases expression |
EXP |
Barium Sulfate results in increased expression of KRT1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lig4 |
DNA ligase 4 |
increases expression |
EXP |
Barium Sulfate results in increased expression of LIG4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040
|
|
G |
Lpo |
lactoperoxidase |
increases expression |
EXP |
Barium Sulfate results in increased expression of LPO mRNA; Barium Sulfate results in increased expression of LPO protein |
CTD |
PMID:29463257 |
|
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
EXP |
Barium Sulfate results in increased expression of MMP12 mRNA; Barium Sulfate results in increased expression of MMP12 protein |
CTD |
PMID:29463257 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mutyh |
mutY DNA glycosylase |
increases expression |
EXP |
Barium Sulfate results in increased expression of MUTYH mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146
|
|
G |
Ngb |
neuroglobin |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of NGB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Noxo1 |
NADPH oxidase organizer 1 |
increases expression |
EXP |
Barium Sulfate results in increased expression of NOXO1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:13,723,253...13,726,008
Ensembl chr10:13,721,473...13,726,061
|
|
G |
Opcml |
opioid binding protein/cell adhesion molecule-like |
increases expression |
EXP |
Barium Sulfate results in increased expression of OPCML mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:26,788,988...27,304,551
Ensembl chr 8:26,192,841...27,300,620
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
EXP |
Barium Sulfate results in increased expression of PF4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Scd |
stearoyl-CoA desaturase |
affects expression |
EXP |
Barium Sulfate affects the expression of SCD1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Tcf21 |
transcription factor 21 |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of TCF21 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 1:22,701,353...22,704,212
Ensembl chr 1:22,701,353...22,704,202
|
|
G |
Thbs2 |
thrombospondin 2 |
increases expression |
EXP |
Barium Sulfate results in increased expression of THBS2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 1:55,670,394...55,699,789
Ensembl chr 1:55,670,394...55,699,789
|
|
G |
Top2a |
DNA topoisomerase II alpha |
increases expression |
EXP |
Barium Sulfate results in increased expression of TOP2A mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
EXP |
Barium Sulfate results in decreased expression of TXNIP mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Xrcc2 |
X-ray repair cross complementing 2 |
increases expression |
EXP |
Barium Sulfate results in increased expression of XRCC2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 4:9,423,873...9,502,980
Ensembl chr 4:9,423,898...9,442,482
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[barium chloride results in increased abundance of Barium] which results in decreased activity of ACHE protein |
CTD |
PMID:31407482 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
ADRA1A protein promotes the reaction [TRPC6 protein results in increased transport of Barium] |
CTD |
PMID:11179201 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
increases transport |
EXP |
CACNA1A protein results in increased transport of Barium |
CTD |
PMID:11313431 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
affects transport increases transport multiple interactions |
ISO |
CACNA1B gene polymorphism affects the transport of Barium CACNA1B protein results in increased transport of Barium [GNB1 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB1 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB1 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB5 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; Cadmium Chloride inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 PMID:11756491 PMID:14559144 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
increases transport |
EXP |
CACNA1C protein results in increased transport of Barium |
CTD |
PMID:17569661 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1d |
calcium voltage-gated channel subunit alpha1 D |
affects transport multiple interactions increases transport |
ISO EXP |
CACNA1D protein affects the transport of Barium CACNA2D2 gene mutant form inhibits the reaction [CACNA1D protein results in increased import of Barium] CACNA1D protein results in increased transport of Barium |
CTD |
PMID:15357422 PMID:17567805 PMID:27798183 |
|
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
increases transport multiple interactions affects transport |
ISO EXP |
CACNA1E mRNA alternative form results in increased transport of Barium; CACNA1E protein results in increased transport of Barium 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; 4-O-methyl-12-O-tetradecanoylphorbol 13-acetate affects the reaction [CACNA1E protein results in increased transport of Barium]; Atropine inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Calcium inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Heparin affects the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; Isradipine inhibits the reaction [CACNA1E protein results in increased transport of Barium]; Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]; Nickel inhibits the reaction [CACNA1E protein results in increased transport of Barium]; omega-conotoxin-MVIIC promotes the reaction [Isradipine inhibits the reaction [CACNA1E protein results in increased transport of Barium]]; Ro 31-8425 inhibits the reaction [4-O-methyl-12-O-tetradecanoylphorbol 13-acetate affects the reaction [CACNA1E protein results in increased transport of Barium]]; Ro 31-8425 inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]]; SNX 482 inhibits the reaction [CACNA1E protein results in increased transport of Barium] SNX 482 inhibits the reaction [CACNA1E mRNA alternative form results in increased transport of Barium] CACNA1E protein affects the transport of Barium |
CTD |
PMID:10627594 PMID:10669483 PMID:11102459 PMID:11179973 PMID:12663092 PMID:15245474 More...
|
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
multiple interactions increases transport |
ISO |
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester promotes the reaction [CACNA1F protein results in increased transport of Barium]; Diltiazem inhibits the reaction [CACNA1F protein results in increased transport of Barium]; Isradipine inhibits the reaction [CACNA1F protein results in increased transport of Barium]; Verapamil inhibits the reaction [CACNA1F protein results in increased transport of Barium] |
CTD |
PMID:14744918 |
|
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
increases transport multiple interactions |
ISO |
CACNA1G mRNA alternative form results in increased transport of Barium; CACNA1G protein results in increased transport of Barium Cerium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Erbium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Gadolinium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Holmium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Lanthanum inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Neodymium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Scandium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Ytterbium inhibits the reaction [CACNA1G protein results in increased transport of Barium]; Yttrium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:11179973 PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases transport |
ISO |
CACNA1H mRNA alternative form results in increased transport of Barium |
CTD |
PMID:11179973 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
increases transport |
ISO |
CACNA1I mRNA alternative form results in increased transport of Barium |
CTD |
PMID:11179973 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
affects transport increases transport |
ISO EXP |
CACNA2D1 protein affects the transport of Barium CACNA2D1 protein results in increased transport of Barium |
CTD |
PMID:11313431 PMID:15245474 PMID:15474003 |
|
NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
multiple interactions |
ISO |
CACNA2D2 gene mutant form inhibits the reaction [CACNA1D protein results in increased import of Barium] |
CTD |
PMID:27798183 |
|
NCBI chr 8:108,072,208...108,203,516
Ensembl chr 8:108,072,454...108,203,173
|
|
G |
Cacnb3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
affects transport |
ISO |
CACNB3 protein affects the transport of Barium |
CTD |
PMID:15245474 |
|
NCBI chr 7:129,784,799...129,797,074
Ensembl chr 7:129,783,674...129,797,074
|
|
G |
Cacnb4 |
calcium voltage-gated channel auxiliary subunit beta 4 |
affects transport |
ISO EXP |
CACNB4 protein affects the transport of Barium |
CTD |
PMID:11313431 PMID:15245474 |
|
NCBI chr 3:36,906,771...37,169,165
Ensembl chr 3:36,910,427...37,168,944
|
|
G |
Cacng2 |
calcium voltage-gated channel auxiliary subunit gamma 2 |
affects transport |
ISO |
CACNG2 protein affects the transport of Barium |
CTD |
PMID:11313431 |
|
NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227
|
|
G |
Cacng3 |
calcium voltage-gated channel auxiliary subunit gamma 3 |
affects transport |
ISO |
CACNG3 protein affects the transport of Barium |
CTD |
PMID:11313431 |
|
NCBI chr 1:177,201,361...177,297,019
Ensembl chr 1:177,201,288...177,297,024
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[barium chloride results in increased abundance of Barium] which results in decreased activity of CAT protein |
CTD |
PMID:31407482 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
1-Butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; 1-Propanol promotes the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; 2-butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; 2-Propanol promotes the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; [CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium; Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]; crotonyl alcohol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; n-pentanol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; tert-Butyl Alcohol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
[CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Barium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Barium results in increased susceptibility to Acetylcholine] |
CTD |
PMID:12754307 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
EXP |
[CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Barium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Barium results in increased susceptibility to Acetylcholine] |
CTD |
PMID:12754307 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
ISO |
1-Butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; 1-Propanol promotes the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; 2-butanol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; 2-Propanol promotes the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; [CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium; Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]; crotonyl alcohol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; isobutyl alcohol affects the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; n-pentanol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]]; tert-Butyl Alcohol inhibits the reaction [Acetylcholine promotes the reaction [[CHRNA2 protein binds to CHRNB4 protein] which results in increased transport of Barium]] |
CTD |
PMID:11821649 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions decreases transport |
EXP |
3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester inhibits the reaction [DRD2 protein results in decreased transport of Barium]; [DRD2 protein affects the abundance of Calcium] which results in decreased transport of Barium; [DRD2 protein results in increased activity of PLCB1 protein] which results in decreased transport of Barium; DRD2 protein affects the reaction [N-n-propylnorapomorphine analog results in decreased transport of Barium]; DRD2 protein affects the reaction [Quinpirole results in decreased transport of Barium]; Nifedipine inhibits the reaction [DRD2 protein affects the reaction [Quinpirole results in decreased transport of Barium]] |
CTD |
PMID:11124974 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
F2 |
coagulation factor II, thrombin |
increases uptake multiple interactions |
ISO |
F2 protein results in increased uptake of Barium Nickel inhibits the reaction [F2 protein results in increased uptake of Barium] |
CTD |
PMID:2125206 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
Barium inhibits the reaction [F2RL1 protein results in increased transport of Chlorides]; F2RL1 protein affects the reaction [1-oleoyl-2-acetoyl-sn-glycerol results in increased transport of Barium] |
CTD |
PMID:11804840 PMID:16123040 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
decreases activity |
ISO |
Barium results in decreased activity of FXYD2 protein |
CTD |
PMID:11533133 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
Gnb1 |
G protein subunit beta 1 |
multiple interactions |
ISO |
[GNB1 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB1 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB1 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr 5:166,075,508...166,142,223
Ensembl chr 5:166,075,629...166,142,124
|
|
G |
Gnb2 |
G protein subunit beta 2 |
multiple interactions |
ISO |
[GNB2 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019
|
|
G |
Gnb3 |
G protein subunit beta 3 |
multiple interactions |
ISO |
[GNB3 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:157,639,469...157,645,173
|
|
G |
Gnb4 |
G protein subunit beta 4 |
multiple interactions |
ISO |
[GNB4 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr 2:115,360,746...115,400,680
Ensembl chr 2:115,364,918...115,400,579
|
|
G |
Gnb5 |
G protein subunit beta 5 |
multiple interactions |
ISO |
[GNB5 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr 8:76,076,120...76,105,069
Ensembl chr 8:76,073,306...76,105,069
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
ISO |
[GNB1 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB5 protein binds to GNG2 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183
|
|
G |
Gng3 |
G protein subunit gamma 3 |
multiple interactions |
ISO |
[GNB1 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNG3 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603
|
|
G |
Gngt1 |
G protein subunit gamma transducin 1 |
multiple interactions |
ISO |
[GNB1 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB2 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB3 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium]; [GNB4 protein binds to GNGT1 protein] inhibits the reaction [CACNA1B protein results in increased transport of Barium] |
CTD |
PMID:11007869 |
|
NCBI chr 4:32,006,267...32,009,252
Ensembl chr 4:32,006,267...32,009,252
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[barium chloride results in increased abundance of Barium] which results in increased expression of IL6 protein |
CTD |
PMID:31407482 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcna10 |
potassium voltage-gated channel subfamily A member 10 |
multiple interactions |
ISO |
Barium inhibits the reaction [KCNA10 protein results in increased transport of Potassium] |
CTD |
PMID:10836990 |
|
NCBI chr 2:194,786,500...194,798,575
Ensembl chr 2:194,786,500...194,798,575
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
Barium results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnh1 |
potassium voltage-gated channel subfamily H member 1 |
decreases activity |
ISO |
Barium results in decreased activity of KCNH1 protein |
CTD |
PMID:10896755 |
|
NCBI chr13:103,722,140...104,024,762
Ensembl chr13:103,722,245...104,024,740
|
|
G |
Kcnh3 |
potassium voltage-gated channel subfamily H member 3 |
multiple interactions |
ISO |
Barium binds to and results in decreased activity of KCNH3 protein |
CTD |
PMID:12193184 |
|
NCBI chr 7:130,365,593...130,383,859
Ensembl chr 7:130,366,011...130,383,855
|
|
G |
Kcnj10 |
potassium inwardly-rectifying channel, subfamily J, member 10 |
decreases activity |
EXP |
Barium results in decreased activity of KCNJ10 protein |
CTD |
PMID:16331678 PMID:17978865 |
|
NCBI chr13:84,802,026...84,835,383
Ensembl chr13:84,802,009...84,835,461
|
|
G |
Kcnj12 |
potassium inwardly-rectifying channel, subfamily J, member 12 |
multiple interactions |
ISO |
Barium inhibits the reaction [KCNJ12 protein results in increased transport of Potassium] |
CTD |
PMID:15958527 |
|
NCBI chr10:45,696,621...45,745,528
Ensembl chr10:45,696,849...45,745,492
|
|
G |
Kcnj14 |
potassium inwardly-rectifying channel, subfamily J, member 14 |
multiple interactions |
ISO EXP |
Barium inhibits the reaction [KCNJ14 protein results in increased transport of Potassium] |
CTD |
PMID:10938328 PMID:17347781 |
|
NCBI chr 1:96,293,159...96,300,810
Ensembl chr 1:96,293,435...96,495,459
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
decreases activity |
ISO |
Barium results in decreased activity of KCNJ15 protein |
CTD |
PMID:15328350 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
multiple interactions decreases activity |
ISO |
Barium inhibits the reaction [KCNJ2 protein results in increased transport of Potassium] Barium results in decreased activity of KCNJ2 protein |
CTD |
PMID:12598232 PMID:15958527 PMID:17347781 PMID:17699636 |
|
NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnj4 |
potassium inwardly-rectifying channel, subfamily J, member 4 |
decreases activity multiple interactions |
ISO |
Barium results in decreased activity of KCNJ4 protein Barium inhibits the reaction [KCNJ4 protein results in increased transport of Potassium] |
CTD |
PMID:12598232 PMID:17091215 |
|
NCBI chr 7:111,047,097...111,074,151
Ensembl chr 7:111,047,094...111,074,151
|
|
G |
Kcnk1 |
potassium two pore domain channel subfamily K member 1 |
multiple interactions |
ISO |
Barium inhibits the reaction [KCNK1 protein results in increased transport of Potassium]; Barium inhibits the reaction [KCNK1 protein results in increased transport of Sodium] |
CTD |
PMID:16847696 |
|
NCBI chr19:53,959,411...53,997,726
Ensembl chr19:53,959,657...53,997,724
|
|
G |
Kcnk18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
ISO |
Barium inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr 1:258,374,671...258,388,945
Ensembl chr 1:258,374,671...258,388,945
|
|
G |
Kcnk9 |
potassium two pore domain channel subfamily K member 9 |
multiple interactions |
EXP |
Barium inhibits the reaction [KCNK9 protein results in increased transport of Potassium] |
CTD |
PMID:10734076 |
|
NCBI chr 7:104,429,186...104,473,924
Ensembl chr 7:104,437,934...104,473,175
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
ISO |
Barium results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Mir30a |
microRNA 30a |
multiple interactions |
ISO |
[Air Pollutants, Occupational results in increased abundance of Barium] which results in decreased expression of MIR30A mRNA |
CTD |
PMID:27506416 |
|
NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
increases expression |
ISO |
Barium results in increased expression of MMP14 protein |
CTD |
PMID:23804419 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
multiple interactions |
ISO |
Barium inhibits the reaction [NPR3 protein affects the reaction [Enterotoxins affects the transport of Potassium]]; Barium inhibits the reaction [NPR3 protein affects the reaction [guanylin affects the transport of Potassium]] |
CTD |
PMID:11889121 |
|
NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium] |
CTD |
PMID:11003599 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions |
EXP |
[DRD2 protein results in increased activity of PLCB1 protein] which results in decreased transport of Barium |
CTD |
PMID:11124974 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases phosphorylation |
ISO |
Barium results in increased phosphorylation of PTK2 protein |
CTD |
PMID:23804419 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
multiple interactions |
ISO |
Barium inhibits the reaction [SGK1 protein results in increased transport of Potassium] |
CTD |
PMID:12590200 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
Barium inhibits the reaction [SGK2 protein results in increased transport of Potassium] |
CTD |
PMID:12590200 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Sgk3 |
serum/glucocorticoid regulated kinase family, member 3 |
multiple interactions |
ISO |
Barium inhibits the reaction [SGK3 protein results in increased transport of Potassium] |
CTD |
PMID:12590200 |
|
NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476
|
|
G |
Slc12a4 |
solute carrier family 12 member 4 |
multiple interactions |
ISO |
Barium inhibits the reaction [SLC12A4 protein results in increased transport of Potassium] |
CTD |
PMID:11703599 |
|
NCBI chr19:33,838,418...33,860,369
Ensembl chr19:33,838,419...33,860,331
|
|
G |
Slc12a7 |
solute carrier family 12 member 7 |
decreases activity |
ISO |
Barium results in decreased activity of SLC12A7 protein |
CTD |
PMID:10913127 |
|
NCBI chr 1:29,472,692...29,554,246
Ensembl chr 1:29,472,692...29,554,302
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO |
Barium promotes the reaction [SLC22A12 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:15284287 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Barium inhibits the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:10966924 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
affects transport |
ISO |
SLC8A1 protein affects the transport of Barium |
CTD |
PMID:17560225 |
|
NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[[Industrial Waste results in increased abundance of Trace Elements] which results in increased abundance of Barium] which affects the expression of SOD1 mRNA |
CTD |
PMID:34083740 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Barium inhibits the reaction [TNF protein results in increased transport of Potassium] |
CTD |
PMID:10783394 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions increases transport |
ISO |
1-oleoyl-2-acetylglycerol promotes the reaction [TRPC3 protein results in increased transport of Barium] 1-oleoyl-2-acetoyl-sn-glycerol affects the reaction [TRPC3 protein results in increased transport of Barium] |
CTD |
PMID:11042129 PMID:16055711 |
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc4 |
transient receptor potential cation channel, subfamily C, member 4 |
multiple interactions increases transport |
ISO |
TRPC4 protein affects the reaction [Carbachol results in increased transport of Barium] TRPC4 protein results in increased transport of Barium |
CTD |
PMID:11042129 PMID:11830588 |
|
NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions increases transport affects transport |
ISO |
1-oleoyl-2-acetoyl-sn-glycerol affects the reaction [TRPC6 protein affects the transport of Barium]; ADRA1A protein promotes the reaction [TRPC6 protein results in increased transport of Barium] |
CTD |
PMID:11179201 PMID:16055711 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
increases uptake |
ISO |
TRPV6 protein results in increased uptake of Barium |
CTD |
PMID:19996302 PMID:21146870 |
|
NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
ISO |
[barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA] |
CTD |
PMID:29957541 |
|
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
|
|
G |
Urod |
uroporphyrinogen decarboxylase |
affects abundance |
ISO |
UROD protein affects the abundance of Barium |
CTD |
PMID:16325539 |
|
NCBI chr 5:130,464,695...130,468,783
Ensembl chr 5:130,455,217...130,468,808
|
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
affects expression |
ISO |
beryllium chloride affects the expression of APEX1 mRNA |
CTD |
PMID:23793613 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
affects expression |
ISO |
beryllium chloride affects the expression of OGG1 mRNA |
CTD |
PMID:23793613 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
beryllium chloride results in increased expression of TRP53 mRNA |
CTD |
PMID:23793613 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
beryllium fluoride promotes the reaction [ABCB1 protein mutant form binds to 8-azidoadenosine 5'-triphosphate] |
CTD |
PMID:11027628 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
EXP |
beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]; Cobalt promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]]; Magnesium Chloride promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]]; Manganese promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]]; Nickel promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]] |
CTD |
PMID:12069597 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
decreases activity |
ISO EXP |
beryllium fluoride results in decreased activity of ABCC8 protein |
CTD |
PMID:17561960 PMID:18025464 |
|
NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression |
ISO |
beryllium fluoride results in increased expression of CREB1 protein |
CTD |
PMID:11867686 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
beryllium fluoride results in increased expression of FOS protein |
CTD |
PMID:11867686 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
increases phosphorylation |
ISO |
beryllium fluoride results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:11867686 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
beryllium fluoride results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:11867686 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
ISO |
beryllium fluoride results in increased expression of MYC protein |
CTD |
PMID:11867686 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
[Beryllium results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA |
CTD |
PMID:11872642 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Esr1 |
estrogen receptor 1 |
increases methylation |
EXP |
Beryllium results in increased methylation of ESR1 gene |
CTD |
PMID:11872642 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Beryllium results in increased mutagenesis of HRAS gene |
CTD |
PMID:7545909 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il1b |
interleukin 1 beta |
increases expression affects expression |
ISO |
Beryllium results in increased expression of IL1B mRNA Beryllium affects the expression of IL1B mRNA |
CTD |
PMID:8473757 PMID:8629860 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
RT1-Hb-ps1 |
RT1 class II, locus Hb, pseudogene 1 |
affects binding increases response to substance |
ISO |
HLA-DPB1 protein mutant form binds to Beryllium HLA-DPB1 gene polymorphism results in increased susceptibility to Beryllium; HLA-DPB1 gene SNP results in increased susceptibility to Beryllium; HLA-DPB1 protein mutant form results in increased susceptibility to Beryllium |
CTD |
PMID:11551429 PMID:15273960 PMID:17956852 |
|
NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases response to substance increases secretion |
ISO |
Beryllium results in increased expression of TNF mRNA TNF promoter polymorphism results in increased susceptibility to Beryllium Beryllium results in increased secretion of TNF protein |
CTD |
PMID:8629860 PMID:12449171 PMID:15127972 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
multiple interactions increases expression |
ISO |
[sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA] |
CTD |
PMID:36843388 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
beryllium sulfate results in increased expression of ACTA2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Amot |
angiomotin |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of AMOT mRNA |
CTD |
PMID:35679967 |
|
NCBI chr X:108,982,399...109,041,265
Ensembl chr X:108,984,022...109,041,272
|
|
G |
Anxa5 |
annexin A5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ANXA5 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Arhgap26 |
Rho GTPase activating protein 26 |
increases expression decreases expression |
ISO |
beryllium sulfate results in increased expression of ARHGAP26 mRNA beryllium sulfate results in decreased expression of ARHGAP26 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr18:30,835,806...31,237,945
Ensembl chr18:30,838,671...31,235,194
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions increases secretion |
ISO |
beryllium sulfate promotes the reaction [RUNX1 protein binds to CCL3 promoter] beryllium sulfate results in increased secretion of CCL3 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CCL4 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of CCL5 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnt1 |
cyclin T1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of CCNT1 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Cd44 |
CD44 molecule |
increases expression |
ISO |
beryllium sulfate results in increased expression of CD44 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
beryllium sulfate results in increased expression of CD86 protein |
CTD |
PMID:19665512 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] beryllium sulfate results in increased expression of CDKN1A mRNA; beryllium sulfate results in increased expression of CDKN1A protein |
CTD |
PMID:17395767 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
beryllium sulfate results in increased expression of CDKN2A mRNA; beryllium sulfate results in increased expression of CDKN2A protein |
CTD |
PMID:17395767 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of CREB1 protein |
CTD |
PMID:10755711 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cryaa |
crystallin, alpha A |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of CRYAA mRNA |
CTD |
PMID:35679967 |
|
NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
beryllium sulfate results in increased expression of CTSL mRNA |
CTD |
PMID:16314022 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cul9 |
cullin 9 |
increases expression decreases expression |
ISO |
beryllium sulfate results in increased expression of CUL9 mRNA beryllium sulfate results in decreased expression of CUL9 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 9:14,435,948...14,479,552
Ensembl chr 9:14,436,111...14,479,548
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CXCL1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases secretion |
ISO |
beryllium sulfate results in increased secretion of CXCL1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Ddhd2 |
DDHD domain containing 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of DDHD2 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr16:66,319,469...66,349,025
Ensembl chr16:66,319,466...66,349,023
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of EGR2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of FOS mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA]; Ro 31-8220 inhibits the reaction [beryllium sulfate results in increased expression of FOS mRNA] |
CTD |
PMID:11568973 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions decreases expression |
ISO |
[sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; [sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 protein] beryllium sulfate results in decreased expression of FTH1 mRNA; beryllium sulfate results in decreased expression of FTH1 protein |
CTD |
PMID:36843388 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions decreases expression |
ISO |
[sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA] |
CTD |
PMID:36843388 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of HNRNPA1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases secretion increases expression |
ISO |
3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beryllium sulfate results in increased expression of ICAM1 mRNA]; 3,3',4,5'-tetrahydroxystilbene inhibits the reaction [beryllium sulfate results in increased secretion of ICAM1 protein]; Dimethyl Sulfoxide inhibits the reaction [beryllium sulfate results in increased secretion of ICAM1 protein] beryllium sulfate results in increased expression of ICAM1 mRNA; beryllium sulfate results in increased expression of ICAM1 protein |
CTD |
PMID:18539414 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of IFNG protein [beryllium sulfate co-treated with IFNG protein] results in increased expression of CREB1 protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUN protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUNB protein; [beryllium sulfate co-treated with IFNG protein] results in increased expression of NFKB1 protein; beryllium sulfate promotes the reaction [IFNG protein results in increased expression of TNF protein] |
CTD |
PMID:10755710 PMID:10755711 PMID:20974702 PMID:33197057 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL10 protein |
CTD |
PMID:33197057 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL18 mRNA; beryllium sulfate results in increased expression of IL18 protein |
CTD |
PMID:16100009 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL2 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il5 |
interleukin 5 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL5 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
beryllium sulfate results in increased expression of IL6 mRNA |
CTD |
PMID:9328138 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb3 |
integrin subunit beta 3 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ITGB3 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA]; [beryllium sulfate co-treated with IFNG protein] results in increased expression of JUN protein; Dactinomycin inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA]; Ro 31-8220 inhibits the reaction [beryllium sulfate results in increased expression of JUN mRNA] |
CTD |
PMID:10755711 PMID:11568973 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of JUNB protein |
CTD |
PMID:10755711 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Krt4 |
keratin 4 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of KRT4 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 7:133,046,067...133,052,027
Ensembl chr 7:133,046,515...133,052,019
|
|
G |
Mfsd14b |
major facilitator superfamily domain containing 14B |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of MFSD14B mRNA |
CTD |
PMID:35679967 |
|
NCBI chr17:77,895...130,837
Ensembl chr17:77,840...130,839
|
|
G |
Mir1306 |
microRNA 1306 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR1306 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr11:82,709,651...82,709,723
Ensembl chr11:82,709,637...82,709,719
|
|
G |
Mir150 |
microRNA 150 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR150 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108
|
|
G |
Mir193b |
microRNA 193b |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR193B mRNA |
CTD |
PMID:33197057 |
|
NCBI chr10:1,317,742...1,317,824
Ensembl chr10:1,317,742...1,317,824
|
|
G |
Mir23b |
microRNA 23b |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of MIR23B mRNA |
CTD |
PMID:33197057 |
|
NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mir324 |
microRNA 324 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR324 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr10:54,734,680...54,734,762
Ensembl chr10:54,734,678...54,734,766
|
|
G |
Mir363 |
microRNA 363 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR363 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr X:132,421,791...132,421,877
Ensembl chr X:132,421,791...132,421,877
|
|
G |
Mir484 |
microRNA 484 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of MIR484 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr10:887,684...887,760
Ensembl chr10:887,684...887,760
|
|
G |
Mir504 |
microRNA 504 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR504 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr X:137,318,540...137,318,616
Ensembl chr X:137,318,540...137,318,616
|
|
G |
Mir877 |
microRNA 877 |
increases expression |
ISO |
beryllium sulfate results in increased expression of MIR877 mRNA |
CTD |
PMID:33197057 |
|
NCBI chr20:2,811,476...2,811,560
Ensembl chr20:2,811,476...2,811,560
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
beryllium sulfate results in increased expression of MYC protein |
CTD |
PMID:2009323 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions increases expression |
ISO |
[sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; [sodium sulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of FTH1 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of GPX4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of ACSL4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of NCOA4 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of NCOA4 protein]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA] beryllium sulfate results in increased expression of NCOA4 mRNA; beryllium sulfate results in increased expression of NCOA4 protein |
CTD |
PMID:36843388 |
|
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Nedd8 |
NEDD8 ubiquitin like modifier |
increases expression |
ISO |
beryllium sulfate results in increased expression of NEDD8 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr15:29,153,556...29,165,575
Ensembl chr15:29,153,556...29,166,160
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[beryllium sulfate co-treated with IFNG protein] results in increased expression of NFKB1 protein |
CTD |
PMID:10755711 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of NOS2 protein |
CTD |
PMID:33197057 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nova1 |
NOVA alternative splicing regulator 1 |
increases expression |
ISO |
beryllium sulfate results in increased expression of NOVA1 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289
|
|
G |
Pdpk1 |
3-phosphoinositide dependent protein kinase-1 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of PDPK1 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr10:13,105,435...13,182,664
Ensembl chr10:13,105,498...13,174,623
|
|
G |
Phf19 |
PHD finger protein 19 |
decreases expression |
ISO |
beryllium sulfate results in decreased expression of PHF19 mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of PTGS2 mRNA; beryllium sulfate results in increased expression of PTGS2 protein [sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in increased expression of PTGS2 mRNA] |
CTD |
PMID:33197057 PMID:36843388 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rhoa |
ras homolog family member A |
increases expression |
ISO |
beryllium sulfate results in increased expression of RHOA mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rpl22 |
ribosomal protein L22 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL22 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 5:162,835,241...162,843,394
Ensembl chr 5:162,833,740...162,843,368 Ensembl chr 7:162,833,740...162,843,368 Ensembl chr 4:162,833,740...162,843,368
|
|
G |
Rpl30 |
ribosomal protein L30 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL30 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:65,648,266...65,651,401
Ensembl chr 7:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363 Ensembl chr10:65,645,991...65,651,363
|
|
G |
Rpl37a |
ribosomal protein L37A |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPL37A mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 9:74,298,843...74,300,926
|
|
G |
Rps7 |
ribosomal protein S7 |
increases expression |
ISO |
beryllium sulfate results in increased expression of RPS7 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 6:45,266,200...45,271,064
Ensembl chr 6:45,223,980...45,271,145
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
increases expression |
ISO |
beryllium sulfate results in increased expression of HLA-A mRNA |
CTD |
PMID:16314022 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
RT1-Db1 |
RT1 class II, locus Db1 |
increases response to substance increases expression |
ISO |
HLA-DRB1 protein mutant form results in increased susceptibility to beryllium sulfate beryllium sulfate results in increased expression of HLA-DRB1 mRNA |
CTD |
PMID:16272364 PMID:16314022 |
|
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
|
|
G |
RT1-Hb-ps1 |
RT1 class II, locus Hb, pseudogene 1 |
affects binding |
ISO |
beryllium sulfate binds to HLA-DPB1 protein |
CTD |
PMID:11423174 |
|
NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
multiple interactions |
ISO |
beryllium sulfate promotes the reaction [RUNX1 protein binds to CCL3 promoter] |
CTD |
PMID:16314022 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
ISO |
beryllium sulfate results in increased expression of SERPINB2 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Sftpd |
surfactant protein D |
increases expression |
ISO |
beryllium sulfate results in increased expression of SFTPD mRNA |
CTD |
PMID:16314022 |
|
NCBI chr16:17,046,491...17,058,968
Ensembl chr16:17,046,483...17,059,927
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions decreases expression |
ISO |
[sodium bisulfide results in increased abundance of Hydrogen Sulfide] inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]; Deferoxamine inhibits the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA]; NCOA4 protein affects the reaction [beryllium sulfate results in decreased expression of SLC7A11 mRNA] |
CTD |
PMID:36843388 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Tat |
tyrosine aminotransferase |
multiple interactions |
EXP |
beryllium sulfate inhibits the reaction [Hydrocortisone results in increased expression of TAT protein] |
CTD |
PMID:6120038 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Thsd7a |
thrombospondin type 1 domain containing 7A |
decreases expression increases expression |
ISO |
beryllium sulfate results in decreased expression of THSD7A mRNA beryllium sulfate results in increased expression of THSD7A mRNA |
CTD |
PMID:35679967 |
|
NCBI chr 4:40,461,124...40,899,345
Ensembl chr 4:40,460,814...40,899,583
|
|
G |
Tmsb4x |
thymosin beta 4, X-linked |
increases expression |
ISO |
beryllium sulfate results in increased expression of TMSB4X mRNA |
CTD |
PMID:16314022 |
|
NCBI chr X:27,144,666...27,146,667
Ensembl chr X:27,128,610...27,146,667
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
beryllium sulfate results in increased expression of TNF mRNA; beryllium sulfate results in increased expression of TNF protein beryllium sulfate promotes the reaction [IFNG protein results in increased expression of TNF protein] |
CTD |
PMID:10755710 PMID:10755711 PMID:33197057 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
beryllium sulfate promotes the reaction [TP53 protein binds to CDKN1A promoter] beryllium sulfate results in increased expression of TP53 protein |
CTD |
PMID:17395767 PMID:20974702 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Wnt4 |
Wnt family member 4 |
increases expression |
ISO |
beryllium sulfate results in increased expression of WNT4 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Zfp77 |
zinc finger protein 77 |
increases expression |
ISO |
beryllium sulfate results in increased expression of ZNF77 mRNA |
CTD |
PMID:16314022 |
|
NCBI chr 7:7,269,879...7,316,286
Ensembl chr 7:7,269,927...7,286,051
|
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
[Beryllium results in increased methylation of CDKN2A promoter] which results in decreased expression of CDKN2A mRNA |
CTD |
PMID:11872642 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Esr1 |
estrogen receptor 1 |
increases methylation |
EXP |
Beryllium results in increased methylation of ESR1 gene |
CTD |
PMID:11872642 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Beryllium results in increased mutagenesis of HRAS gene |
CTD |
PMID:7545909 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Il1b |
interleukin 1 beta |
increases expression affects expression |
ISO |
Beryllium results in increased expression of IL1B mRNA Beryllium affects the expression of IL1B mRNA |
CTD |
PMID:8473757 PMID:8629860 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
RT1-Hb-ps1 |
RT1 class II, locus Hb, pseudogene 1 |
increases response to substance affects binding |
ISO |
HLA-DPB1 gene polymorphism results in increased susceptibility to Beryllium; HLA-DPB1 gene SNP results in increased susceptibility to Beryllium; HLA-DPB1 protein mutant form results in increased susceptibility to Beryllium HLA-DPB1 protein mutant form binds to Beryllium |
CTD |
PMID:11551429 PMID:15273960 PMID:17956852 |
|
NCBI chr20:4,775,598...4,779,590
Ensembl chr20:4,774,650...4,780,618
|
|
G |
Tnf |
tumor necrosis factor |
increases response to substance increases secretion increases expression |
ISO |
TNF promoter polymorphism results in increased susceptibility to Beryllium Beryllium results in increased secretion of TNF protein Beryllium results in increased expression of TNF mRNA |
CTD |
PMID:8629860 PMID:12449171 PMID:15127972 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of BGLAP protein |
CTD |
PMID:2027271 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Capn1 |
calpain 1 |
increases activity |
ISO |
Calcium Carbonate analog results in increased activity of CAPN1 protein |
CTD |
PMID:24412303 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Calcium Carbonate analog results in increased activity of CASP3 protein |
CTD |
PMID:24412303 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Calcium Carbonate analog results in increased expression of DDIT3 |
CTD |
PMID:24412303 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Pth |
parathyroid hormone |
affects expression decreases expression |
ISO |
Calcium Carbonate affects the expression of PTH protein Calcium Carbonate results in decreased expression of PTH protein |
CTD |
PMID:1752077 PMID:2027271 PMID:3826069 PMID:7891547 PMID:8481062 PMID:16006300 More...
|
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of PTHLH protein |
CTD |
PMID:16006300 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
Calcium Carbonate results in decreased expression of SPP1 protein |
CTD |
PMID:17977878 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
increases expression |
EXP |
Calcium Chloride results in increased expression of ADAM10 mRNA; Calcium Chloride results in increased expression of ADAM10 protein |
CTD |
PMID:20621845 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
increases expression |
EXP |
Calcium Chloride results in increased expression of ADAM17 mRNA; Calcium Chloride results in increased expression of ADAM17 protein |
CTD |
PMID:20621845 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Calcium Chloride results in increased expression of ALPL mRNA |
CTD |
PMID:25824407 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoc3 |
apolipoprotein C3 |
increases expression |
ISO |
Calcium Chloride results in increased expression of APOC3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Atp5pf |
ATP synthase peripheral stalk subunit F6 |
increases expression |
ISO |
Calcium Chloride results in increased expression of ATP5PF protein |
CTD |
PMID:25824407 |
|
NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119
|
|
G |
Bag4 |
BAG cochaperone 4 |
increases expression |
ISO |
Calcium Chloride results in increased expression of BAG4 protein |
CTD |
PMID:25824407 |
|
NCBI chr16:66,288,678...66,305,893
Ensembl chr16:66,288,678...66,308,663
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression |
ISO |
Calcium Chloride results in increased expression of BGLAP mRNA |
CTD |
PMID:25824407 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bicd2 |
BICD cargo adaptor 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of BICD2 protein |
CTD |
PMID:25824407 |
|
NCBI chr17:15,259,773...15,304,889
Ensembl chr17:15,259,773...15,304,889
|
|
G |
Calm3 |
calmodulin 3 |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [CALM3 protein binds to and results in decreased activity of UBE3B protein] |
CTD |
PMID:28003368 |
|
NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
EXP |
cordycepin inhibits the reaction [Calcium Chloride results in increased cleavage of CASP3 protein] |
CTD |
PMID:36731150 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
EXP |
Calcium Chloride results in increased cleavage of CASP9 protein cordycepin inhibits the reaction [Calcium Chloride results in increased cleavage of CASP9 protein] |
CTD |
PMID:36731150 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions increases activity |
ISO |
Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein] Calcium Chloride results in increased activity of CASR protein |
CTD |
PMID:16316325 PMID:17376781 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases phosphorylation increases expression multiple interactions |
ISO |
Calcium Chloride results in increased phosphorylation of CCL2 protein Calcium Chloride results in increased expression of CCL2 mRNA; Calcium Chloride results in increased expression of CCL2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CCL2 protein]; Resveratrol inhibits the reaction [Calcium Chloride results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [Calcium Chloride results in increased phosphorylation of CCL2 protein] |
CTD |
PMID:21530968 PMID:22728078 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CCT6A protein |
CTD |
PMID:25824407 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions increases expression |
ISO |
resveratrol inhibits the reaction [Calcium Chloride results in increased expression of CD68 mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein] |
CTD |
PMID:12189186 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
EXP |
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein] |
CTD |
PMID:12189186 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases activity |
ISO |
Calcium Chloride results in increased activity of CEBPA protein |
CTD |
PMID:17214633 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Clec3b |
C-type lectin domain family 3, member B |
increases expression |
ISO |
Calcium Chloride results in increased expression of CLEC3B protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:122,810,120...122,815,837
Ensembl chr 8:122,810,149...122,815,835
|
|
G |
Clic3 |
chloride intracellular channel 3 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CLIC3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 3:8,271,416...8,274,023
Ensembl chr 3:8,272,097...8,274,018
|
|
G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
increases expression |
ISO |
Calcium Chloride results in increased expression of CMTM6 protein |
CTD |
PMID:25824407 |
|
NCBI chr 8:114,422,934...114,441,034
Ensembl chr 8:114,422,921...114,441,033
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Calcium Chloride results in increased expression of COL1A1 mRNA |
CTD |
PMID:25824407 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
increases expression |
ISO |
Calcium Chloride results in increased expression of COL8A1 protein |
CTD |
PMID:25824407 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
increases expression |
ISO |
Calcium Chloride results in increased expression of COPS3 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Calcium Chloride results in increased expression of CST3 protein |
CTD |
PMID:25824407 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Cthrc1 |
collagen triple helix repeat containing 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of CTHRC1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:70,122,474...70,132,756
Ensembl chr 7:70,122,474...70,132,756
|
|
G |
Ctsb |
cathepsin B |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of CTSB protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CTSB protein] |
CTD |
PMID:22728078 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsk |
cathepsin K |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of CTSK protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of CTSK protein] |
CTD |
PMID:22728078 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of DCN protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddx39b |
DExD-box helicase 39B |
increases expression |
ISO |
Calcium Chloride results in increased expression of DDX39B protein |
CTD |
PMID:25824407 |
|
NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996
|
|
G |
Ehd2 |
EH-domain containing 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of EHD2 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:76,639,568...76,658,747
Ensembl chr 1:76,637,482...76,658,783
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F11 |
coagulation factor XI |
multiple interactions |
ISO |
[F11 protein co-treated with Calcium Chloride] results in increased activity of F9 protein |
CTD |
PMID:6604052 |
|
NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein; aspalathin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein]; nothofagin inhibits the reaction [[F5 protein co-treated with F10 protein co-treated with Calcium Chloride] results in increased metabolism of F2 protein] |
CTD |
PMID:25325928 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
F9 |
coagulation factor IX |
multiple interactions |
ISO |
[F11 protein co-treated with Calcium Chloride] results in increased activity of F9 protein |
CTD |
PMID:6604052 |
|
NCBI chr X:138,352,334...138,396,835
Ensembl chr X:138,352,298...138,396,835
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Calcium Chloride results in increased expression of FYN protein |
CTD |
PMID:25824407 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Git1 |
GIT ArfGAP 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of GIT1 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373
|
|
G |
Gnrh1 |
gonadotropin releasing hormone 1 |
multiple interactions |
EXP |
[manganese chloride co-treated with Calcium Chloride] results in increased secretion of GNRH1 protein |
CTD |
PMID:18603625 |
|
NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581 Ensembl chr15:41,972,905...41,973,581
|
|
G |
Gpr89b |
G protein-coupled receptor 89B |
increases expression |
ISO |
Calcium Chloride results in increased expression of GPR89B protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:184,408,136...184,445,560
Ensembl chr 2:184,401,438...184,445,584
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of GPX1 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of GPX1 mRNA] |
CTD |
PMID:21530968 PMID:24337353 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions increases expression |
ISO |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of GPX3 mRNA]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of GPX3 mRNA] |
CTD |
PMID:21530968 PMID:24337353 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21443188 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of HTRA1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of ICAM1 mRNA resveratrol inhibits the reaction [Calcium Chloride results in increased expression of ICAM1 mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ift27 |
intraflagellar transport 27 |
increases expression |
ISO |
Calcium Chloride results in increased expression of IFT27 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:109,738,622...109,754,416
Ensembl chr 7:109,738,622...109,754,416
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
ISO EXP |
Calcium Chloride results in increased expression of IL1B protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of IL1B protein] |
CTD |
PMID:22728078 PMID:36731150 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases activity |
ISO |
Calcium Chloride results in increased activity of KLK8 protein |
CTD |
PMID:16800733 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of LASP1 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lrrfip1 |
LRR binding FLII interacting protein 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of LRRFIP1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
EXP |
Calcium Chloride results in increased phosphorylation of MAPK1 protein [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:21215118 PMID:33621091 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression multiple interactions increases phosphorylation |
ISO EXP |
Calcium Chloride results in increased expression of MAPK3 protein [4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of MAPK3 protein] Calcium Chloride results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:21215118 PMID:25824407 PMID:33621091 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
increases expression increases activity multiple interactions |
EXP ISO |
Calcium Chloride results in increased expression of MMP2 mRNA; Calcium Chloride results in increased expression of MMP2 protein Calcium Chloride results in increased activity of MMP2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of MMP2 protein]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP2 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP2 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased activity of MMP2 protein] Calcium Chloride inhibits the reaction [2,3-dihydroxybenzoic acid results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [Deferoxamine results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [Ferrichrome results in decreased activity of MMP2 protein]; Calcium Chloride inhibits the reaction [rhodotorulic acid results in decreased activity of MMP2 protein] |
CTD |
PMID:10086886 PMID:16159824 PMID:20621845 PMID:21530968 PMID:22728078 PMID:24337353 More...
|
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression increases activity multiple interactions |
EXP ISO |
Calcium Chloride results in increased expression of MMP9 mRNA; Calcium Chloride results in increased expression of MMP9 protein Calcium Chloride results in increased activity of MMP9 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of MMP9 protein]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP9 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of MMP9 protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased activity of MMP9 protein] |
CTD |
PMID:20621845 PMID:21530968 PMID:22728078 PMID:24337353 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC protein] |
CTD |
PMID:12189186 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of NCF1 mRNA; Calcium Chloride results in increased expression of NCF1 protein Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NCF1 mRNA]; Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NCF1 protein] |
CTD |
PMID:24337353 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
Calcium Chloride promotes the reaction [NOS1 protein results in increased reduction of Trinitrotoluene] |
CTD |
PMID:15223068 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of NOS2 mRNA Quercetin inhibits the reaction [Calcium Chloride results in increased expression of NOS2 mRNA] |
CTD |
PMID:24337353 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nt5c |
5', 3'-nucleotidase, cytosolic |
increases expression |
ISO |
Calcium Chloride results in increased expression of NT5C protein |
CTD |
PMID:25824407 |
|
NCBI chr10:100,739,591...100,742,276
Ensembl chr10:100,739,588...100,741,954
|
|
G |
Nxn |
nucleoredoxin |
increases expression |
ISO |
Calcium Chloride results in increased expression of NXN protein |
CTD |
PMID:25824407 |
|
NCBI chr10:61,109,322...61,247,578
Ensembl chr10:61,110,020...61,248,251
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [PON1 protein results in increased hydrolysis of Paraoxon] |
CTD |
PMID:16052486 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Postn |
periostin |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of POSTN protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Ppid |
peptidylprolyl isomerase D |
increases expression |
ISO |
Calcium Chloride results in increased expression of PPID mRNA; Calcium Chloride results in increased expression of PPID protein |
CTD |
PMID:18614807 |
|
NCBI chr 2:164,727,803...164,740,168
Ensembl chr 2:164,727,779...164,740,221
|
|
G |
Psen2 |
presenilin 2 |
increases expression |
ISO |
Calcium Chloride results in increased expression of PSEN2 protein |
CTD |
PMID:25824407 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of RAD50 protein |
CTD |
PMID:25824407 |
|
NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression |
ISO |
Calcium Chloride results in increased expression of RECK protein |
CTD |
PMID:25824407 |
|
NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
multiple interactions |
ISO |
[Calcium Chloride co-treated with cuprous chloride] binds to and affects the folding of S100A13 protein; Calcium Chloride binds to and affects the folding of S100A13 protein |
CTD |
PMID:16766622 |
|
NCBI chr 2:175,999,439...176,005,933
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
Calcium Chloride results in increased expression of S100A8 mRNA; Calcium Chloride results in increased expression of S100A8 protein |
CTD |
PMID:17214633 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Calcium Chloride results in increased expression of S100A9 mRNA; Calcium Chloride results in increased expression of S100A9 protein |
CTD |
PMID:17214633 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Shc1 |
SHC adaptor protein 1 |
increases expression |
ISO |
Calcium Chloride results in increased expression of SHC1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases activity multiple interactions |
ISO |
Calcium Chloride results in increased activity of SOD2 protein Quercetin inhibits the reaction [Calcium Chloride results in increased activity of SOD2 protein] |
CTD |
PMID:24337353 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of STAT6 protein |
CTD |
PMID:25824407 |
|
NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495
|
|
G |
Syn1 |
synapsin I |
multiple interactions |
EXP |
[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein; typhaneoside inhibits the reaction [[4-Aminopyridine co-treated with Calcium Chloride] results in increased phosphorylation of SYN1 protein] |
CTD |
PMID:33621091 |
|
NCBI chr X:1,172,208...1,227,400
Ensembl chr X:1,172,208...1,227,396
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
Calcium Chloride results in decreased expression of TGFB1 protein |
CTD |
PMID:25824407 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression multiple interactions |
ISO |
Calcium Chloride results in decreased expression of TIMP1 mRNA Quercetin inhibits the reaction [Calcium Chloride results in decreased expression of TIMP1 mRNA] |
CTD |
PMID:22728078 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
Quercetin inhibits the reaction [Calcium Chloride results in increased expression of TNF protein]; resveratrol inhibits the reaction [Calcium Chloride results in increased expression of TNF mRNA] cordycepin inhibits the reaction [Calcium Chloride results in increased expression of TNF protein] Calcium Chloride inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein] Calcium Chloride results in increased expression of TNF mRNA; Calcium Chloride results in increased expression of TNF protein |
CTD |
PMID:21530968 PMID:22728078 PMID:36416909 PMID:36731150 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
Calcium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein]; Calcium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases activity |
ISO EXP |
Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]; Ionomycin promotes the reaction [Calcium Chloride inhibits the reaction [resiniferatoxin affects the reaction [[Sodium Chloride co-treated with benzamil] results in increased activity of TRPV1 protein]]] Ionomycin inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [Calcium Chloride results in increased activity of TRPV1 protein]; resiniferatoxin promotes the reaction [Calcium Chloride results in increased activity of TRPV1 protein] |
CTD |
PMID:19553475 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Ube3b |
ubiquitin protein ligase E3B |
multiple interactions |
ISO |
Calcium Chloride inhibits the reaction [CALM3 protein binds to and results in decreased activity of UBE3B protein] |
CTD |
PMID:28003368 |
|
NCBI chr12:42,183,756...42,230,094
Ensembl chr12:42,183,760...42,230,094
|
|
G |
Uqcrfs1 |
ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
decreases phosphorylation multiple interactions |
EXP |
Calcium Chloride results in decreased phosphorylation of UQCRFS1 protein [oxophenylarsine co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein; [tert-Butylhydroperoxide co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein; Cyclosporine inhibits the reaction [[oxophenylarsine co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein]; Cyclosporine inhibits the reaction [[tert-Butylhydroperoxide co-treated with Calcium Chloride] results in decreased phosphorylation of UQCRFS1 protein] |
CTD |
PMID:16023995 |
|
NCBI chr17:33,977,908...33,982,478
Ensembl chr17:33,977,921...33,982,479
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
Calcium Chloride results in increased expression of VEGFA mRNA resveratrol inhibits the reaction [Calcium Chloride results in increased expression of VEGFA mRNA] |
CTD |
PMID:21530968 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Calcium Hydroxide results in increased expression of ALPL mRNA |
CTD |
PMID:22083529 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Calcium Hydroxide results in increased expression of COL1A1 mRNA |
CTD |
PMID:22083529 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Calcium Hydroxide results in increased expression of ESR1 mRNA |
CTD |
PMID:22083529 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Polg |
DNA polymerase gamma, catalytic subunit |
affects expression |
ISO |
Calcium Hydroxide affects the expression of POLG mRNA |
CTD |
PMID:30615914 |
|
NCBI chr 1:133,382,764...133,399,578
Ensembl chr 1:133,382,766...133,398,567
|
|
G |
Polg2 |
DNA polymerase gamma 2, accessory subunit |
affects expression |
ISO |
Calcium Hydroxide affects the expression of POLG2 mRNA |
CTD |
PMID:30615914 |
|
NCBI chr10:91,712,586...91,723,008
Ensembl chr10:91,712,586...91,723,008
|
|
G |
Tfam |
transcription factor A, mitochondrial |
affects expression |
ISO |
Calcium Hydroxide affects the expression of TFAM mRNA |
CTD |
PMID:30615914 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases expression |
ISO |
Calcium Hydroxide results in increased expression of TRPV1 mRNA |
CTD |
PMID:22083529 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
decreases activity |
EXP |
Calcium ion decreases activity of purified Hmbs protein |
RGD |
PMID:6732900 |
RGD:25394584 |
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased expression of BAX protein] |
CTD |
PMID:34333021 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in decreased expression of BCL2 protein] |
CTD |
PMID:34333021 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO |
SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased cleavage of CASP3 protein] |
CTD |
PMID:34333021 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CAT protein] |
CTD |
PMID:37454925 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
EXP |
Calcium Oxalate results in decreased expression of CCL2 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CCL2 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CCL2 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of CD44 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CD44 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions increases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in increased expression of NOX2 protein] |
CTD |
PMID:37454925 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp2c7 |
cytochrome P450, family 2, subfamily c, polypeptide 7 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CYP2C9 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of CYP2C9 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
|
|
G |
Hdac1 |
histone deacetylase 1 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC1 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC1 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC2 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC2 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac3 |
histone deacetylase 3 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC3 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC3 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac8 |
histone deacetylase 8 |
multiple interactions |
EXP |
[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC8 mRNA; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of HDAC8 mRNA] |
CTD |
PMID:37414240 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
phenyl-N-tert-butylnitrone inhibits the reaction [Calcium Oxalate results in increased expression of HMOX1 protein] |
CTD |
PMID:34333021 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases expression multiple interactions |
EXP |
Calcium Oxalate results in increased expression of ITPR1 protein Losartan inhibits the reaction [Calcium Oxalate results in increased expression of ITPR1 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions increases expression |
EXP |
Losartan inhibits the reaction [Calcium Oxalate results in increased expression of ITPR2 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Itpr3 |
inositol 1,4,5-trisphosphate receptor, type 3 |
increases expression |
EXP |
Calcium Oxalate results in increased expression of ITPR3 protein |
CTD |
PMID:37454925 |
|
NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression multiple interactions |
EXP |
Calcium Oxalate results in increased expression of NOX4 protein 2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in increased expression of NOX4 protein] |
CTD |
PMID:37454925 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
phenyl-N-tert-butylnitrone inhibits the reaction [Calcium Oxalate results in decreased expression of SIRT1 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in decreased expression of BCL2 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased cleavage of CASP3 protein]; SIRT1 protein inhibits the reaction [Calcium Oxalate results in increased expression of BAX protein] |
CTD |
PMID:34333021 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of SOD1 protein] |
CTD |
PMID:37454925 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions decreases expression |
EXP |
2-aminoethyl diphenylborinate inhibits the reaction [Calcium Oxalate results in decreased expression of SPP1 protein]; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 mRNA; [Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 protein; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 mRNA]; Butyric Acid inhibits the reaction [[Ethylene Glycol co-treated with Calcium Oxalate] results in increased expression of SPP1 protein] |
CTD |
PMID:37414240 PMID:37454925 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
calcium phosphate results in increased expression of CXCL10 protein |
CTD |
PMID:14600836 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
calcium phosphate results in increased expression of CXCL12 protein |
CTD |
PMID:14600836 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
Calcium deficiency inhibits the reaction [ABCB11 protein results in increased export of Taurocholic Acid] |
CTD |
PMID:25862123 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
Calcium deficiency inhibits the reaction [ABCB1 protein results in increased export of Xanthenes]; Calcium inhibits the reaction [Magnesium results in increased activity of ABCB1 protein] |
CTD |
PMID:2900677 PMID:25862123 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
Calcium deficiency inhibits the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] |
CTD |
PMID:25862123 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Aco2 |
aconitase 2 |
increases activity multiple interactions |
ISO |
Calcium results in increased activity of ACO2 protein [Calcium results in increased activity of ACO2 protein] which results in increased reduction of thiazolyl blue; [Nicardipine results in decreased uptake of Calcium] which results in decreased activity of ACO2 protein |
CTD |
PMID:12548706 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Actb |
actin, beta |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of ACTB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Adcy5 |
adenylate cyclase 5 |
decreases activity increases response to substance |
ISO |
Calcium results in decreased activity of ADCY5 protein ADCY5 protein results in increased susceptibility to Calcium |
CTD |
PMID:12065575 PMID:12869393 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adcy9 |
adenylate cyclase 9 |
multiple interactions |
ISO |
Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]; Tacrolimus inhibits the reaction [Calcium inhibits the reaction [Miconazole results in increased activity of ADCY9 protein]] |
CTD |
PMID:30607468 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases abundance affects abundance multiple interactions |
EXP |
ADCYAP1 protein results in increased abundance of Calcium ADCYAP1 protein affects the abundance of Calcium Calcium affects the reaction [ADCYAP1 protein results in increased expression of SELENOT mRNA]; SELENOT protein affects the reaction [ADCYAP1 protein results in increased abundance of Calcium] |
CTD |
PMID:18198219 PMID:21039959 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adgrl1 |
adhesion G protein-coupled receptor L1 |
multiple interactions |
EXP |
[alpha-latrotoxin binds to ADGRL1 protein] which results in increased uptake of Calcium; [black widow spider venom binds to ADGRL1 protein] which results in increased uptake of Calcium |
CTD |
PMID:10026162 |
|
NCBI chr19:24,202,405...24,244,137
Ensembl chr19:24,204,360...24,244,139
|
|
G |
Adgrl2 |
adhesion G protein-coupled receptor L2 |
multiple interactions |
EXP |
[alpha-latrotoxin binds to ADGRL2 protein] which results in increased uptake of Calcium; [black widow spider venom binds to ADGRL2 protein] which results in increased uptake of Calcium |
CTD |
PMID:10026162 |
|
NCBI chr 2:237,696,055...238,327,141
Ensembl chr 2:237,696,056...238,327,141
|
|
G |
Adm |
adrenomedullin |
decreases expression |
ISO |
Calcium results in decreased expression of ADM mRNA |
CTD |
PMID:20682585 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions affects transport |
EXP ISO |
[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; [Phenylephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of EIF4EBP1 protein]; Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of MTOR protein]; Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of RPS6KB1 protein] 5-methylurapidil inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; [A 61603 results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Norepinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Oxymetazoline binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium] ADRA1A protein affects the transport of Calcium |
CTD |
PMID:12935885 PMID:15306222 PMID:15639650 PMID:15672411 PMID:16498073 PMID:20030735 More...
|
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Norepinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium] |
CTD |
PMID:15306222 PMID:16498073 PMID:20030735 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Norepinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Phentolamine inhibits the reaction [[Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium] |
CTD |
PMID:15306222 PMID:20030735 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; [Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium |
CTD |
PMID:20030735 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adra2b |
adrenoceptor alpha 2B |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; [Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; [Oxymetazoline binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; [xylometazoline binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium |
CTD |
PMID:20030735 |
|
NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
multiple interactions |
ISO |
[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; [Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium |
CTD |
PMID:20030735 |
|
NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
EXP ISO |
[Terbutaline binds to and results in increased activity of ADRB2 protein] which affects the abundance of Calcium [Benzo(a)pyrene binds to ADRB2 protein] which results in increased transport of Calcium; ADRB2 protein promotes the reaction [Benzo(a)pyrene results in increased transport of Calcium] |
CTD |
PMID:10372813 PMID:22167199 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions |
EXP |
Calcium affects the reaction [PICK1 protein binds to AGO2 protein]; Calcium deficiency inhibits the reaction [Excitatory Amino Acid Agonists inhibits the reaction [PICK1 protein binds to AGO2 protein]] |
CTD |
PMID:28404816 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agt |
angiotensinogen |
increases uptake affects localization multiple interactions increases abundance |
ISO EXP |
AGT protein results in increased uptake of Calcium AGT protein affects the localization of Calcium 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [AGT protein affects the localization of Calcium]; bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium]; Heparin inhibits the reaction [AGT protein affects the localization of Calcium]; Losartan inhibits the reaction [AGT protein affects the localization of Calcium]; Saralasin inhibits the reaction [AGT protein affects the localization of Calcium]; Sirolimus inhibits the reaction [AGT protein affects the localization of Calcium]; xestospongin C inhibits the reaction [AGT protein affects the localization of Calcium] [AGT protein results in increased abundance of Calcium] which results in increased abundance of Reactive Oxygen Species Calcium deficiency inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Calcium deficiency inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] benidipine inhibits the reaction [AGT protein results in increased uptake of Calcium]; Mibefradil inhibits the reaction [AGT protein results in increased uptake of Calcium] |
CTD |
PMID:10660688 PMID:18331727 PMID:18854758 PMID:21613610 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
affects expression |
EXP |
Calcium affects the expression of AGTR1A mRNA |
CTD |
PMID:15913539 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr1b |
angiotensin II receptor, type 1b |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of AGTR1B mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 2:102,844,969...102,920,232
Ensembl chr 2:102,844,969...102,920,232
|
|
G |
Akap1 |
A-kinase anchoring protein 1 |
affects expression |
EXP |
Calcium affects the expression of AKAP1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:73,621,021...73,654,123
Ensembl chr10:73,621,883...73,653,896
|
|
G |
Akap11 |
A-kinase anchoring protein 11 |
affects expression |
EXP |
Calcium affects the expression of AKAP11 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr15:53,911,635...53,956,138
Ensembl chr15:53,911,657...53,941,605
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects abundance affects expression multiple interactions affects response to substance |
ISO EXP |
AKT1 protein affects the abundance of Calcium Calcium affects the expression of AKT1 mRNA [Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein; Calcium affects the reaction [P2RY1 protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; PX-866 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; STO 609 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein]; W 7 inhibits the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] AKT1 protein affects the susceptibility to Calcium |
CTD |
PMID:15913539 PMID:16094411 PMID:16236484 PMID:28634229 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
ALDH2 protein inhibits the reaction [Ethanol affects the abundance of Calcium] Calcium affects the reaction [ALDH2 gene SNP affects the abundance of Lead] |
CTD |
PMID:17590987 PMID:28212632 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Alg2 |
ALG2, alpha-1,3/1,6-mannosyltransferase |
affects binding |
ISO |
Calcium binds to ALG2 protein |
CTD |
PMID:18997320 |
|
NCBI chr 5:61,768,738...61,773,297
Ensembl chr 5:61,768,740...61,773,297
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
Calcium promotes the reaction [L 708714 binds to ALOX5 protein] |
CTD |
PMID:7577949 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpp |
alkaline phosphatase, placental |
affects binding |
ISO |
Calcium binds to ALPP protein |
CTD |
PMID:16815919 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Ano1 |
anoctamin 1 |
increases activity multiple interactions |
ISO |
Calcium results in increased activity of ANO1 protein 9-phenanthrol inhibits the reaction [Calcium results in increased activity of ANO1 protein] |
CTD |
PMID:25573456 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Anxa1 |
annexin A1 |
affects activity |
EXP |
Calcium affects the activity of ANXA1 protein |
CTD |
PMID:20655937 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions |
ISO |
Calcium binds to and results in increased activity of ANXA5 protein; Calcium promotes the reaction [Phosphatidylserines binds to ANXA5 protein] |
CTD |
PMID:11578147 PMID:16076491 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
affects binding |
ISO |
AOC1 protein binds to Calcium |
CTD |
PMID:12072962 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Apoe |
apolipoprotein E |
affects abundance affects expression |
ISO EXP |
APOE protein affects the abundance of Calcium Calcium affects the expression of APOE mRNA |
CTD |
PMID:15913539 PMID:17899169 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apom |
apolipoprotein M |
affects expression |
EXP |
Calcium affects the expression of APOM mRNA |
CTD |
PMID:15913539 |
|
NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases uptake affects abundance |
ISO EXP |
2,4-Dinitrophenol affects the reaction [APP protein affects the abundance of Calcium]; 3-nitrophenol affects the reaction [APP protein affects the abundance of Calcium]; 4-anisidine affects the reaction [APP protein affects the abundance of Calcium] APP protein modified form results in increased uptake of Calcium; APP protein results in increased uptake of Calcium Calcium deficiency inhibits the reaction [APP protein modified form results in increased uptake of Calcium]; EDN3 protein inhibits the reaction [APP protein results in increased uptake of Calcium]; Flurbiprofen inhibits the reaction [APP protein results in increased uptake of Calcium]; Ibuprofen inhibits the reaction [APP protein results in increased uptake of Calcium]; Indomethacin inhibits the reaction [APP protein results in increased uptake of Calcium]; Nimodipine inhibits the reaction [APP protein results in increased uptake of Calcium]; Ruthenium Red inhibits the reaction [APP protein modified form results in increased uptake of Calcium]; Salicylates inhibits the reaction [APP protein results in increased uptake of Calcium]; sulindac sulfide inhibits the reaction [APP protein results in increased uptake of Calcium] |
CTD |
PMID:12383957 PMID:18648507 PMID:18949129 PMID:24457011 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO EXP |
ARRB2 protein affects the abundance of and affects the localization of Calcium ARRB2 promotes the reaction [carvedilol results in increased uptake of Calcium] |
CTD |
PMID:16210646 PMID:21078978 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of ATP1A1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
EXP |
Calcium affects the reaction [Ouabain results in increased expression of ATP1B1 mRNA] |
CTD |
PMID:11204457 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
affects transport multiple interactions |
EXP ISO |
ATP2A1 protein affects the transport of Calcium [Phenols results in decreased activity of ATP2A1 protein] which results in decreased transport of Calcium |
CTD |
PMID:11230109 PMID:18773882 |
|
NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
affects abundance multiple interactions affects transport affects uptake affects export |
ISO EXP |
ATP2A2 protein affects the abundance of Calcium Calcium promotes the reaction [Clioquinol results in decreased expression of ATP2A2 mRNA]; Calcium promotes the reaction [Clioquinol results in decreased expression of ATP2A2 protein] ATP2A2 protein affects the transport of Calcium [[Phenylephrine results in increased activity of SLC9A1 protein] which results in increased transport of Calcium] which results in increased expression of ATP2A2 protein; [Phenylephrine results in decreased expression of ATP2A2 protein] which results in decreased transport of Calcium; [Thapsigargin results in decreased activity of ATP2A2 protein] which results in decreased transport of Calcium Calcium promotes the reaction [Clioquinol results in decreased expression of ATP2A2 mRNA]; Calcium promotes the reaction [Clioquinol results in decreased expression of ATP2A2 protein]; PPP3R1 gene mutant form inhibits the reaction [ATP2A2 protein affects the transport of Calcium] ATP2A2 protein alternative form affects the uptake of Calcium ATP2A2 protein alternative form affects the export of Calcium |
CTD |
PMID:11679415 PMID:16236312 PMID:17287366 PMID:19244478 PMID:19328205 PMID:19700627 PMID:33511738 More...
|
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions increases export |
ISO |
caloxin 1b1 inhibits the reaction [ATP2B1 protein results in increased export of Calcium] |
CTD |
PMID:16452157 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
increases export multiple interactions |
ISO |
ATP2B4 protein results in increased export of Calcium caloxin 1b1 inhibits the reaction [ATP2B4 protein results in increased export of Calcium] |
CTD |
PMID:16452157 |
|
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
EXP |
Calcium inhibits the reaction [ATP8B1 protein results in increased transport of Phosphatidylserines] |
CTD |
PMID:11584374 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases uptake increases abundance |
EXP |
1-Butanol inhibits the reaction [AVP protein results in increased abundance of Calcium]; 2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid inhibits the reaction [AVP protein results in increased abundance of Calcium]; [[[AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium] which results in increased activity of CHRM1 protein] which results in decreased susceptibility to Scopolamine; [[AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium] which results in increased activity of CHRM1 protein; [AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium; [AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium; AVP protein results in increased import of and results in increased abundance of Calcium; Carvedilol inhibits the reaction [AVP protein results in increased import of and results in increased abundance of Calcium]; Chromium affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]; Chromium affects the reaction [INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; chromium tripicolinate affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]; chromium tripicolinate affects the reaction [INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]; INS1 protein affects the reaction [Chromium affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; INS1 protein affects the reaction [chromium tripicolinate affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; Nicardipine inhibits the reaction [AVP protein results in increased import of and results in increased abundance of Calcium]; Nifedipine inhibits the reaction [AVP protein results in increased import of and results in increased abundance of Calcium] |
CTD |
PMID:9446840 PMID:11356622 PMID:11553362 PMID:14711191 PMID:21039959 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
EXP |
[[[AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium] which results in increased activity of CHRM1 protein] which results in decreased susceptibility to Scopolamine; [[AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium] which results in increased activity of CHRM1 protein; [AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium; [NC 1900 results in increased activity of AVPR1A protein] which results in increased abundance of Calcium; Carbachol promotes the reaction [[NC 1900 results in increased activity of AVPR1A protein] which results in increased abundance of Calcium]; Nicardipine inhibits the reaction [[NC 1900 results in increased activity of AVPR1A protein] which results in increased abundance of Calcium]; Nicardipine inhibits the reaction [Carbachol promotes the reaction [[NC 1900 results in increased activity of AVPR1A protein] which results in increased abundance of Calcium]] |
CTD |
PMID:11553362 PMID:12646291 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
affects expression |
EXP |
Calcium affects the expression of AVPR2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989
|
|
G |
Axin1 |
axin 1 |
affects expression |
EXP |
Calcium affects the expression of AXIN1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:15,163,477...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
Bad |
BCL2-associated agonist of cell death |
affects expression |
EXP |
Calcium affects the expression of BAD mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
ISO EXP |
2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [[kallidin, des-Arg(10)- results in increased activity of BDKRB1 protein] which results in increased abundance of Calcium]; [kallidin, des-Arg(10)- results in increased activity of BDKRB1 protein] which results in increased abundance of Calcium; Sodium affects the reaction [[kallidin, des-Arg(10)- results in increased activity of BDKRB1 protein] which results in increased abundance of Calcium] [kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB1 protein] which results in increased abundance of Calcium; bradykinin, Lys-Leu(8)-desArg(9)- inhibits the reaction [[kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB1 protein] which results in increased abundance of Calcium]; Indomethacin inhibits the reaction [[kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:15703175 PMID:22554775 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
BDKRB2 protein affects the reaction [KNG1 protein affects the abundance of Calcium] BDKRB2 protein affects the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]] |
CTD |
PMID:16473424 PMID:18054572 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases transport |
ISO |
[Cadmium results in decreased transport of Calcium] inhibits the reaction [Oxygen deficiency results in increased secretion of BDNF protein]; Calcium affects the reaction [Oxygen deficiency results in increased secretion of BDNF protein] BDNF protein results in increased transport of Calcium 3,5-dichloro-N-(1-(2,2-dimethyltetrahydropyran-4-ylmethyl)-4-fluoropiperidin-4-ylmethyl)benzamide inhibits the reaction [Oxygen deficiency promotes the reaction [BDNF protein results in increased transport of Calcium]]; 3,5-dichloro-N-(1-(2,2-dimethyltetrahydropyran-4-ylmethyl)-4-fluoropiperidin-4-ylmethyl)benzamide promotes the reaction [Tetrodotoxin inhibits the reaction [Oxygen deficiency promotes the reaction [BDNF protein results in increased transport of Calcium]]]; Oxygen deficiency promotes the reaction [BDNF protein results in increased transport of Calcium]; Tetrodotoxin inhibits the reaction [Oxygen deficiency promotes the reaction [BDNF protein results in increased transport of Calcium]] |
CTD |
PMID:16553631 PMID:26095976 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Best1 |
bestrophin 1 |
increases activity multiple interactions |
ISO |
Calcium results in increased activity of BEST1 protein [PAR-1-activating peptide results in increased abundance of Calcium] which results in increased activity of BEST1 protein |
CTD |
PMID:19828819 PMID:25573456 |
|
NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
affects expression multiple interactions |
EXP ISO |
Calcium affects the expression of BMP4 mRNA [Calcium binds to MGP protein] which binds to and results in decreased activity of BMP4 protein; [Edetic Acid inhibits the reaction [Calcium binds to MGP protein]] inhibits the reaction [MGP protein binds to BMP4 protein] |
CTD |
PMID:15913539 PMID:18369157 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Btk |
Bruton tyrosine kinase |
affects transport |
ISO |
BTK protein affects the transport of Calcium |
CTD |
PMID:12848851 |
|
NCBI chr X:97,722,796...97,762,315
Ensembl chr X:97,722,802...97,761,853
|
|
G |
C5 |
complement C5 |
multiple interactions |
ISO |
[C5 protein results in increased activity of and results in increased localization of SPHK1 protein] which results in increased abundance of Calcium; resveratrol inhibits the reaction [[C5 protein results in increased activity of and results in increased localization of SPHK1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:19284563 PMID:19346296 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
increases transport multiple interactions |
EXP |
CACNA1A protein results in increased transport of Calcium Allethrins inhibits the reaction [CACNA1A protein results in increased transport of Calcium] |
CTD |
PMID:14634047 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cacna1b |
calcium voltage-gated channel subunit alpha1 B |
multiple interactions decreases uptake increases transport |
EXP |
decamethrin inhibits the reaction [CACNA1B protein results in increased transport of Calcium]; decamethrin promotes the reaction [CACNA1B gene mutant form results in increased transport of Calcium] CACNA1B protein alternative form results in decreased uptake of Calcium |
CTD |
PMID:18383452 PMID:22891239 |
|
NCBI chr 3:7,380,892...7,546,104
Ensembl chr 3:7,380,922...7,546,091
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
increases transport multiple interactions |
ISO EXP |
CACNA1C protein results in increased transport of Calcium [CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium; [CACNA2D4 protein binds to CACNA1C protein binds to CACNB3 protein] which results in increased transport of Calcium; CACNA2D4 protein promotes the reaction [[CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium] Allethrins inhibits the reaction [CACNA1C protein results in increased transport of Calcium] |
CTD |
PMID:12181424 PMID:14634047 PMID:15299022 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1d |
calcium voltage-gated channel subunit alpha1 D |
affects transport multiple interactions |
ISO EXP |
CACNA1D protein affects the transport of Calcium CACNA2D2 gene mutant form inhibits the reaction [CACNA1D protein results in increased import of Calcium] [CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium; [CACNA1D protein results in increased uptake of Calcium] which affects the localization of SLC2A2 protein; [CACNA1D protein results in increased uptake of Calcium] which results in increased phosphorylation of MYL9 protein; CACNA2D1 protein promotes the reaction [[CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium]; gabapentin affects the reaction [[CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium]; SLC5A1 protein affects the reaction [CACNA1D protein results in increased uptake of Calcium] |
CTD |
PMID:15357422 PMID:17272349 PMID:19796812 PMID:27798183 |
|
NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
increases transport multiple interactions |
ISO EXP |
CACNA1E protein results in increased transport of Calcium Calcium inhibits the reaction [Methacholine Chloride affects the reaction [CACNA1E protein results in increased transport of Barium]] Cadmium inhibits the reaction [CACNA1E protein results in increased transport of Calcium]; Nickel inhibits the reaction [CACNA1E protein results in increased transport of Calcium] |
CTD |
PMID:10627594 PMID:10669483 PMID:12663092 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
increases transport |
ISO |
CACNA1F protein results in increased transport of Calcium |
CTD |
PMID:14744918 |
|
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
increases transport multiple interactions |
ISO EXP |
CACNA1G protein results in increased transport of Calcium Allethrins inhibits the reaction [CACNA1G protein results in increased transport of Calcium] CACNG2 protein affects the reaction [CACNA1G protein results in increased transport of Calcium]; CACNG4 protein affects the reaction [CACNA1G protein results in increased transport of Calcium]; CACNG5 protein affects the reaction [CACNA1G protein results in increased transport of Calcium] |
CTD |
PMID:10734232 PMID:11073957 PMID:14634047 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
increases transport multiple interactions |
ISO EXP |
CACNA1H protein results in increased transport of Calcium Amiloride inhibits the reaction [CACNA1H protein results in increased transport of Calcium]; Nickel inhibits the reaction [CACNA1H protein results in increased transport of Calcium] Amiloride inhibits the reaction [CACNA1H protein results in increased transport of Calcium]; Mibefradil inhibits the reaction [CACNA1H protein results in increased transport of Calcium]; Nickel inhibits the reaction [CACNA1H protein results in increased transport of Calcium] |
CTD |
PMID:9930755 PMID:11073957 PMID:11897840 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
increases transport |
EXP |
CACNA1I protein results in increased transport of Calcium |
CTD |
PMID:11073957 |
|
NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
multiple interactions increases transport |
ISO EXP |
[gabapentin results in decreased activity of CACNA2D1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]; CACNA2D1 protein affects the reaction [Potassium Chloride results in increased transport of Calcium] CACNA2D1 protein promotes the reaction [[CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium] CACNA2D1 protein results in increased transport of Calcium |
CTD |
PMID:15474003 PMID:17442347 PMID:17881535 PMID:19796812 |
|
NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
|
|
G |
Cacna2d2 |
calcium voltage-gated channel auxiliary subunit alpha2delta 2 |
affects transport multiple interactions |
ISO |
CACNA2D2 protein affects the transport of Calcium CACNA2D2 gene mutant form inhibits the reaction [CACNA1D protein results in increased import of Calcium] |
CTD |
PMID:14660671 PMID:27798183 |
|
NCBI chr 8:108,072,208...108,203,516
Ensembl chr 8:108,072,454...108,203,173
|
|
G |
Cacna2d4 |
calcium voltage-gated channel auxiliary subunit alpha2delta 4 |
multiple interactions |
ISO |
[CACNA2D4 protein binds to CACNA1C protein binds to CACNB3 protein] which results in increased transport of Calcium; CACNA2D4 protein promotes the reaction [[CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium] |
CTD |
PMID:12181424 |
|
NCBI chr 4:152,408,588...152,521,478
Ensembl chr 4:152,408,657...152,521,268
|
|
G |
Cacnb3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
multiple interactions |
ISO EXP |
[CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium; [CACNA2D4 protein binds to CACNA1C protein binds to CACNB3 protein] which results in increased transport of Calcium; CACNA2D4 protein promotes the reaction [[CACNA1C protein co-treated with CACNB3 protein] results in increased transport of Calcium] [CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium; CACNA2D1 protein promotes the reaction [[CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium]; gabapentin affects the reaction [[CACNA1D protein co-treated with CACNB3 protein] results in increased transport of Calcium] |
CTD |
PMID:12181424 PMID:19796812 |
|
NCBI chr 7:129,784,799...129,797,074
Ensembl chr 7:129,783,674...129,797,074
|
|
G |
Cacng2 |
calcium voltage-gated channel auxiliary subunit gamma 2 |
multiple interactions |
ISO |
CACNG2 protein affects the reaction [CACNA1G protein results in increased transport of Calcium] |
CTD |
PMID:10734232 |
|
NCBI chr 7:109,572,838...109,698,516
Ensembl chr 7:109,574,459...109,697,227
|
|
G |
Cacng4 |
calcium voltage-gated channel auxiliary subunit gamma 4 |
multiple interactions |
ISO |
CACNG4 protein affects the reaction [CACNA1G protein results in increased transport of Calcium] |
CTD |
PMID:10734232 |
|
NCBI chr10:92,683,778...92,745,842
Ensembl chr10:92,683,761...92,746,126
|
|
G |
Cacng5 |
calcium voltage-gated channel auxiliary subunit gamma 5 |
multiple interactions |
ISO |
CACNG5 protein affects the reaction [CACNA1G protein results in increased transport of Calcium] |
CTD |
PMID:10734232 |
|
NCBI chr10:92,827,441...92,869,632
Ensembl chr10:92,829,196...92,869,614
|
|
G |
Calb1 |
calbindin 1 |
affects expression |
EXP |
Calcium affects the expression of CALB1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions increases expression |
ISO EXP |
rimabotulinumtoxinB inhibits the reaction [[Capsaicin co-treated with Calcium] results in increased secretion of CALCA protein]; rimabotulinumtoxinB inhibits the reaction [[Potassium co-treated with Calcium] results in increased secretion of CALCA protein] Calcium promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA] Calcium results in increased expression of CALCA mRNA Calcium results in increased expression of CALCA protein [Capsaicin co-treated with Calcium] results in increased secretion of CALCA protein; [KNG1 protein alternative form co-treated with Calcium] results in increased secretion of CALCA protein; [Potassium co-treated with Calcium] results in increased secretion of CALCA protein; [Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]; botulinum toxin type D inhibits the reaction [[Capsaicin co-treated with Calcium] results in increased secretion of CALCA protein]; botulinum toxin type D inhibits the reaction [[Potassium co-treated with Calcium] results in increased secretion of CALCA protein]; Botulinum Toxins, Type A inhibits the reaction [[Potassium co-treated with Calcium] results in increased secretion of CALCA protein]; Calcium affects the reaction [Capsaicin inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]]; Calcium affects the reaction [Capsaicin inhibits the reaction [mustard oil results in increased secretion of CALCA protein]]; Calcium affects the reaction [mustard oil inhibits the reaction [Capsaicin results in increased secretion of CALCA protein]]; Calcium deficiency inhibits the reaction [safranal results in increased secretion of CALCA protein]; Calcium inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] |
CTD |
PMID:2470235 PMID:12574409 PMID:17590514 PMID:17666428 PMID:20682585 PMID:30636360 More...
|
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions affects binding |
EXP ISO |
[Calcium binds to CALM1 protein] promotes the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide]; [Calcium binds to CALM1 protein] which binds to and affects the folding of and results in increased activity of NOS1 protein; Calcium affects the reaction [CALM1 protein binds to and affects the activity of RYR1 protein]; Calcium affects the reaction [CALM1 protein modified form binds to and affects the activity of RYR1 protein]; Calcium binds to and affects the folding of CALM1 protein Calcium affects the folding of [CALM1 protein binds to RYR1 protein modified form]; Calcium affects the reaction [CALM1 protein binds to and affects the activity of RYR1 protein] |
CTD |
PMID:15381065 PMID:15628869 PMID:17098364 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calr |
calreticulin |
affects response to substance multiple interactions |
ISO |
CALR protein affects the susceptibility to Calcium CALR protein promotes the reaction [KNG1 protein modified form results in increased abundance of Calcium] |
CTD |
PMID:7961812 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
affects expression multiple interactions |
EXP ISO |
Calcium affects the expression of CAMK2D mRNA [Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein |
CTD |
PMID:15913539 PMID:33392831 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
multiple interactions |
ISO |
CAMKK2 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:28634229 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Capn1 |
calpain 1 |
multiple interactions increases cleavage increases activity |
ISO EXP |
[Caffeine co-treated with Alprazolam] promotes the reaction [Calcium results in increased activity of CAPN1 protein]; [Calcium co-treated with CAPN1 protein] results in increased degradation of TP73 protein modified form; [sodium arsenite results in increased abundance of Arsenic] promotes the reaction [[Calcium results in increased cleavage of CAPN1 protein] which results in increased degradation of CAPN1 protein] calpain inhibitor III inhibits the reaction [Calcium results in increased activity of CAPN1 protein] |
CTD |
PMID:19490937 PMID:21516125 PMID:21985864 PMID:31398423 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Car4 |
carbonic anhydrase 4 |
affects expression |
EXP |
Calcium affects the expression of CA4 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
[Calcium co-treated with Zinc] affects the reaction [monoisoamyl-2,3-dimercaptosuccinate affects the reaction [sodium arsenite results in increased expression of CASP3 mRNA]]; [Calcium co-treated with Zinc] affects the reaction [sodium arsenite results in increased expression of CASP3 mRNA]; Calcium affects the reaction [sodium arsenite results in increased expression of CASP3 mRNA] Calcium deficiency inhibits the reaction [Dasatinib results in increased activity of CASP3 protein]; Calcium deficiency inhibits the reaction [Ionomycin results in increased activity of CASP3 protein] |
CTD |
PMID:24184500 PMID:29803841 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
[Calcium co-treated with Zinc] affects the reaction [monoisoamyl-2,3-dimercaptosuccinate affects the reaction [sodium arsenite results in increased expression of CASP9 mRNA]]; Calcium affects the reaction [sodium arsenite results in increased expression of CASP9 mRNA] |
CTD |
PMID:24184500 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casr |
calcium-sensing receptor |
increases phosphorylation multiple interactions increases uptake increases activity affects expression decreases response to substance increases response to substance |
ISO EXP |
Calcium results in increased phosphorylation of CASR protein [Aluminum binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Calcium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Calcium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Magnesium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Neomycin binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; Calcium binds to and results in increased activity of CASR protein; Gadolinium inhibits the reaction [Calcium binds to and results in increased activity of CASR protein] CASR protein results in increased uptake of Calcium Calcium results in increased activity of CASR protein 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [CASR protein results in increased uptake of Calcium]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [CASR protein results in increased uptake of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; 2-aminoethoxydiphenyl borate inhibits the reaction [CASR protein results in increased uptake of Calcium]; [2-quinoxaline-carboxamide-N-adamantan-1-yl binds to and results in decreased activity of CASR protein] inhibits the reaction [Nickel results in increased abundance of Calcium]; [Calcium binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; [CASR protein mutant form results in increased susceptibility to Calcium] which results in increased abundance of Inositol 1,4,5-Trisphosphate; [Spermine binds to and results in increased activity of CASR protein] which results in increased uptake of Calcium; bisindolylmaleimide I inhibits the reaction [NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]]; Calcium Chloride promotes the reaction [Calcium results in increased phosphorylation of CASR protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of WNT5A protein]; CASR protein affects the reaction [Nickel results in increased abundance of Calcium]; CASR protein promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; chelerythrine inhibits the reaction [CASR protein results in increased uptake of Calcium]; Flufenamic Acid promotes the reaction [CASR protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; Lanthanum inhibits the reaction [CASR protein results in increased uptake of Calcium]; methyl-beta-cyclodextrin inhibits the reaction [CASR protein results in increased uptake of Calcium]; N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine affects the reaction [CASR gene mutant form results in increased susceptibility to Calcium]; N-(2-chlorophenylpropyl)-1-(3-methoxyphenyl)ethylamine promotes the reaction [CASR protein results in increased susceptibility to Calcium]; NPS R-467 promotes the reaction [Calcium results in increased phosphorylation of CASR protein]; Pertussis Toxin inhibits the reaction [CASR protein results in increased uptake of Calcium] Calcium affects the expression of CASR mRNA; Calcium affects the expression of CASR protein CASR protein mutant form results in decreased susceptibility to Calcium CASR gene mutant form results in increased susceptibility to Calcium; CASR protein mutant form results in increased susceptibility to Calcium |
CTD |
PMID:7874174 PMID:9011580 PMID:10231437 PMID:11071898 PMID:11089548 PMID:11701698 PMID:15788476 PMID:17041782 PMID:17376781 PMID:19781536 PMID:21562303 PMID:24658506 More...
|
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Cat |
catalase |
multiple interactions |
ISO EXP |
CAT protein inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; CAT protein inhibits the reaction [Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]] [Calcium co-treated with Zinc] affects the reaction [monoisoamyl-2,3-dimercaptosuccinate affects the reaction [sodium arsenite results in decreased activity of CAT protein]]; [Calcium co-treated with Zinc] affects the reaction [sodium arsenite results in decreased activity of CAT protein]; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CAT protein]; Calcium affects the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:21127073 PMID:22534743 PMID:24184500 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
affects transport |
ISO |
CAV1 protein affects the transport of Calcium |
CTD |
PMID:16428350 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav3 |
caveolin 3 |
multiple interactions |
ISO |
CAV3 protein affects the reaction [Potassium Chloride results in increased uptake of Calcium] |
CTD |
PMID:21294223 |
|
NCBI chr 4:145,582,168...145,598,142
Ensembl chr 4:145,582,060...145,598,137
|
|
G |
Cbfb |
core-binding factor subunit beta |
affects expression |
EXP |
Calcium affects the expression of CBFB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases uptake |
ISO |
CCL11 protein results in increased uptake of Calcium |
CTD |
PMID:10984371 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases uptake |
ISO |
CCL13 protein results in increased uptake of Calcium |
CTD |
PMID:10984371 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases abundance multiple interactions increases uptake |
ISO |
CCL2 protein results in increased abundance of Calcium montelukast inhibits the reaction [CCL2 protein results in increased abundance of Calcium]; Piperidines analog inhibits the reaction [CCL2 protein results in increased uptake of Calcium]; resveratrol inhibits the reaction [CCL2 protein affects the localization of Calcium] |
CTD |
PMID:10843593 PMID:10984371 PMID:16212921 PMID:16771778 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
resveratrol inhibits the reaction [CCL3 protein affects the localization of Calcium] |
CTD |
PMID:16212921 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases uptake |
ISO |
CCL5 protein results in increased uptake of Calcium |
CTD |
PMID:10984371 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases uptake multiple interactions |
ISO |
CCL7 protein results in increased uptake of Calcium Piperidines analog inhibits the reaction [CCL7 protein results in increased uptake of Calcium] |
CTD |
PMID:10843593 PMID:10984371 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccnd1 |
cyclin D1 |
affects expression increases expression |
EXP ISO |
Calcium affects the expression of CCND1 mRNA Calcium results in increased expression of CCND1 mRNA |
CTD |
PMID:15913539 PMID:24658506 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr10 |
C-C motif chemokine receptor 10 |
affects abundance |
ISO |
CCR10 protein affects the abundance of Calcium |
CTD |
PMID:12055238 |
|
NCBI chr10:86,108,551...86,110,988
Ensembl chr10:86,108,551...86,110,988
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
affects abundance |
ISO |
CCR4 protein affects the abundance of Calcium |
CTD |
PMID:12055238 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
affects abundance |
ISO |
CCR8 protein affects the abundance of Calcium |
CTD |
PMID:12055238 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G |
Ccr9 |
C-C motif chemokine receptor 9 |
affects abundance |
ISO |
CCR9 protein affects the abundance of Calcium |
CTD |
PMID:12055238 |
|
NCBI chr 8:123,396,157...123,410,199
Ensembl chr 8:123,395,813...123,413,969
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions increases abundance |
ISO |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 5-diisopropoxyphosphoryl-5-methyl-1-pyrroline-N-oxide inhibits the reaction [CD28 protein results in increased abundance of Calcium]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [CD28 protein results in increased abundance of Calcium] |
CTD |
PMID:14607919 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
CD38 gene mutant form inhibits the reaction [FASL protein affects the localization of Calcium]; CD38 protein inhibits the reaction [CD38 gene mutant form inhibits the reaction [FASL protein affects the localization of Calcium]] |
CTD |
PMID:20200208 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cdc42 |
cell division cycle 42 |
multiple interactions |
ISO |
Calcium promotes the reaction [PAFAH1B1 protein binds to IQGAP1 protein binds to CDC42 protein] |
CTD |
PMID:16369480 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc42bpb |
CDC42 binding protein kinase beta |
affects expression |
EXP |
Calcium affects the expression of CDC42BPB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 6:130,333,712...130,416,631
Ensembl chr 6:130,333,712...130,416,377
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
increases cleavage multiple interactions |
ISO |
Calcium results in increased cleavage of CDK5R1 protein calpeptin inhibits the reaction [Calcium results in increased cleavage of CDK5R1 protein] |
CTD |
PMID:18242949 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects expression |
EXP |
Calcium affects the expression of CEBPB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cerk |
ceramide kinase |
multiple interactions |
ISO |
Calcium affects the reaction [CERK protein results in increased phosphorylation of Ceramides] |
CTD |
PMID:16269826 |
|
NCBI chr 7:117,225,855...117,269,436
Ensembl chr 7:117,225,855...117,268,759
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
CFD protein affects the reaction [[cobra venom factor co-treated with Magnesium co-treated with Calcium] results in increased cleavage of CFB protein] |
CTD |
PMID:11724962 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
CFD protein affects the reaction [[cobra venom factor co-treated with Magnesium co-treated with Calcium] results in increased cleavage of CFB protein] |
CTD |
PMID:11724962 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cfl1 |
cofilin 1 |
multiple interactions |
ISO |
[Capsaicin results in decreased phosphorylation of and results in increased activity of CFL1 protein] which results in increased import of Calcium |
CTD |
PMID:17303079 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO EXP |
[Acetylcholine results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; [Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; [Pilocarpine results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; CHRM1 protein promotes the reaction [Methacholine Compounds results in increased abundance of Calcium] 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; 1-oleoyl-2-acetylglycerol promotes the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; [Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium; Atropine inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Flufenamic Acid inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Gadolinium inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Lanthanum inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Pirenzepine inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium]; Thapsigargin inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] [[[AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium] which results in increased activity of CHRM1 protein] which results in decreased susceptibility to Scopolamine; [[AVP binds to and results in increased activity of AVPR1A protein] which results in increased abundance of Calcium] which results in increased activity of CHRM1 protein |
CTD |
PMID:11527950 PMID:11553362 PMID:12456425 PMID:18316702 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
EXP |
[CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] |
CTD |
PMID:12754307 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO EXP |
[[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] co-treated with [PNU-282987 binds to and results in increased activity of CHRNA7 protein]] results in increased uptake of Calcium; [[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] which results in increased uptake of Calcium] inhibits the reaction [CHRNA7 protein results in decreased susceptibility to Okadaic Acid]; [Acetylcholine results in increased activity of CHRNA7 protein] which results in increased uptake of Calcium; [Bungarotoxins binds to and results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; [methyllycaconitine binds to and results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; [Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium; [PNU-282987 binds to and results in increased activity of CHRNA7 protein] which results in increased uptake of Calcium; Bungarotoxins inhibits the reaction [[[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] co-treated with [PNU-282987 binds to and results in increased activity of CHRNA7 protein]] results in increased uptake of Calcium]; Mecamylamine inhibits the reaction [[[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] co-treated with [PNU-282987 binds to and results in increased activity of CHRNA7 protein]] results in increased uptake of Calcium]; methyllycaconitine inhibits the reaction [[[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] co-treated with [PNU-282987 binds to and results in increased activity of CHRNA7 protein]] results in increased uptake of Calcium]; methyllycaconitine promotes the reaction [[Nicotine results in increased activity of CHRNA7 protein] which results in increased transport of Calcium] |
CTD |
PMID:17709503 PMID:21051662 PMID:21715663 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO EXP |
[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium; alpha-conotoxin MII inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium]; Calcium affects the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased susceptibility to Okadaic Acid]; Dihydro-beta-Erythroidine inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium]; Mecamylamine inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium] [CHRNA4 protein co-treated with CHRNB2 protein mutant form] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein co-treated with CHRNB2 protein] affects the reaction [Calcium results in increased susceptibility to Acetylcholine]; [CHRNA4 protein mutant form co-treated with CHRNB2 protein] inhibits the reaction [Calcium results in increased susceptibility to Acetylcholine] |
CTD |
PMID:12754307 PMID:21715663 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
affects expression |
EXP |
Calcium affects the expression of CITED2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Cln8 |
CLN8, transmembrane ER and ERGIC protein |
multiple interactions |
ISO |
CLN8 protein affects the reaction [[Ionomycin co-treated with Calcium] results in increased transport of D-Aspartic Acid]; CLN8 protein affects the reaction [[Potassium Chloride co-treated with Calcium] results in increased transport of D-Aspartic Acid] |
CTD |
PMID:22302580 |
|
NCBI chr16:74,749,662...74,759,553
Ensembl chr16:74,749,662...74,759,774
|
|
G |
Cnnm4 |
cyclin and CBS domain divalent metal cation transport mediator 4 |
affects expression |
EXP |
Calcium affects the expression of CNNM4 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 9:38,711,726...38,750,942
Ensembl chr 9:38,711,710...38,750,942
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] affects the reaction [Potassium Chloride results in increased transport of Calcium]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] affects the reaction [Potassium Chloride results in increased transport of Calcium]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium results in increased transport of Calcium]; Calcium affects the reaction [Potassium Chloride results in decreased expression of CNR1 mRNA]; Calcium affects the reaction [Potassium Chloride results in decreased expression of CNR1 protein]; CNR1 protein affects the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; CNR1 protein affects the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]]; Rimonabant inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Potassium Chloride results in increased transport of Calcium]] |
CTD |
PMID:12421626 PMID:14973253 PMID:16412482 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] |
CTD |
PMID:10617657 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
affects abundance |
ISO |
COL18A1 protein affects the abundance of Calcium |
CTD |
PMID:15296943 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
affects abundance |
ISO |
COL1A2 protein affects the abundance of Calcium |
CTD |
PMID:10913914 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cp |
ceruloplasmin |
affects binding multiple interactions |
ISO EXP |
Calcium binds to CP protein [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of CP protein] |
CTD |
PMID:17242517 PMID:22534743 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
affects expression multiple interactions |
EXP |
Calcium affects the expression of CREB1 mRNA [Estradiol results in increased import of Calcium] which results in increased activity of CREB1 protein; Calcium promotes the reaction [2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased phosphorylation of CREB1 protein]; Calcium promotes the reaction [Dopamine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:14622123 PMID:15802184 PMID:15913539 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
affects expression |
EXP |
Calcium affects the expression of CSNK1A1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
|
|
G |
Csnk1g3 |
casein kinase 1, gamma 3 |
affects expression |
EXP |
Calcium affects the expression of CSNK1G3 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr18:47,299,547...47,386,538
Ensembl chr18:47,299,579...47,386,535
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Calcium results in increased expression of CTNNB1 mRNA; Calcium results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of KRT1 protein]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN protein] |
CTD |
PMID:24658506 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
[CTSS protein results in increased cleavage of and results in decreased activity of CXCL10 protein] which results in decreased uptake of Calcium; [CTSS protein results in increased cleavage of and results in decreased activity of CXCL9 protein] which results in decreased uptake of Calcium; [CTSS protein results in increased cleavage of and results in increased activity of CXCL2 protein] which results in increased uptake of Calcium; [CTSS protein results in increased cleavage of and results in increased activity of CXCL5 protein] which results in increased uptake of Calcium |
CTD |
PMID:25833952 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases abundance multiple interactions |
EXP |
CXCL1 protein results in increased abundance of Calcium epigallocatechin gallate inhibits the reaction [CXCL1 protein results in increased abundance of Calcium] |
CTD |
PMID:9430702 PMID:15237969 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[CTSS protein results in increased cleavage of and results in decreased activity of CXCL10 protein] which results in decreased uptake of Calcium; [CXCL10 protein binds to and results in increased activity of CXCR3 protein] which results in increased uptake of Calcium |
CTD |
PMID:25833952 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions increases uptake |
ISO |
resveratrol inhibits the reaction [CXCL12 protein affects the localization of Calcium] CXCL12 protein results in increased uptake of Calcium |
CTD |
PMID:10984371 PMID:11872090 PMID:16212921 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[CTSS protein results in increased cleavage of and results in increased activity of CXCL2 protein] which results in increased uptake of Calcium; [CXCL2 protein modified form binds to and results in increased activity of CXCR2 protein] which results in increased uptake of Calcium |
CTD |
PMID:25833952 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions increases abundance |
ISO |
[[CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased abundance of Calcium] which results in increased expression of EGR1 mRNA; [CTSS protein results in increased cleavage of and results in decreased activity of CXCL9 protein] which results in decreased uptake of Calcium; [CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased abundance of Calcium; [CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased uptake of Calcium CXCL9 protein results in increased abundance of Calcium |
CTD |
PMID:12517959 PMID:25833952 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions affects abundance |
ISO |
[CXCL8 protein binds to and results in increased activity of CXCR1 protein] which results in increased abundance of and results in increased activity of Calcium CXCR1 protein affects the abundance of Calcium |
CTD |
PMID:11298490 PMID:12055238 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
affects transport multiple interactions |
ISO |
CXCR2 protein affects the transport of Calcium [CXCL2 protein modified form binds to and results in increased activity of CXCR2 protein] which results in increased uptake of Calcium; [CXCL5 protein modified form binds to and results in increased activity of CXCR2 protein] which results in increased uptake of Calcium; [CXCL8 protein binds to and results in increased activity of CXCR2 protein] which results in increased abundance of and results in increased activity of Calcium Excitatory Amino Acid Agonists inhibits the reaction [CXCR2 protein affects the localization of Calcium] |
CTD |
PMID:11298490 PMID:15618463 PMID:15914698 PMID:25833952 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
affects abundance multiple interactions |
ISO |
CXCR3 protein affects the abundance of Calcium [[CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased abundance of Calcium] which results in increased expression of EGR1 mRNA; [CXCL10 protein binds to and results in increased activity of CXCR3 protein] which results in increased uptake of Calcium; [CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased abundance of Calcium; [CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased uptake of Calcium |
CTD |
PMID:12055238 PMID:12517959 PMID:25833952 |
|
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
affects abundance |
ISO |
CXCR4 protein affects the abundance of Calcium |
CTD |
PMID:12055238 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
affects abundance |
ISO |
CXCR5 protein affects the abundance of Calcium |
CTD |
PMID:12055238 |
|
NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions increases secretion decreases secretion |
EXP |
[Calcium co-treated with Phosphates] affects the localization of CYCS protein; caffeic acid phenethyl ester inhibits the reaction [Calcium results in increased secretion of CYCS protein]; Cyclosporine inhibits the reaction [[Calcium co-treated with Phosphates] affects the localization of CYCS protein]; Nicotine inhibits the reaction [[Calcium co-treated with Phosphates] affects the localization of CYCS protein]; xestospongin C inhibits the reaction [Calcium results in decreased secretion of CYCS protein] |
CTD |
PMID:15345483 PMID:15469948 PMID:15985439 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
2-aminoethoxydiphenyl borate inhibits the reaction [[oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA]; [2,3,7,8-tetrachlorodibenzofuran co-treated with Calcium] results in increased expression of CYP1A1 mRNA; [oltipraz results in increased abundance of Calcium] which results in increased expression of CYP1A1 mRNA; Calcium promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Calcium promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] Calcium deficiency inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein] |
CTD |
PMID:1979076 PMID:11959854 PMID:16237193 PMID:23298284 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
Calcium promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA]; Calcium promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] Calcium deficiency inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:16237193 PMID:19782052 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
affects expression multiple interactions |
EXP |
Calcium affects the expression of CYP24A1 mRNA [Calcium co-treated with Calcitriol] affects the expression of CYP24A1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
affects expression |
EXP |
Calcium affects the expression of CYP27B1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects expression decreases uptake |
EXP ISO |
Calcium affects the expression of CYP2E1 mRNA CYP2E1 protein results in decreased uptake of Calcium |
CTD |
PMID:15913539 PMID:19028543 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions |
ISO |
[CP 199330 binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; [CP 199331 binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; [CP 265298 binds to and results in decreased activity of CYSLTR1 protein] which results in decreased abundance of Calcium; [CP 288886 binds to and results in decreased activity of CYSLTR1 protein] which results in decreased abundance of Calcium; [Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [pranlukast binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; [Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [zafirlukast binds to and results in decreased activity of CYSLTR1 protein] which affects the abundance of Calcium; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]; montelukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pobilukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pranlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; verlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Uridine Diphosphate binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]] |
CTD |
PMID:8014876 PMID:9934474 PMID:10391245 PMID:10462554 PMID:10509933 PMID:11093801 PMID:11705452 PMID:12853847 PMID:15792791 PMID:15990778 PMID:18704935 PMID:20083671 More...
|
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions |
ISO |
[Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene C4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene E4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium] |
CTD |
PMID:10851239 PMID:11093801 |
|
NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
affects expression |
EXP |
Calcium affects the expression of DDR1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Dmd |
dystrophin |
increases abundance multiple interactions |
ISO |
DMD gene mutant form results in increased abundance of Calcium Nifedipine inhibits the reaction [DMD gene mutant form results in increased abundance of Calcium] |
CTD |
PMID:24349043 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions decreases transport |
ISO |
[DNAJB11 protein binds to HSPA5 protein] which results in decreased transport of Calcium; [DNAJB11 protein results in decreased transport of Calcium] which results in increased susceptibility to Thapsigargin; DNAJB11 protein inhibits the reaction [SEC61A1 protein results in increased transport of Calcium] |
CTD |
PMID:26085089 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions decreases transport |
ISO |
[DNAJC3 protein binds to HSPA5 protein] which results in decreased transport of Calcium; [DNAJC3 protein results in decreased transport of Calcium] which results in increased susceptibility to Thapsigargin; DNAJC3 protein inhibits the reaction [SEC61A1 protein results in increased transport of Calcium] |
CTD |
PMID:26085089 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
[2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine results in increased activity of DRD1 protein] which results in increased abundance of Calcium |
CTD |
PMID:14622123 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO EXP |
[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; [Quinpirole binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; Sulpiride inhibits the reaction [[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium]; Sulpiride inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium] [DRD2 protein affects the abundance of Calcium] which results in decreased transport of Barium |
CTD |
PMID:8032591 PMID:11124974 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd3 |
dopamine receptor D3 |
increases phosphorylation |
EXP |
Calcium results in increased phosphorylation of DRD3 protein |
CTD |
PMID:19217379 |
|
NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
EXP |
Calcium affects the reaction [Potassium Chloride results in increased expression of DUSP1 mRNA] |
CTD |
PMID:11577072 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Edn1 |
endothelin 1 |
increases abundance increases uptake multiple interactions affects transport affects localization |
EXP ISO |
EDN1 protein results in increased abundance of Calcium EDN1 protein results in increased uptake of Calcium EDN1 protein affects the localization of and affects the abundance of Calcium Carvedilol inhibits the reaction [EDN1 protein results in increased import of and results in increased abundance of Calcium]; EDN1 protein affects the abundance of and affects the localization of Calcium; EDN1 protein results in increased import of and results in increased abundance of Calcium; Glucose affects the reaction [EDN1 protein affects the abundance of and affects the localization of Calcium]; Heparin inhibits the reaction [EDN1 protein results in increased abundance of Calcium] EDN1 protein affects the transport of Calcium EDN1 protein results in increased transport of and results in increased abundance of Calcium; Propofol inhibits the reaction [EDN1 protein affects the transport of Calcium] EDN1 protein affects the localization of Calcium |
CTD |
PMID:1443220 PMID:9138053 PMID:11425647 PMID:12628492 PMID:12821678 PMID:14711191 PMID:27226631 More...
|
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
increases uptake multiple interactions |
ISO |
EDN2 protein results in increased uptake of Calcium EDN2 protein affects the localization of and affects the abundance of Calcium |
CTD |
PMID:11425647 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Edn3 |
endothelin 3 |
multiple interactions increases uptake |
ISO EXP |
EDN3 protein affects the localization of and affects the abundance of Calcium BQ 788 inhibits the reaction [EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium]]; EDN3 protein inhibits the reaction [APP protein results in increased uptake of Calcium]; EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium] EDN3 protein results in increased uptake of Calcium |
CTD |
PMID:11425647 PMID:12383957 PMID:15695168 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednra |
endothelin receptor type A |
affects activity |
EXP |
Calcium affects the activity of EDNRA protein |
CTD |
PMID:12628492 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of EEF2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Egf |
epidermal growth factor |
increases abundance multiple interactions increases transport affects expression |
ISO EXP |
EGF protein results in increased abundance of Calcium [IGF2 protein co-treated with EGF protein] results in increased import of Calcium EGF protein results in increased transport of Calcium [Calcium co-treated with Calcitriol] affects the expression of EGF mRNA RTKI cpd inhibits the reaction [EGF protein results in increased abundance of Calcium] Calcium affects the expression of EGF mRNA |
CTD |
PMID:2442157 PMID:11527950 PMID:15913539 PMID:24990931 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Calcium affects the phosphorylation of and affects the expression of EGFR protein |
CTD |
PMID:8393775 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[[CXCL9 protein binds to and results in increased activity of CXCR3 protein] which results in increased abundance of Calcium] which results in increased expression of EGR1 mRNA; [Ionomycin results in increased abundance of Calcium] which results in increased expression of EGR1 protein |
CTD |
PMID:12517959 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
Calcium promotes the reaction [Diclofenac results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26609140 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of EIF4A2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr11:77,764,126...77,770,810
Ensembl chr11:77,764,124...77,770,781
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:12935885 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
affects expression |
EXP |
Calcium affects the expression of EPHX2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
F2 |
coagulation factor II, thrombin |
increases abundance increases localization multiple interactions increases uptake |
ISO |
F2 protein results in increased abundance of Calcium F2 protein results in increased localization of Calcium 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [F2 protein results in increased localization of Calcium]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [F2 protein results in increased localization of Calcium]; Apigenin inhibits the reaction [F2 protein results in increased localization of Calcium]; arsenite inhibits the reaction [F2 protein results in increased abundance of Calcium]; Genistein inhibits the reaction [F2 protein results in increased localization of Calcium]; Nickel inhibits the reaction [F2 protein results in increased uptake of Calcium]; Quercetin inhibits the reaction [F2 protein results in increased localization of Calcium] |
CTD |
PMID:2125206 PMID:19814731 PMID:22244921 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[Peptides results in increased activity of F2R protein] which results in increased abundance of Calcium |
CTD |
PMID:15086339 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]; PRKCE protein affects the reaction [F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]] |
CTD |
PMID:16793902 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
F2RL3 protein affects the localization of and affects the transport of Calcium [alanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanine binds to and results in increased activity of F2RL3 protein] which results in increased uptake of Calcium |
CTD |
PMID:16702038 PMID:17707436 |
|
NCBI chr16:17,117,441...17,119,434
Ensembl chr16:17,117,441...17,119,472
|
|
G |
F8 |
coagulation factor VIII |
multiple interactions |
ISO |
[Copper co-treated with Calcium] results in increased activity of [F8 protein alternative form binds to F8 protein alternative form]; Calcium results in increased activity of [F8 protein alternative form binds to F8 protein alternative form] |
CTD |
PMID:11513607 |
|
NCBI chr18:140,848...172,330
Ensembl chr18:140,955...171,857
|
|
G |
Faslg |
Fas ligand |
multiple interactions affects localization |
ISO |
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium]; CD38 gene mutant form inhibits the reaction [FASL protein affects the localization of Calcium]; CD38 protein inhibits the reaction [CD38 gene mutant form inhibits the reaction [FASL protein affects the localization of Calcium]]; Ryanodine inhibits the reaction [FASL protein affects the localization of Calcium] |
CTD |
PMID:20200208 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
EXP |
Calcium results in increased expression of FGF1 protein |
CTD |
PMID:15264218 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
affects expression |
ISO |
Calcium affects the expression of FGF23 mRNA; Calcium affects the expression of FGF23 protein |
CTD |
PMID:15086938 PMID:16381997 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
affects expression |
EXP |
Calcium affects the expression of FGF9 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of FGFR1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fis1 |
fission, mitochondrial 1 |
affects expression |
EXP |
Calcium affects the expression of FIS1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
multiple interactions |
ISO |
FKBP1A protein inhibits the reaction [Calcium results in increased activity of RYR2 protein] |
CTD |
PMID:17872463 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
FKBP1B gene mutant form inhibits the reaction [Acetylcholine affects the localization of and affects the abundance of Calcium]; Ryanodine inhibits the reaction [FKBP1B gene mutant form inhibits the reaction [Acetylcholine affects the localization of and affects the abundance of Calcium]] |
CTD |
PMID:17261647 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
affects expression |
EXP |
Calcium affects the expression of FURIN mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fxyd2 |
FXYD domain-containing ion transport regulator 2 |
multiple interactions decreases activity |
ISO |
Calcium inhibits the reaction [FXYD2 protein results in increased transport of Deoxyglucose]; Calcium inhibits the reaction [FXYD2 protein results in increased transport of Inulin] Calcium results in decreased activity of FXYD2 protein |
CTD |
PMID:11533133 |
|
NCBI chr 8:45,712,901...45,720,032
Ensembl chr 8:45,712,903...45,720,203
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
affects expression |
EXP |
Calcium affects the expression of G6PC1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabbr1 |
gamma-aminobutyric acid type B receptor subunit 1 |
multiple interactions affects expression |
ISO EXP |
Calcium promotes the reaction [3-aminopropylphosphinic acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]; Calcium promotes the reaction [CGP 55845A inhibits the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]]; Calcium promotes the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]] Calcium affects the expression of GABBR1 mRNA |
CTD |
PMID:15627515 PMID:15913539 |
|
NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994
|
|
G |
Gabbr2 |
gamma-aminobutyric acid type B receptor subunit 2 |
multiple interactions |
ISO |
Calcium promotes the reaction [3-aminopropylphosphinic acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]; Calcium promotes the reaction [CGP 55845A inhibits the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]]]; Calcium promotes the reaction [gamma-Aminobutyric Acid binds to and results in increased activity of [GABBR1 protein binds to GABBR2 protein]] |
CTD |
PMID:15627515 |
|
NCBI chr 5:60,947,517...61,288,104
Ensembl chr 5:60,947,526...61,288,104
|
|
G |
Gast |
gastrin |
multiple interactions |
ISO |
Calcium promotes the reaction [Colforsin results in increased secretion of GAST protein]; Calcium promotes the reaction [Terbutaline results in increased secretion of GAST protein] |
CTD |
PMID:9277405 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gata1 |
GATA binding protein 1 |
affects expression |
EXP |
Calcium affects the expression of GATA1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gc |
GC, vitamin D binding protein |
affects expression |
EXP |
Calcium affects the expression of GC mRNA |
CTD |
PMID:15913539 |
|
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
|
|
G |
Gcg |
glucagon |
multiple interactions |
EXP |
Calcium affects the reaction [Pyruvic Acid results in increased secretion of GCG protein] |
CTD |
PMID:15919803 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of GCLC mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Calcium affects the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein]; Calcium deficiency inhibits the reaction [Ethanol results in increased expression of GFAP protein] |
CTD |
PMID:17888892 PMID:21879721 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ghr |
growth hormone receptor |
affects expression multiple interactions |
EXP |
Calcium affects the expression of GHR mRNA [Calcium co-treated with Calcitriol] affects the expression of GHR mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
|
|
G |
Gipc3 |
GIPC PDZ domain containing family, member 3 |
affects uptake |
ISO |
GIPC3 protein affects the uptake of Calcium |
CTD |
PMID:27462107 |
|
NCBI chr 7:8,374,941...8,383,281
|
|
G |
Glrx3 |
glutaredoxin 3 |
affects response to substance |
EXP |
GLRX3 protein affects the susceptibility to Calcium |
CTD |
PMID:16809552 |
|
NCBI chr 1:192,241,707...192,272,012
Ensembl chr 1:192,241,701...192,272,010
|
|
G |
Gnai2 |
G protein subunit alpha i2 |
affects expression |
EXP |
Calcium affects the expression of GNAI2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 8:108,288,401...108,309,009
Ensembl chr 8:108,288,401...108,308,979
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium |
CTD |
PMID:23022524 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Calcium [[6alpha-ethyl-23(S)-methylcholic acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium; [[Oleanolic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased activity of GNAS protein] which results in increased abundance of Calcium |
CTD |
PMID:23022524 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
multiple interactions |
EXP |
Calcium deficiency inhibits the reaction [Excitatory Amino Acid Agonists results in decreased phosphorylation of GRIA1 protein] |
CTD |
PMID:28404816 |
|
NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
EXP |
Calcium promotes the reaction [PICK1 protein binds to GRIA2 protein] |
CTD |
PMID:28404816 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
multiple interactions |
EXP |
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium]; [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium; Flufenamic Acid inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium]; GRM1 protein promotes the reaction [Propionates results in increased transport of Calcium]; Ruthenium Red inhibits the reaction [[3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:14622174 PMID:24582715 |
|
NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
[Calcium co-treated with Zinc] affects the reaction [monoisoamyl-2,3-dimercaptosuccinate affects the reaction [sodium arsenite results in decreased activity of GSR protein]]; [Calcium co-treated with Zinc] affects the reaction [sodium arsenite results in decreased activity of GSR protein]; [Carmustine results in decreased activity of GSR protein] which results in increased uptake of Calcium; Calcium affects the reaction [sodium arsenite results in decreased activity of GSR protein] |
CTD |
PMID:15321730 PMID:24184500 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hectd4 |
HECT domain E3 ubiquitin protein ligase 4 |
multiple interactions |
ISO |
Calcium affects the reaction [HECTD4 gene SNP affects the abundance of Lead] |
CTD |
PMID:28212632 |
|
NCBI chr12:35,182,165...35,330,935
Ensembl chr12:35,182,154...35,330,987
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
affects expression |
EXP |
Calcium affects the expression of HES1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hgf |
hepatocyte growth factor |
increases abundance |
EXP |
HGF protein results in increased abundance of Calcium |
CTD |
PMID:10963052 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
affects expression |
EXP |
Calcium affects the expression of HMGCS2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Calcium affects the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA] |
CTD |
PMID:21443188 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
affects expression |
EXP |
Calcium affects the expression of HNF4A mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hnrnpd |
heterogeneous nuclear ribonucleoprotein D |
multiple interactions |
EXP |
Calcium deficiency promotes the reaction [HNRNPD protein binds to PTH 3' UTR] |
CTD |
PMID:18583400 |
|
NCBI chr14:9,615,375...9,638,975
Ensembl chr14:9,615,479...9,633,786
|
|
G |
Hnrnpu |
heterogeneous nuclear ribonucleoprotein U |
affects expression |
EXP |
Calcium affects the expression of SP120 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr13:90,069,058...90,086,905
Ensembl chr13:90,074,181...90,086,588
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
EXP |
HOMER1 protein alternative form inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]]; HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Hpca |
hippocalcin |
decreases response to substance |
ISO |
HPCA protein results in decreased susceptibility to Calcium |
CTD |
PMID:12445469 |
|
NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions increases abundance |
ISO |
[6-((2-(4-imidazolyl)ethyl)amino)heptanoic acid 4-toluidide binds to and results in increased activity of HRH1 protein] which results in increased abundance of Calcium; [Histamine results in increased activity of HRH1 protein] which results in increased abundance of Calcium; [HRH1 protein binds to Histamine] which results in increased import of Calcium; [HRH1 protein binds to Lidocaine] which results in increased import of Calcium; [HRH1 protein binds to Procaine] which results in increased import of Calcium; [HRH1 protein binds to Tetracaine] which results in increased import of Calcium; fexofenadine inhibits the reaction [[Histamine binds to and results in increased activity of HRH1 protein] which results in increased abundance of Calcium]; HRH1 protein promotes the reaction [Histamine results in increased export of Calcium]; Triprolidine inhibits the reaction [[Histamine results in increased activity of HRH1 protein] which results in increased abundance of Calcium]; Triprolidine inhibits the reaction [HRH1 protein promotes the reaction [Histamine results in increased export of Calcium]] HRH1 protein results in increased abundance of Calcium |
CTD |
PMID:2419744 PMID:11238657 PMID:11527950 PMID:19443731 PMID:32061592 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
ISO |
[4-(1H-imidazol-4-ylmethyl)piperidine binds to and results in increased activity of HRH3 protein] which results in increased transport of Calcium; [Histamine binds to and results in increased activity of HRH3 protein] which results in increased transport of Calcium; [imetit binds to and results in increased activity of HRH3 protein] which results in increased transport of Calcium; [Methylhistamines binds to and results in increased activity of HRH3 protein] which results in increased transport of Calcium; clobenpropit inhibits the reaction [[Methylhistamines binds to and results in increased activity of HRH3 protein] which results in increased transport of Calcium] |
CTD |
PMID:12706455 |
|
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Hrh4 |
histamine receptor H4 |
multiple interactions |
ISO |
1-((5-chloro-1H-indol-2-yl)carbonyl)-4-methylpiperazine inhibits the reaction [[4-methylhistamine binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium]; 1-((5-chloro-1H-indol-2-yl)carbonyl)-4-methylpiperazine inhibits the reaction [[clobenpropit binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium]; [4-methylhistamine binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium; [alpha-methylhistamine binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium; [clobenpropit binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium; [Histamine binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium; [imetit binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium; [N-methylhistamine binds to and results in increased activity of HRH4 protein] which results in increased abundance of Calcium |
CTD |
PMID:11181941 PMID:17507084 |
|
NCBI chr18:4,166,270...4,182,426
Ensembl chr18:4,166,270...4,246,345
|
|
G |
Hsd17b12 |
hydroxysteroid (17-beta) dehydrogenase 12 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of HSD17B12 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions decreases transport |
ISO |
[DNAJB11 protein binds to HSPA5 protein] which results in decreased transport of Calcium; [DNAJC3 protein binds to HSPA5 protein] which results in decreased transport of Calcium; [HSPA5 protein binds to SEC61A1 protein] which results in decreased transport of Calcium; [HSPA5 protein results in decreased transport of Calcium] which results in increased susceptibility to Thapsigargin |
CTD |
PMID:26085089 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
increases abundance |
EXP |
HSPA9 protein results in increased abundance of Calcium |
CTD |
PMID:34308505 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
increases activity |
ISO |
Calcium results in increased activity of HTR1A protein |
CTD |
PMID:11356925 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
EXP |
HTR2A protein promotes the reaction [[Freund's Adjuvant results in increased activity of TRPV1 protein] which results in increased transport of Calcium] |
CTD |
PMID:16901936 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Htr2b |
5-hydroxytryptamine receptor 2B |
multiple interactions |
ISO |
Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18758753 |
|
NCBI chr 9:86,735,793...86,756,638
Ensembl chr 9:86,742,102...86,755,108
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
EXP |
HTR7 protein promotes the reaction [[Freund's Adjuvant results in increased activity of TRPV1 protein] which results in increased transport of Calcium] |
CTD |
PMID:16901936 |
|
NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
KL protein inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]] [IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]; [TNF protein co-treated with IFNG protein] promotes the reaction [Diclofenac affects the abundance of Calcium]; Calcium promotes the reaction [[Diclofenac co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:23747339 PMID:26609140 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ift88 |
intraflagellar transport 88 |
multiple interactions increases uptake |
ISO |
Gadolinium inhibits the reaction [IFT88 protein mutant form results in increased uptake of Calcium]; IFT88 protein affects the reaction [PKD2 protein results in increased uptake of Calcium] |
CTD |
PMID:16396941 |
|
NCBI chr15:31,573,325...31,666,068
Ensembl chr15:31,573,376...31,672,147
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression multiple interactions increases import |
EXP ISO |
Calcium affects the expression of IGF1 mRNA Cobalt inhibits the reaction [IGF1 protein results in increased import of Calcium]; tetramethrin inhibits the reaction [IGF1 protein results in increased import of Calcium] |
CTD |
PMID:1550224 PMID:2460452 PMID:2539779 PMID:15913539 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions increases import |
ISO |
[IGF2 protein co-treated with EGF protein] results in increased import of Calcium; Cobalt inhibits the reaction [IGF2 protein results in increased import of Calcium]; Lanthanum inhibits the reaction [IGF2 protein results in increased import of Calcium]; Pertussis Toxin inhibits the reaction [IGF2 protein results in increased import of Calcium]; tetramethrin inhibits the reaction [IGF2 protein results in increased import of Calcium] |
CTD |
PMID:2442157 PMID:2460452 PMID:2539779 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
affects expression |
EXP |
Calcium affects the expression of IGFBP2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp5 |
insulin-like growth factor binding protein 5 |
affects expression decreases degradation |
EXP |
Calcium affects the expression of IGFBP5 mRNA Calcium results in decreased degradation of IGFBP5 protein |
CTD |
PMID:8894652 PMID:15913539 |
|
NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156
|
|
G |
Il11 |
interleukin 11 |
multiple interactions increases abundance |
ISO |
Flurbiprofen inhibits the reaction [IL11 protein results in increased abundance of Calcium]; IL13 protein inhibits the reaction [IL11 protein results in increased abundance of Calcium]; IL4 protein inhibits the reaction [IL11 protein results in increased abundance of Calcium]; IL6ST protein promotes the reaction [IL11 protein results in increased abundance of Calcium]; Indomethacin inhibits the reaction [IL11 protein results in increased abundance of Calcium]; TNFRSF11B protein inhibits the reaction [IL11 protein results in increased abundance of Calcium] |
CTD |
PMID:12110441 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
IL13 protein inhibits the reaction [IL11 protein results in increased abundance of Calcium] |
CTD |
PMID:12110441 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
KL protein inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]] |
CTD |
PMID:23747339 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
IL4 protein inhibits the reaction [IL11 protein results in increased abundance of Calcium] |
CTD |
PMID:12110441 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
Calcimycin inhibits the reaction [Calcium promotes the reaction [Histamine results in increased expression of IL6 protein]]; Calcium promotes the reaction [Histamine results in increased expression of IL6 protein]; Edetic Acid inhibits the reaction [Calcium promotes the reaction [Histamine results in increased expression of IL6 protein]] Calcium results in increased expression of IL6 mRNA |
CTD |
PMID:11238657 PMID:20682585 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions |
ISO |
IL6ST protein promotes the reaction [IL11 protein results in increased abundance of Calcium] |
CTD |
PMID:12110441 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Ilf3 |
interleukin enhancer binding factor 3 |
multiple interactions |
ISO |
Calcium affects the reaction [Vanadates results in increased activity of ILF3 protein] |
CTD |
PMID:10623810 |
|
NCBI chr 8:19,922,409...19,960,495
Ensembl chr 8:19,922,460...19,960,350
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
Calcium deficiency inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; Calcium deficiency inhibits the reaction [INS1 protein results in increased activity of SLC2A1 protein]; Chromium affects the reaction [INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; chromium tripicolinate affects the reaction [INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; INS1 protein affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]; INS1 protein affects the reaction [Chromium affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]]; INS1 protein affects the reaction [chromium tripicolinate affects the reaction [[AVP protein results in increased uptake of Calcium] which results in increased secretion of Calcium]] |
CTD |
PMID:9446840 PMID:10780946 PMID:10970766 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Iqgap1 |
IQ motif containing GTPase activating protein 1 |
multiple interactions |
ISO |
Calcium promotes the reaction [PAFAH1B1 protein binds to IQGAP1 protein binds to CDC42 protein] |
CTD |
PMID:16369480 |
|
NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]; TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]] |
CTD |
PMID:18234883 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:66,572,537...66,577,174
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
Calcium promotes the reaction [ITIH1 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
Calcium promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
ITPR1 protein promotes the reaction [Acetaldehyde metabolite results in increased abundance of Calcium]; ITPR1 protein promotes the reaction [Ethanol metabolite results in increased abundance of Calcium] |
CTD |
PMID:17241155 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Itpr2 |
inositol 1,4,5-trisphosphate receptor, type 2 |
multiple interactions |
ISO |
2-aminoethoxydiphenyl borate inhibits the reaction [[adenophostin A results in increased activity of ITPR2 protein] which results in increased transport of Calcium]; [adenophostin A results in increased activity of ITPR2 protein] which results in increased transport of Calcium; xestospongin C inhibits the reaction [[adenophostin A results in increased activity of ITPR2 protein] which results in increased transport of Calcium] |
CTD |
PMID:15201137 |
|
NCBI chr 4:179,028,594...179,434,657
Ensembl chr 4:179,027,281...179,404,164
|
|
G |
Itpr3 |
inositol 1,4,5-trisphosphate receptor, type 3 |
affects expression |
EXP |
Calcium affects the expression of ITPR3 protein |
CTD |
PMID:10963052 |
|
NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,136,441...5,202,337
|
|
G |
Ivl |
involucrin |
increases expression multiple interactions |
ISO |
Calcium results in increased expression of IVL mRNA NPS R-467 promotes the reaction [Calcium results in increased expression of IVL mRNA] |
CTD |
PMID:10469331 |
|
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
JAK2 protein promotes the reaction [LEP protein results in increased transport of Calcium] |
CTD |
PMID:20107083 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
increases activity multiple interactions |
ISO |
Calcium results in increased activity of KCNE1 protein W 7 inhibits the reaction [Calcium results in increased activity of KCNE1 protein] |
CTD |
PMID:1655403 |
|
NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Nimodipine inhibits the reaction [KCNH2 protein affects the abundance of Calcium] |
CTD |
PMID:11040061 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions affects abundance |
ISO |
Dantrolene inhibits the reaction [KCNJ11 protein mutant form results in increased abundance of Calcium]; KCNJ11 protein affects the reaction [[Manganese co-treated with Dobutamine] results in increased abundance of Calcium]; W 7 inhibits the reaction [KCNJ11 protein mutant form results in increased abundance of Calcium] KCNJ11 protein affects the abundance of Calcium |
CTD |
PMID:17189350 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions increases response to substance |
ISO EXP |
[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium; Lithocholic Acid promotes the reaction [[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium] KCNMA1 mRNA alternative form results in increased susceptibility to Calcium |
CTD |
PMID:22123969 PMID:28090300 |
|
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
|
|
G |
Kcnmb1 |
potassium calcium-activated channel subfamily M regulatory beta subunit 1 |
multiple interactions |
ISO |
[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium; Lithocholic Acid promotes the reaction [[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium] |
CTD |
PMID:22123969 |
|
NCBI chr10:18,557,510...18,614,824
Ensembl chr10:18,557,904...18,565,798
|
|
G |
Kcnn2 |
potassium calcium-activated channel subfamily N member 2 |
increases activity multiple interactions |
ISO |
Calcium results in increased activity of KCNN2 protein cyclohexyl-(2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine promotes the reaction [Calcium results in increased activity of KCNN2 protein] |
CTD |
PMID:17486140 |
|
NCBI chr18:37,817,966...38,258,347
Ensembl chr18:37,817,957...38,258,347
|
|
G |
Kcnn3 |
potassium calcium-activated channel subfamily N member 3 |
multiple interactions increases activity |
ISO |
6,7-dichloro-1H-indole-2,3-dione 3-oxime promotes the reaction [Calcium results in increased activity of KCNN3 protein]; cyclohexyl-(2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-yl)amine promotes the reaction [Calcium results in increased activity of KCNN3 protein] |
CTD |
PMID:17486140 |
|
NCBI chr 2:174,929,846...175,088,910
Ensembl chr 2:174,936,629...175,081,145
|
|
G |
Kcnn4 |
potassium calcium-activated channel subfamily N member 4 |
affects abundance multiple interactions |
ISO |
KCNN4 protein affects the abundance of Calcium KCNN4 protein affects the reaction [Calcium results in increased transport of Potassium] |
CTD |
PMID:11826162 PMID:14985237 |
|
NCBI chr 1:79,956,380...79,974,354
Ensembl chr 1:79,959,322...79,974,340
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
[VEGFA protein results in increased activity of KDR protein] which results in increased abundance of Calcium; TRPC6 protein promotes the reaction [[VEGFA protein results in increased activity of KDR protein] which results in increased abundance of Calcium] Calcium promotes the reaction [Corticosterone results in decreased expression of KDR protein] |
CTD |
PMID:14551041 PMID:21647420 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Khsrp |
KH-type splicing regulatory protein |
multiple interactions |
EXP |
Calcium deficiency inhibits the reaction [KHSRP protein binds to PTH 3' UTR] |
CTD |
PMID:18583400 |
|
NCBI chr 9:1,862,555...1,872,403
Ensembl chr 9:1,862,899...1,872,451
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
multiple interactions |
ISO |
2-aminoethyl diphenylborinate inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; [KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium; Flufenamic Acid inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; Tetrodotoxin inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; Tetrodotoxin promotes the reaction [2-aminoethyl diphenylborinate inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]] |
CTD |
PMID:18948403 |
|
NCBI chr13:44,775,106...44,780,707
Ensembl chr13:44,774,823...44,780,612
|
|
G |
Kiss1r |
KISS1 receptor |
multiple interactions |
ISO |
2-aminoethyl diphenylborinate inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; [KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium; Flufenamic Acid inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; Tetrodotoxin inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]; Tetrodotoxin promotes the reaction [2-aminoethyl diphenylborinate inhibits the reaction [[KISS1 protein results in increased activity of KISS1R protein] which results in increased abundance of Calcium]] |
CTD |
PMID:18948403 |
|
NCBI chr 7:9,785,135...9,790,283
Ensembl chr 7:9,785,135...9,788,793
|
|
G |
Kl |
Klotho |
affects abundance multiple interactions |
ISO |
KL protein affects the abundance of Calcium KL protein inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]] |
CTD |
PMID:11796525 PMID:23747339 |
|
NCBI chr12:490,402...531,417
Ensembl chr12:490,399...530,080
|
|
G |
Klk1 |
kallikrein 1 |
decreases activity |
ISO |
Calcium results in decreased activity of KLK1 protein |
CTD |
PMID:15558947 |
|
NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases activity |
ISO |
Calcium results in increased activity of KLK8 protein |
CTD |
PMID:16800733 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Kng1 |
kininogen 1 |
affects abundance multiple interactions increases abundance |
ISO EXP |
KNG1 protein affects the abundance of Calcium B 4162 inhibits the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]]; BDKRB2 protein affects the reaction [pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium]]; CALR protein promotes the reaction [KNG1 protein modified form results in increased abundance of Calcium]; KNG1 protein affects the transport of and affects the localization of Calcium; pyranoprofen inhibits the reaction [KNG1 protein affects the transport of and affects the localization of Calcium] [KNG1 protein alternative form co-treated with Calcium] results in increased secretion of CALCA protein; Calcium affects the reaction [KNG1 protein results in increased secretion of Excitatory Amino Acid Agents] BDKRB2 protein affects the reaction [KNG1 protein affects the abundance of Calcium] KNG1 protein results in increased abundance of Calcium |
CTD |
PMID:7961812 PMID:8592139 PMID:10535458 PMID:12582005 PMID:16473424 PMID:17666428 PMID:18054572 More...
|
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Krt1 |
keratin 1 |
multiple interactions increases expression |
ISO |
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; 8-hydroxyeicosatetraenoic acid promotes the reaction [Calcium results in increased expression of KRT1 mRNA]; Masoprocol inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; morin inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; Quercetin inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Calcium results in increased expression of KRT1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Calcium results in increased expression of KRT1 protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of KRT1 protein]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of KRT1 protein]; SB 203580 inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; SB 203580 inhibits the reaction [Calcium results in increased expression of KRT1 protein]; WNT5A protein promotes the reaction [Calcium results in increased expression of KRT1 mRNA]; WNT5A protein promotes the reaction [Calcium results in increased expression of KRT1 protein] Calcium results in increased expression of KRT1 mRNA; Calcium results in increased expression of KRT1 protein |
CTD |
PMID:12069687 PMID:21524694 PMID:24658506 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lep |
leptin |
affects abundance multiple interactions affects secretion increases transport affects expression decreases abundance |
ISO EXP |
LEP protein affects the abundance of Calcium Calcium deficiency inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein] Calcium deficiency affects the secretion of LEP protein LEP protein results in increased transport of Calcium 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [LEP protein results in increased transport of Calcium]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [LEP protein results in increased transport of Calcium]; 2-aminoethoxydiphenyl borate inhibits the reaction [LEP protein results in increased transport of Calcium]; acetovanillone inhibits the reaction [LEP protein affects the abundance of Calcium]; alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide inhibits the reaction [LEP protein results in increased transport of Calcium]; BQ 788 inhibits the reaction [LEP protein affects the abundance of Calcium]; Calcium promotes the reaction [LEP protein results in increased transport of Calcium]; cyclo(Trp-Asp-Pro-Val-Leu) inhibits the reaction [LEP protein affects the abundance of Calcium]; edelfosine inhibits the reaction [LEP protein results in increased transport of Calcium]; Flufenamic Acid inhibits the reaction [LEP protein results in increased transport of Calcium]; JAK2 protein promotes the reaction [LEP protein results in increased transport of Calcium]; Lanthanum promotes the reaction [LEP protein results in increased transport of Calcium]; LEP protein promotes the reaction [TRPC1 protein results in increased transport of Calcium]; LEP protein promotes the reaction [TRPC4 protein results in increased transport of Calcium]; LEP protein promotes the reaction [TRPC5 protein results in increased transport of Calcium]; wortmannin inhibits the reaction [LEP protein results in increased transport of Calcium] Calcium affects the expression of LEP mRNA LEP protein results in decreased abundance of Calcium |
CTD |
PMID:10780946 PMID:14657008 PMID:15913539 PMID:16380530 PMID:20107083 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
affects expression |
EXP |
Calcium affects the expression of LEPR mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases abundance |
EXP |
LIF protein results in increased abundance of Calcium |
CTD |
PMID:11073891 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
increases expression multiple interactions |
ISO |
Calcium results in increased expression of LORICRIN mRNA; Calcium results in increased expression of LORICRIN protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Calcium results in increased expression of LORICRIN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Calcium results in increased expression of LORICRIN protein]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; CASR mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; CTNNB1 mutant form inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; SB 203580 inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; SB 203580 inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; WNT5A protein promotes the reaction [Calcium results in increased expression of LORICRIN mRNA]; WNT5A protein promotes the reaction [Calcium results in increased expression of LORICRIN protein] |
CTD |
PMID:21524694 PMID:24658506 |
|
NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807
|
|
G |
Lypla1 |
lysophospholipase 1 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of LYPLA1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]; Calcium inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA] |
CTD |
PMID:12574409 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
affects expression |
EXP |
Calcium affects the expression of MAP2K2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Calcium results in increased phosphorylation of MAPK1 protein Calcium promotes the reaction [Diclofenac results in increased phosphorylation of MAPK1 protein] Calcium affects the reaction [Ptychodiscus brevis T2 toxin affects the phosphorylation of MAPK1 protein]; Calcium deficiency inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Calcium deficiency inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein] Calcium deficiency inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:10660688 PMID:15086530 PMID:16877402 PMID:17537980 PMID:18758753 PMID:19782052 PMID:26609140 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
affects expression |
EXP |
Calcium affects the expression of MAPK14 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO EXP |
Calcium results in increased phosphorylation of MAPK3 protein Calcium promotes the reaction [Diclofenac results in increased phosphorylation of MAPK3 protein] Calcium deficiency inhibits the reaction [Carbachol results in increased phosphorylation of and results in increased activity of MAPK3 protein] Calcium affects the reaction [Ptychodiscus brevis T2 toxin affects the phosphorylation of MAPK3 protein]; Calcium deficiency inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]; Calcium deficiency inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Calcium promotes the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:10660688 PMID:15086530 PMID:16877402 PMID:17537980 PMID:18758753 PMID:19782052 PMID:26609140 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk4 |
mitogen-activated protein kinase 4 |
affects expression |
EXP |
Calcium affects the expression of MAPK4 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr18:67,512,805...67,661,271
Ensembl chr18:67,512,807...67,661,842
|
|
G |
Marco |
macrophage receptor with collagenous structure |
multiple interactions |
ISO |
Calcium promotes the reaction [titanium dioxide binds to MARCO protein] |
CTD |
PMID:18836211 |
|
NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521
|
|
G |
Mcoln1 |
mucolipin TRP cation channel 1 |
multiple interactions |
ISO |
[NAADP results in increased activity of MCOLN1 protein] which affects the localization of Calcium |
CTD |
PMID:21613607 |
|
NCBI chr12:1,560,341...1,574,252
Ensembl chr12:1,560,359...1,574,252
|
|
G |
Mcu |
mitochondrial calcium uniporter |
affects localization |
ISO |
MCU protein affects the localization of Calcium |
CTD |
PMID:22829870 |
|
NCBI chr20:27,417,529...27,580,110
Ensembl chr20:27,417,526...27,580,110
|
|
G |
Mgp |
matrix Gla protein |
multiple interactions affects expression affects binding |
ISO EXP |
[Calcium binds to MGP protein] which binds to and results in decreased activity of BMP4 protein; [Edetic Acid inhibits the reaction [Calcium binds to MGP protein]] inhibits the reaction [MGP protein binds to BMP4 protein]; Edetic Acid inhibits the reaction [Calcium binds to MGP protein] Calcium affects the expression of MGP mRNA |
CTD |
PMID:15913539 PMID:18369157 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
affects expression |
ISO |
Calcium affects the expression of MMP1 mRNA; Calcium affects the expression of MMP1 protein |
CTD |
PMID:17508023 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of MTOR protein] |
CTD |
PMID:12935885 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mybpc3 |
myosin binding protein C3 |
multiple interactions increases response to substance |
ISO |
epigallocatechin gallate inhibits the reaction [MYBPC3 gene mutant form results in increased susceptibility to Calcium] |
CTD |
PMID:27994558 |
|
NCBI chr 3:77,095,165...77,113,406
Ensembl chr 3:77,095,252...77,113,405
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases transport |
ISO |
MYH7 gene mutant form results in increased transport of Calcium |
CTD |
PMID:29741611 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl2 |
myosin light chain 2 |
multiple interactions |
ISO |
Calcium affects the reaction [MYL2 gene SNP affects the abundance of Lead] |
CTD |
PMID:28212632 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myl3 |
myosin light chain 3 |
affects expression |
EXP |
Calcium affects the expression of MYL3 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:110,738,661...110,744,816
|
|
G |
Myl9 |
myosin light chain 9 |
multiple interactions affects phosphorylation decreases phosphorylation |
EXP |
[[Calcium results in increased activity of MYLK protein] which results in increased phosphorylation of MYL9 protein] which results in decreased secretion of REN protein; [CACNA1D protein results in increased uptake of Calcium] which results in increased phosphorylation of MYL9 protein; [Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein; Glycodeoxycholic Acid inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein]; Y 27632 inhibits the reaction [[Escin affects the susceptibility to Calcium] which results in increased phosphorylation of MYL9 protein] Calcium affects the phosphorylation of MYL9 protein Calcium deficiency results in decreased phosphorylation of MYL9 protein |
CTD |
PMID:7503253 PMID:9618396 PMID:17272349 PMID:29660437 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
increases activity multiple interactions |
ISO EXP |
Calcium deficiency results in increased activity of MYLK protein; Calcium results in increased activity of MYLK protein [[Calcium results in increased activity of MYLK protein] which results in increased phosphorylation of MYL9 protein] which results in decreased secretion of REN protein ML 7 inhibits the reaction [Calcium deficiency results in increased activity of MYLK protein] |
CTD |
PMID:9618396 PMID:10640419 PMID:11054866 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Myo1b |
myosin Ib |
increases activity |
EXP |
Calcium deficiency results in increased activity of MYO1B protein |
CTD |
PMID:10419463 |
|
NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798
|
|
G |
Myo5a |
myosin VA |
affects activity |
ISO |
Calcium affects the activity of MYO5A protein |
CTD |
PMID:10660602 |
|
NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
decreases response to substance |
ISO |
NAIP protein results in decreased susceptibility to Calcium |
CTD |
PMID:12445469 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
affects abundance |
ISO |
NCF1 protein affects the abundance of Calcium |
CTD |
PMID:16280459 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndufs1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of NDUFS1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
affects expression |
EXP |
Calcium affects the expression of NEDD4 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nedd4l |
NEDD4 like E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[NEDD4L gene mutant form results in increased susceptibility to Sodium, Dietary] which results in increased abundance of Calcium; Thiazides inhibits the reaction [[NEDD4L gene mutant form results in increased susceptibility to Sodium, Dietary] which results in increased abundance of Calcium] |
CTD |
PMID:23348737 |
|
NCBI chr18:58,393,759...58,726,709
Ensembl chr18:58,393,509...58,723,137
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
Calcium affects the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein]; calpeptin inhibits the reaction [Calcium results in increased degradation of NEFL protein]; Indomethacin inhibits the reaction [Calcium results in increased degradation of NEFL protein] |
CTD |
PMID:11071371 PMID:21879721 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nefm |
neurofilament medium chain |
multiple interactions |
EXP |
Calcium affects the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein] |
CTD |
PMID:21879721 |
|
NCBI chr15:42,360,449...42,365,753
Ensembl chr15:42,360,454...42,365,755
|
|
G |
Nek9 |
NIMA-related kinase 9 |
affects expression |
EXP |
Calcium affects the expression of NEK9 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 6:104,944,056...104,984,538
Ensembl chr 6:104,944,056...104,984,538
|
|
G |
Nf1 |
neurofibromin 1 |
decreases transport |
ISO |
NF1 protein results in decreased transport of Calcium |
CTD |
PMID:21949590 |
|
NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
multiple interactions |
ISO |
4-methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide inhibits the reaction [[Muscarine co-treated with Calcium] affects the localization of NFATC2 protein]; 4-methyl-4'-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)-1,2,3-thiadiazole-5-carboxanilide inhibits the reaction [[Thapsigargin co-treated with Calcium] affects the localization of NFATC2 protein]; [Muscarine co-treated with Calcium] affects the localization of NFATC2 protein; [Thapsigargin co-treated with Calcium] affects the localization of NFATC2 protein |
CTD |
PMID:24990931 |
|
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases abundance |
ISO |
NFE2L2 gene mutant form results in increased abundance of Calcium |
CTD |
PMID:29618784 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
affects expression multiple interactions |
EXP ISO |
Calcium affects the expression of NFKBIA mRNA Calcium affects the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]] |
CTD |
PMID:15913539 PMID:24068670 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngb |
neuroglobin |
affects transport |
ISO |
NGB protein affects the transport of Calcium |
CTD |
PMID:19154338 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases uptake |
EXP |
[NGF protein co-treated with 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester] results in increased uptake of Calcium; [NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium; cadmium acetate inhibits the reaction [NGF protein results in increased uptake of Calcium]; Cadmium inhibits the reaction [NGF protein results in increased uptake of Calcium]; calmidazolium inhibits the reaction [NGF protein results in increased uptake of Calcium]; Fluphenazine inhibits the reaction [NGF protein results in increased uptake of Calcium]; Nifedipine inhibits the reaction [NGF protein results in increased uptake of Calcium]; Okadaic Acid promotes the reaction [NGF protein results in increased uptake of Calcium]; Staurosporine inhibits the reaction [NGF protein results in increased uptake of Calcium] |
CTD |
PMID:1374475 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nherf4 |
NHERF family PDZ scaffold protein 4 |
multiple interactions |
ISO |
[[USP2 gene mutant form results in increased expression of NHERF4 protein] which results in increased activity of TRPV6 protein] which results in increased uptake of Calcium |
CTD |
PMID:26756164 |
|
NCBI chr 8:44,584,390...44,588,838
Ensembl chr 8:44,584,390...44,588,860
|
|
G |
Noa1 |
nitric oxide associated 1 |
multiple interactions |
EXP |
[Tamoxifen results in increased abundance of Calcium] which results in increased activity of NOA1 protein |
CTD |
PMID:17283165 |
|
NCBI chr14:30,835,264...30,851,294
Ensembl chr14:30,835,247...30,851,293
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
[Calcium binds to CALM1 protein] promotes the reaction [NOS1 protein results in increased chemical synthesis of Nitric Oxide]; [Calcium binds to CALM1 protein] which binds to and affects the folding of and results in increased activity of NOS1 protein |
CTD |
PMID:17098364 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos3 |
nitric oxide synthase 3 |
affects response to substance increases activity multiple interactions |
ISO EXP |
NOS3 protein affects the susceptibility to Calcium Calcium results in increased activity of NOS3 protein Calcium affects the reaction [Polycyclic Aromatic Hydrocarbons results in increased expression of and results in increased activity of NOS3 protein]; Calcium deficiency inhibits the reaction [Digitoxin results in increased activity of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:15183461 PMID:17403420 PMID:17490654 PMID:19380615 PMID:19446813 PMID:22244921 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
1-(3-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido(3,4-b)indole-3-carboxylic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]]; NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [NOX1 protein promotes the reaction [glycylphenylalanine 2-naphthylamide results in increased export of Calcium]] |
CTD |
PMID:24912985 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nppc |
natriuretic peptide C |
increases uptake multiple interactions |
EXP |
NPPC protein results in increased uptake of Calcium Ammonia inhibits the reaction [NPPC protein results in increased uptake of Calcium]; Nimodipine inhibits the reaction [NPPC protein results in increased uptake of Calcium] |
CTD |
PMID:18222015 |
|
NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251
|
|
G |
Npr1 |
natriuretic peptide receptor 1 |
affects expression |
EXP |
Calcium affects the expression of NPR1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
affects expression |
EXP |
Calcium affects the expression of NR0B2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
affects expression |
EXP |
Calcium affects the expression of NR1D2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553
|
|
G |
Nrxn1 |
neurexin 1 |
multiple interactions |
ISO |
Calcium affects the reaction [alpha-latrotoxin binds to NRXN1 protein]; Calcium affects the reaction [black widow spider venom binds to NRXN1 protein] |
CTD |
PMID:9430716 |
|
NCBI chr 6:3,177,788...4,323,848
Ensembl chr 6:3,177,897...4,322,710
|
|
G |
Nucb2 |
nucleobindin 2 |
multiple interactions |
EXP |
KT 5720 inhibits the reaction [NUCB2 protein results in increased import of Calcium] |
CTD |
PMID:17627999 |
|
NCBI chr 1:170,750,830...170,787,356
Ensembl chr 1:170,750,877...170,787,353
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
Calcium deficiency inhibits the reaction [TJP1 protein binds to OCLN protein] |
CTD |
PMID:11054866 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Oprm1 |
opioid receptor, mu 1 |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Calcium] inhibits the reaction [Zinc promotes the reaction [OPRM1 protein binds to PRKCG protein]] |
CTD |
PMID:18652891 |
|
NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409
|
|
G |
Or1d2 |
olfactory receptor family 1 subfamily D member 2 |
multiple interactions |
ISO |
[bourgeonal binds to and results in increased activity of OR1D2 protein] which results in increased abundance of Calcium |
CTD |
PMID:21454470 |
|
NCBI chr10:59,212,947...59,213,882
Ensembl chr10:59,207,257...59,214,085
|
|
G |
Or5d18 |
olfactory receptor family 5 subfamily D member 18 |
multiple interactions |
ISO |
[ethyl vanillin binds to and results in increased activity of OR5D18 protein] which results in increased transport of Calcium; [Eugenol binds to and results in increased activity of OR5D18 protein] which results in increased transport of Calcium; [Eugenol binds to OR5D18 protein] which results in increased transport of Calcium; [isomethyleugenol binds to and results in decreased activity of OR5D18 protein] which results in decreased transport of Calcium; isomethyleugenol inhibits the reaction [[Eugenol binds to OR5D18 protein] which results in increased transport of Calcium] |
CTD |
PMID:14685265 PMID:15716417 |
|
NCBI chr 3:73,516,522...73,517,463
Ensembl chr 3:73,516,364...73,519,858 Ensembl chr 3:73,516,364...73,519,858
|
|
G |
Orai1 |
ORAI calcium release-activated calcium modulator 1 |
multiple interactions increases uptake |
EXP ISO |
[Calcium affects the activity of and affects the localization of STIM1 protein] which affects the activity of ORAI1 protein ORAI1 protein results in increased uptake of Calcium |
CTD |
PMID:23212906 PMID:24990931 |
|
NCBI chr12:33,533,151...33,548,361
Ensembl chr12:33,534,344...33,548,405
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
ISO EXP |
OXT protein promotes the reaction [TRPC3 protein results in increased transport of Calcium] [Thapsigargin results in increased transport of Calcium] which results in increased secretion of OXT protein |
CTD |
PMID:12700192 PMID:22028774 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
multiple interactions |
ISO |
[alpha,beta-methyleneadenosine 5'-triphosphate binds to and results in increased activity of P2RX3 protein] which results in increased abundance of Calcium; Trichloroethylene inhibits the reaction [[alpha,beta-methyleneadenosine 5'-triphosphate binds to and results in increased activity of P2RX3 protein] which results in increased abundance of Calcium] |
CTD |
PMID:12694404 |
|
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased import of Calcium; KN 62 inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased import of Calcium]; protoberberine analog inhibits the reaction [[3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] which results in increased import of Calcium] |
CTD |
PMID:21320518 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Calcium affects the reaction [P2RY1 protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium] [N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium] |
CTD |
PMID:12694404 PMID:16236484 PMID:16973929 |
|
NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
multiple interactions affects response to substance |
ISO EXP |
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium P2RY2 protein affects the susceptibility to Calcium [Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium; Go 6976 promotes the reaction [P2RY2 protein results in increased uptake of Calcium]; Tetradecanoylphorbol Acetate inhibits the reaction [P2RY2 protein results in increased uptake of Calcium] |
CTD |
PMID:11527950 PMID:17003265 PMID:18343036 |
|
NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium] |
CTD |
PMID:12694404 |
|
NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of P4HB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
increases abundance multiple interactions |
ISO |
PAFAH1B1 protein results in increased abundance of Calcium Calcium promotes the reaction [PAFAH1B1 protein binds to IQGAP1 protein binds to CDC42 protein] PKD1 protein promotes the reaction [PAFAH1B1 protein results in increased abundance of Calcium]; PKD2 protein promotes the reaction [PAFAH1B1 protein results in increased abundance of Calcium] |
CTD |
PMID:15001556 PMID:16369480 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
multiple interactions |
ISO |
PARG protein promotes the reaction [Hydrogen Peroxide results in increased uptake of Calcium] |
CTD |
PMID:20878536 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
PARP1 protein promotes the reaction [Hydrogen Peroxide results in increased uptake of Calcium] |
CTD |
PMID:20878536 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pask |
PAS domain containing serine/threonine kinase |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of PASK mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 9:93,844,275...93,886,036
Ensembl chr 9:93,844,278...93,885,111
|
|
G |
Pax6 |
paired box 6 |
affects expression |
EXP |
Calcium affects the expression of PAX6 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pax8 |
paired box 8 |
affects expression |
EXP |
Calcium affects the expression of PAX8 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:7,185,721...7,242,363
Ensembl chr 3:7,185,723...7,242,363
|
|
G |
Pcdh19 |
protocadherin 19 |
affects binding |
ISO |
Calcium binds to PCDH19 protein |
CTD |
PMID:18469813 |
|
NCBI chr X:96,767,686...96,873,477
Ensembl chr X:96,771,947...96,873,524
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases import |
ISO |
PDGFB protein results in increased import of Calcium |
CTD |
PMID:19576918 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects abundance |
ISO |
PDK1 protein affects the reaction [[Calcium co-treated with Ionomycin] results in increased phosphorylation of AKT1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester affects the reaction [PDK1 protein affects the abundance of Calcium]; [PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; PDK1 protein affects the reaction [Thapsigargin affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium]; tubacin affects the reaction [PDK1 protein affects the abundance of Calcium]; tubacin inhibits the reaction [PDK1 protein affects the reaction [Thapsigargin affects the abundance of Calcium]] |
CTD |
PMID:28634229 PMID:28887310 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases activity |
ISO |
Calcium results in decreased activity of PGP protein |
CTD |
PMID:24338473 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pick1 |
protein interacting with PRKCA 1 |
multiple interactions |
EXP |
Calcium affects the reaction [PICK1 protein binds to AGO2 protein]; Calcium deficiency inhibits the reaction [Excitatory Amino Acid Agonists inhibits the reaction [PICK1 protein binds to AGO2 protein]]; Calcium promotes the reaction [PICK1 protein binds to GRIA2 protein] |
CTD |
PMID:28404816 |
|
NCBI chr 7:110,796,623...110,816,850
Ensembl chr 7:110,797,117...110,816,848
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
affects transport |
EXP |
PIK3CB protein affects the transport of Calcium |
CTD |
PMID:11597992 |
|
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
affects transport |
ISO |
PIK3CD protein affects the transport of Calcium |
CTD |
PMID:16179367 |
|
NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930
|
|
G |
Pip5k1b |
phosphatidylinositol-4-phosphate 5-kinase type 1 beta |
affects expression |
EXP |
Calcium affects the expression of PIP5K1B mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 1:221,907,220...222,183,672
Ensembl chr 1:221,914,159...222,183,672
|
|
G |
Pkd1 |
polycystin 1, transient receptor potential channel interacting |
multiple interactions |
ISO |
PKD1 protein promotes the reaction [PAFAH1B1 protein results in increased abundance of Calcium] PKD1 protein affects the reaction [Caffeine affects the abundance of Calcium]; PKD1 protein affects the reaction [Thapsigargin affects the abundance of Calcium] |
CTD |
PMID:15001556 PMID:18679710 |
|
NCBI chr10:13,573,779...13,621,138
Ensembl chr10:13,573,021...13,621,128
|
|
G |
Pkd2 |
polycystin 2, transient receptor potential cation channel |
multiple interactions increases transport |
ISO |
PKD2 protein promotes the reaction [PAFAH1B1 protein results in increased abundance of Calcium] IFT88 protein affects the reaction [PKD2 protein results in increased uptake of Calcium] PKD2 protein results in increased transport of Calcium |
CTD |
PMID:15001556 PMID:15100357 PMID:16396941 |
|
NCBI chr14:5,237,135...5,280,455
Ensembl chr14:5,237,135...5,280,825
|
|
G |
Pklr |
pyruvate kinase L/R |
multiple interactions |
EXP |
Calcium inhibits the reaction [Phenylephrine results in decreased activity of PKLR protein] |
CTD |
PMID:747652 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pla2g1b |
phospholipase A2 group IB |
multiple interactions increases abundance |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[PLA2G1B protein results in increased abundance of Calcium] which results in increased expression of CXCL8 protein]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [PLA2G1B protein results in increased abundance of Calcium]; [PLA2G1B protein results in increased abundance of Calcium] which results in increased expression of CXCL8 protein |
CTD |
PMID:15528384 |
|
NCBI chr12:41,142,193...41,151,967
Ensembl chr12:41,142,200...41,153,226
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
increases uptake multiple interactions |
EXP |
PLA2G2A protein results in increased uptake of Calcium BQ 788 inhibits the reaction [EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium]]; EDN3 protein inhibits the reaction [PLA2G2A protein affects the uptake of Calcium] |
CTD |
PMID:15695168 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
increases activity multiple interactions |
EXP |
Calcium deficiency results in increased activity of PLA2G6 protein 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G6 protein] which results in increased susceptibility to Calcium]; [Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G6 protein] which results in increased susceptibility to Calcium |
CTD |
PMID:17885217 PMID:21178110 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Plcg2 |
phospholipase C, gamma 2 |
multiple interactions |
ISO |
Calcium promotes the reaction [PLCG2 protein mutant form results in increased chemical synthesis of Inositol Phosphates]; Calcium promotes the reaction [PLCG2 protein results in increased chemical synthesis of Inositol Phosphates] |
CTD |
PMID:27542411 |
|
NCBI chr19:45,547,416...45,683,930
Ensembl chr19:45,547,416...45,683,930
|
|
G |
Pnoc |
prepronociceptin |
decreases abundance |
EXP |
PNOC protein results in decreased abundance of Calcium |
CTD |
PMID:21039959 |
|
NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity multiple interactions |
ISO EXP |
Calcium results in increased activity of PON1 protein [Calcium results in increased activity of PON1 protein] which affects the susceptibility to O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate; [Calcium results in increased activity of PON1 protein] which affects the susceptibility to oxamyl; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Aldicarb; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to methylparaoxon; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Paraoxon [Calcium co-treated with 1,2-dioleoyl-sn-glycero-3-phosphoglycerol] results in increased stability of PON1 protein; [Calcium co-treated with Oleic Acid] results in increased stability of PON1 protein; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Aldicarb; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to methylparaoxon; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to oxamyl; [Calcium results in increased activity of PON1 protein] which results in decreased susceptibility to Paraoxon; Calcium promotes the reaction [Oleic Acid inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of PON1 protein]] |
CTD |
PMID:12871208 PMID:27132127 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
affects abundance multiple interactions |
ISO |
PON2 gene polymorphism affects the abundance of Calcium Calcium inhibits the reaction [lead acetate results in decreased activity of PON2 protein] |
CTD |
PMID:16141008 PMID:22271317 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Pou6f1 |
POU class 6 homeobox 1 |
affects expression |
EXP |
Calcium affects the expression of POU6F1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 7:131,677,719...131,700,869
Ensembl chr 7:131,680,141...131,686,843 Ensembl chr 7:131,680,141...131,686,843
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[GW 7647 binds to and results in increased activity of PPARA protein] affects the reaction [Glucose affects the abundance of Calcium]; [Oleylethanolamide binds to and results in increased activity of PPARA protein] affects the reaction [Glucose affects the abundance of Calcium]; [pirinixic acid binds to and results in increased activity of PPARA protein] affects the reaction [Glucose affects the abundance of Calcium] |
CTD |
PMID:19017711 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
affects expression |
EXP |
Calcium affects the expression of PPP1CA mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp1cb |
protein phosphatase 1 catalytic subunit beta |
affects expression |
EXP |
Calcium affects the expression of PPP1CB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 6:23,958,813...23,992,841
Ensembl chr 6:23,960,998...23,992,824
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
multiple interactions |
EXP |
[Egtazic Acid co-treated with Calcium deficiency] results in increased expression of PPP1R15A mRNA |
CTD |
PMID:9878749 |
|
NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
affects abundance affects transport |
ISO |
PPP2CA protein affects the abundance of Calcium PPP2CA protein affects the transport of Calcium |
CTD |
PMID:15247211 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Ppp3r1 |
protein phosphatase 3, regulatory subunit B, alpha |
multiple interactions affects response to substance |
ISO |
PPP3R1 gene mutant form inhibits the reaction [ATP2A2 protein affects the transport of Calcium]; PPP3R1 gene mutant form inhibits the reaction [SLC8A1 protein affects the transport of Calcium] PPP3R1 gene mutant form affects the susceptibility to Calcium |
CTD |
PMID:19700627 |
|
NCBI chr14:91,556,743...91,606,391
Ensembl chr14:91,604,121...91,606,907
|
|
G |
Prdx6 |
peroxiredoxin 6 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of PRDX6 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases response to substance |
EXP |
[Tretinoin co-treated with Calcium] results in increased activity of PRKCA protein PRKCA protein results in increased susceptibility to Calcium |
CTD |
PMID:12388232 PMID:16114872 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
ISO |
Calcium inhibits the reaction [Chlordecone results in increased activity of PRKCB protein]; Calcium inhibits the reaction [Dicofol results in increased activity of PRKCB protein] |
CTD |
PMID:1724372 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcd |
protein kinase C, delta |
affects expression |
EXP |
Calcium affects the expression of PRKCD mRNA |
CTD |
PMID:15913539 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions increases phosphorylation affects response to substance |
ISO |
PRKCE protein affects the reaction [Oxygen deficiency results in increased abundance of Calcium] Calcium results in increased phosphorylation of PRKCE protein chelerythrine inhibits the reaction [Calcium results in increased phosphorylation of PRKCE protein]; PRKCE protein affects the reaction [F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]] PRKCE protein affects the susceptibility to Calcium |
CTD |
PMID:15242976 PMID:16793902 PMID:17087917 PMID:21562303 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prkcg |
protein kinase C, gamma |
multiple interactions |
ISO |
[Tetradecanoylphorbol Acetate co-treated with Calcium] inhibits the reaction [Zinc promotes the reaction [OPRM1 protein binds to PRKCG protein]] |
CTD |
PMID:18652891 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Prkd1 |
protein kinase D1 |
multiple interactions |
ISO EXP |
PRKD1 promotes the reaction [Capsaicin results in increased uptake of Calcium] PRKD1 mutant form inhibits the reaction [Capsaicin results in increased uptake of Calcium] |
CTD |
PMID:15471852 |
|
NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
increases response to substance |
ISO |
PRKG1 protein results in increased susceptibility to Calcium |
CTD |
PMID:16533816 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
Calcium inhibits the reaction [PRL protein binds to PRLR protein] |
CTD |
PMID:6197504 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prlr |
prolactin receptor |
affects expression multiple interactions |
EXP ISO |
Calcium affects the expression of PRLR mRNA Calcium inhibits the reaction [PRL protein binds to PRLR protein] |
CTD |
PMID:6197504 PMID:15913539 |
|
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
|
|
G |
Prok2 |
prokineticin 2 |
multiple interactions increases abundance |
ISO |
PROKR1 protein affects the reaction [PROK2 protein results in increased abundance of Calcium] |
CTD |
PMID:16793879 PMID:17107623 |
|
NCBI chr 4:132,346,681...132,361,754
Ensembl chr 4:132,347,103...132,361,385
|
|
G |
Prokr1 |
prokineticin receptor 1 |
multiple interactions |
ISO |
PROKR1 protein affects the reaction [Capsaicin results in increased abundance of Calcium]; PROKR1 protein affects the reaction [PROK2 protein results in increased abundance of Calcium] |
CTD |
PMID:16793879 |
|
NCBI chr 4:120,022,301...120,033,367
Ensembl chr 4:120,021,747...120,033,379
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [PTAFR protein affects the localization of and affects the abundance of Calcium] |
CTD |
PMID:11297424 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
PTGDR2 protein affects the abundance of and affects the localization of Calcium |
CTD |
PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
multiple interactions increases abundance |
ISO |
17-phenyltrinorprostaglandin E2 inhibits the reaction [PTGER1 protein results in increased abundance of Calcium] |
CTD |
PMID:11809688 |
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions |
EXP |
PTGER3 protein affects the reaction [Dinoprostone results in decreased transport of Calcium]; PTGER3 protein affects the reaction [ONO AE 248 results in decreased transport of Calcium] |
CTD |
PMID:12535167 |
|
NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
|
|
G |
Ptgir |
prostaglandin I2 receptor |
multiple interactions |
ISO |
[cicaprost results in increased activity of PTGIR protein] which results in increased abundance of Calcium |
CTD |
PMID:11895442 |
|
NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:77,579,596...77,581,979
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
affects expression |
EXP |
Calcium affects the expression of PTGS1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
Calcium affects the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA] Calcium deficiency inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA] Calcium deficiency inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:12493747 PMID:19782052 PMID:21262218 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth |
parathyroid hormone |
multiple interactions increases stability increases abundance decreases abundance affects metabolic processing decreases expression |
ISO EXP |
[Calcitriol co-treated with Calcium] results in decreased expression of PTH protein; [Cholecalciferol co-treated with Calcium] results in decreased expression of PTH protein Calcium deficiency results in increased stability of PTH mRNA Calcium affects the reaction [Aluminum Compounds results in decreased expression of PTH mRNA]; Calcium affects the reaction [Aluminum Compounds results in decreased secretion of PTH protein]; Calcium affects the reaction [Calcitriol results in decreased expression of PTH mRNA]; Calcium affects the reaction [Calcitriol results in decreased secretion of PTH protein]; Calcium deficiency inhibits the reaction [KHSRP protein binds to PTH 3' UTR]; Calcium deficiency promotes the reaction [HNRNPD protein binds to PTH 3' UTR] PTH protein modified form results in increased abundance of Calcium PTH protein results in decreased abundance of Calcium PTH protein affects the metabolism of Calcium Calcium results in decreased expression of PTH protein |
CTD |
PMID:80633 PMID:6330156 PMID:15891005 PMID:16094769 PMID:16316325 PMID:17476578 PMID:18583400 More...
|
|
NCBI chr 1:167,508,121...167,511,530
Ensembl chr 1:167,508,598...167,511,530
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
affects expression |
EXP |
Calcium affects the expression of PTH1R mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO EXP |
Calcium affects the reaction [(N)-methanocarba-2MeSADP results in increased phosphorylation of PTK2B protein] Calcium affects the phosphorylation of and affects the activity of PTK2B protein |
CTD |
PMID:16236484 PMID:16877402 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptpn12 |
protein tyrosine phosphatase, non-receptor type 12 |
affects expression |
EXP |
Calcium affects the expression of PTPN12 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927
|
|
G |
Pygl |
glycogen phosphorylase L |
multiple interactions |
EXP |
[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein; Calcium deficiency inhibits the reaction [Calcimycin results in increased activity of PYGL protein]; Glucose inhibits the reaction [[Phenylephrine co-treated with Calcium] results in increased activity of PYGL protein] |
CTD |
PMID:747652 PMID:6430282 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
affects expression |
EXP |
Calcium affects the expression of RAB7 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Ralgds |
ral guanine nucleotide dissociation stimulator |
affects expression |
EXP |
Calcium affects the expression of RALGDS mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
Calcium promotes the reaction [ibandronic acid results in decreased prenylation of RAP1A protein] |
CTD |
PMID:18190680 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rapgef3 |
Rap guanine nucleotide exchange factor 3 |
multiple interactions |
ISO |
RAPGEF3 protein promotes the reaction [Benzo(a)pyrene results in increased transport of Calcium] |
CTD |
PMID:22167199 |
|
NCBI chr 7:128,875,772...128,898,203
Ensembl chr 7:128,875,773...128,898,521
|
|
G |
Rbp1 |
retinol binding protein 1 |
affects expression |
EXP |
Calcium affects the expression of RBP1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 8:99,025,218...99,046,740
Ensembl chr 8:99,025,206...99,046,743
|
|
G |
Ren |
renin |
decreases secretion multiple interactions |
EXP |
Calcium results in decreased secretion of REN protein [[Calcium results in increased activity of MYLK protein] which results in increased phosphorylation of MYL9 protein] which results in decreased secretion of REN protein; ML 7 inhibits the reaction [Calcium results in decreased secretion of REN protein] |
CTD |
PMID:9618396 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
EXP |
RGS4 protein inhibits the reaction [PTAFR protein affects the localization of and affects the abundance of Calcium] |
CTD |
PMID:11297424 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Rps3a |
ribosomal protein S3a |
affects expression |
EXP |
Calcium affects the expression of RPS3A mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 2:171,524,685...171,529,054
Ensembl chr 2:171,524,500...171,529,055
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
EXP ISO |
Calcium affects the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased phosphorylation of RPS6KB1 protein] [Resveratrol results in increased abundance of Calcium] which results in decreased expression of RPS6KB1 protein modified form; dorsomorphin inhibits the reaction [[Resveratrol results in increased abundance of Calcium] which results in decreased expression of RPS6KB1 protein modified form] |
CTD |
PMID:12935885 PMID:23680031 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
ISO |
[Resveratrol results in increased abundance of Calcium] which results in increased activity of RPTOR protein modified form; dorsomorphin inhibits the reaction [[Resveratrol results in increased abundance of Calcium] which results in increased activity of RPTOR protein modified form] |
CTD |
PMID:23680031 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Rraga |
Ras-related GTP binding A |
affects expression |
EXP |
Calcium affects the expression of RRAGA mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 5:101,113,341...101,114,936
Ensembl chr 5:101,112,859...101,114,510
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions affects abundance increases secretion increases abundance |
ISO EXP |
[Caffeine results in increased activity of RYR1 protein] which affects the localization of Calcium; [chlorocresol results in increased activity of RYR1 protein] which affects the localization of Calcium; [chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium; [Halothane results in increased activity of RYR1 protein] which affects the localization of Calcium; [RYR1 protein co-treated with 2,3,6,2',3',6'-hexachlorobiphenyl] affects the susceptibility to Calcium; Calcium affects the folding of [CALM1 protein binds to RYR1 protein modified form]; Calcium affects the reaction [CALM1 protein binds to and affects the activity of RYR1 protein]; Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium]; RYR1 protein polymorphism affects the reaction [Caffeine results in increased secretion of Calcium]; RYR1 protein polymorphism affects the reaction [chlorocresol results in increased secretion of Calcium] RYR1 protein polymorphism affects the abundance of Calcium RYR1 protein mutant form results in increased secretion of Calcium RYR1 gene mutant form results in increased abundance of Calcium Calcium affects the reaction [CALM1 protein binds to and affects the activity of RYR1 protein]; Calcium affects the reaction [CALM1 protein modified form binds to and affects the activity of RYR1 protein] |
CTD |
PMID:15381065 PMID:15628869 PMID:16372898 PMID:17707769 PMID:18719443 PMID:18954145 PMID:19191329 PMID:21485675 More...
|
|
NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions |
ISO EXP |
FKBP1A protein inhibits the reaction [Calcium results in increased activity of RYR2 protein] Dantrolene inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]]; HOMER1 protein alternative form inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]]; HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 PMID:17872463 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
S100a13 |
S100 calcium binding protein A13 |
multiple interactions |
ISO |
[Calcium co-treated with Copper] binds to and affects the folding of S100A13 protein; Calcium binds to and affects the folding of S100A13 protein |
CTD |
PMID:16766622 |
|
NCBI chr 2:175,999,439...176,005,933
|
|
G |
S100a2 |
S100 calcium binding protein A2 |
affects binding multiple interactions |
ISO |
Calcium binds to S100A2 protein [Zinc binds to S100A2 protein] inhibits the reaction [Calcium binds to S100A2 protein] |
CTD |
PMID:17239974 |
|
NCBI chr 2:176,077,081...176,078,325
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
affects response to substance |
ISO |
S100A6 protein affects the susceptibility to Calcium |
CTD |
PMID:15068510 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions affects binding |
ISO |
[Zinc co-treated with Calcium] binds to [S100A8 protein binds to S100A9 protein] Calcium binds to [S100A8 protein binds to S100A9 protein] |
CTD |
PMID:17050004 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
affects binding multiple interactions |
ISO |
Calcium binds to [S100A8 protein binds to S100A9 protein] [Zinc co-treated with Calcium] binds to [S100A8 protein binds to S100A9 protein] |
CTD |
PMID:17050004 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
S100g |
S100 calcium binding protein G |
affects expression |
EXP |
Calcium affects the expression of S100G mRNA |
CTD |
PMID:15913539 |
|
NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433
|
|
G |
Scgb1a1 |
secretoglobin family 1A member 1 |
increases expression |
ISO |
Calcium results in increased expression of SCGB1A1 mRNA; Calcium results in increased expression of SCGB1A1 protein |
CTD |
PMID:16237193 |
|
NCBI chr 1:205,977,060...205,980,610
Ensembl chr 1:205,977,060...205,980,610
|
|
G |
Sct |
secretin |
increases abundance |
ISO |
SCT protein results in increased abundance of Calcium |
CTD |
PMID:1220513 |
|
NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658
|
|
G |
Sec61a1 |
SEC61 translocon subunit alpha 1 |
multiple interactions increases transport |
ISO |
[HSPA5 protein binds to SEC61A1 protein] which results in decreased transport of Calcium; [SEC61A1 protein results in increased transport of Calcium] which results in increased susceptibility to Thapsigargin; DNAJB11 protein inhibits the reaction [SEC61A1 protein results in increased transport of Calcium]; DNAJC3 protein inhibits the reaction [SEC61A1 protein results in increased transport of Calcium] |
CTD |
PMID:26085089 |
|
NCBI chr 4:120,973,519...120,987,871
Ensembl chr 4:120,960,626...120,987,925
|
|
G |
Selenot |
selenoprotein T |
multiple interactions affects abundance |
EXP |
Calcium affects the reaction [ADCYAP1 protein results in increased expression of SELENOT mRNA]; SELENOT protein affects the reaction [ADCYAP1 protein results in increased abundance of Calcium]; Thapsigargin promotes the reaction [SELENOT protein affects the abundance of Calcium] |
CTD |
PMID:18198219 |
|
NCBI chr 2:142,804,387...142,821,438
Ensembl chr 2:142,804,405...142,821,427
|
|
G |
Serpine1 |
serpin family E member 1 |
increases stability |
ISO |
Calcium results in increased stability of SERPINE1 protein |
CTD |
PMID:21280127 PMID:21280128 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc12a5 |
solute carrier family 12 member 5 |
multiple interactions |
EXP |
Calcium affects the reaction [Zinc results in increased activity of SLC12A5 protein] |
CTD |
PMID:22441041 |
|
NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
decreases expression multiple interactions increases expression |
ISO |
Calcium deficiency results in decreased expression of SLC23A2 mRNA Foscarnet inhibits the reaction [Calcium results in increased expression of SLC23A2 mRNA]; Nifedipine inhibits the reaction [Calcium results in increased expression of SLC23A2 mRNA] Calcium results in increased expression of SLC23A2 mRNA; Calcium results in increased expression of SLC23A2 protein |
CTD |
PMID:12788230 |
|
NCBI chr 3:119,302,651...119,395,289
Ensembl chr 3:119,302,666...119,460,343
|
|
G |
Slc24a2 |
solute carrier family 24 member 2 |
increases uptake |
EXP |
SLC24A2 protein results in increased uptake of Calcium |
CTD |
PMID:14660663 |
|
NCBI chr 5:101,497,916...101,741,840
Ensembl chr 5:101,502,278...101,739,337
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
EXP |
Calcium deficiency inhibits the reaction [2,3-dinitrophenol results in increased activity of SLC2A1 protein]; Calcium deficiency inhibits the reaction [Arsenates results in increased activity of SLC2A1 protein]; Calcium deficiency inhibits the reaction [Azides results in increased activity of SLC2A1 protein]; Calcium deficiency inhibits the reaction [INS1 protein results in increased activity of SLC2A1 protein] |
CTD |
PMID:10970766 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions |
EXP |
[CACNA1D protein results in increased uptake of Calcium] which affects the localization of SLC2A2 protein |
CTD |
PMID:17272349 |
|
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
[[Chloroquine results in increased abundance of Calcium] which affects the localization of SLC2A4 protein] which results in increased uptake of Glucose; [Chloroquine results in increased abundance of Calcium] which affects the localization of SLC2A4 protein |
CTD |
PMID:27160165 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of SLC30A1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Slc5a1 |
solute carrier family 5 member 1 |
multiple interactions |
EXP |
SLC5A1 protein affects the reaction [CACNA1D protein results in increased uptake of Calcium] |
CTD |
PMID:17272349 |
|
NCBI chr14:77,553,990...77,618,589
Ensembl chr14:77,553,843...77,618,547
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
multiple interactions increases transport |
ISO EXP |
Calcium inhibits the reaction [SLC8A1 protein results in increased uptake of Nickel] PPP3R1 gene mutant form inhibits the reaction [SLC8A1 protein affects the transport of Calcium] SLC8A1 protein results in increased transport of Calcium 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate inhibits the reaction [SLC8A1 protein results in increased transport of Calcium] |
CTD |
PMID:10329968 PMID:18822394 PMID:19700627 |
|
NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628
|
|
G |
Slc8a2 |
solute carrier family 8 member A2 |
increases uptake |
EXP |
SLC8A2 protein results in increased uptake of Calcium |
CTD |
PMID:14660663 |
|
NCBI chr 1:76,816,583...76,852,928
Ensembl chr 1:76,808,725...76,847,072
|
|
G |
Slc8a3 |
solute carrier family 8 member A3 |
increases transport increases uptake |
EXP ISO |
SLC8A3 protein results in increased transport of Calcium SLC8A3 protein results in increased uptake of Calcium |
CTD |
PMID:14660663 PMID:17585341 PMID:29434186 |
|
NCBI chr 6:100,874,359...101,007,989
Ensembl chr 6:100,874,369...101,007,508
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
multiple interactions |
EXP |
3-methylsulfonyl-4-piperidinobenzoyl guanidine inhibits the reaction [[Phenylephrine results in increased activity of SLC9A1 protein] which results in increased transport of Calcium]; [[Phenylephrine results in increased activity of SLC9A1 protein] which results in increased transport of Calcium] which results in increased expression of ATP2A2 protein; [Phenylephrine results in increased activity of SLC9A1 protein] which results in increased transport of Calcium |
CTD |
PMID:16236312 |
|
NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases uptake |
EXP |
omega-Conotoxin GVIA inhibits the reaction [SNCA protein results in increased uptake of Calcium] |
CTD |
PMID:17179863 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases transport |
ISO EXP |
SOD1 protein mutant form promotes the reaction [SOD1 protein binds to Calcium] SOD1 protein modified form results in increased transport of Calcium; SOD1 protein results in increased transport of Calcium [Calcium co-treated with Zinc] affects the reaction [monoisoamyl-2,3-dimercaptosuccinate affects the reaction [sodium arsenite results in decreased activity of SOD1 protein]]; [Calcium co-treated with Zinc] affects the reaction [sodium arsenite results in decreased activity of SOD1 protein]; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD1 protein]; Calcium affects the reaction [sodium arsenite results in decreased activity of SOD1 protein] |
CTD |
PMID:19227972 PMID:22534743 PMID:24184500 PMID:28085149 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
[Calcium co-treated with Zinc] affects the reaction [monoisoamyl-2,3-dimercaptosuccinate affects the reaction [sodium arsenite results in decreased activity of SOD2 protein]]; [Calcium co-treated with Zinc] affects the reaction [sodium arsenite results in decreased activity of SOD2 protein]; [Zinc co-treated with Iron co-treated with Calcium] inhibits the reaction [lead acetate results in decreased expression of SOD2 protein]; Calcium affects the reaction [sodium arsenite results in decreased activity of SOD2 protein] |
CTD |
PMID:22534743 PMID:24184500 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sp7 |
Sp7 transcription factor |
affects secretion |
EXP |
SP7 protein affects the secretion of Calcium |
CTD |
PMID:19064586 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sphk1 |
sphingosine kinase 1 |
multiple interactions |
ISO |
[C5 protein results in increased activity of and results in increased localization of SPHK1 protein] which results in increased abundance of Calcium; resveratrol inhibits the reaction [[C5 protein results in increased activity of and results in increased localization of SPHK1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:19284563 PMID:19346296 |
|
NCBI chr10:101,758,567...101,764,240
Ensembl chr10:101,758,711...101,764,240
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression affects expression multiple interactions |
ISO EXP |
Calcium results in increased expression of SPP1 mRNA Calcium affects the expression of SPP1 mRNA Foscarnet inhibits the reaction [Calcium results in increased expression of SPP1 mRNA]; Nifedipine inhibits the reaction [Calcium results in increased expression of SPP1 mRNA] |
CTD |
PMID:12788230 PMID:15913539 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Spp2 |
secreted phosphoprotein 2 |
affects expression |
EXP |
Calcium affects the expression of SPP2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 9:89,006,858...89,026,676
Ensembl chr 9:89,007,175...89,026,688
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
multiple interactions increases cleavage |
EXP |
((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester inhibits the reaction [Calcium results in increased cleavage of SPTAN1 protein]; Edetic Acid inhibits the reaction [Calcium results in increased cleavage of SPTAN1 protein]; N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal inhibits the reaction [Calcium results in increased cleavage of SPTAN1 protein] |
CTD |
PMID:17069801 |
|
NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046
|
|
G |
Sqstm1 |
sequestosome 1 |
affects expression |
EXP |
Calcium affects the expression of SQSTM1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
affects transport multiple interactions affects response to substance |
ISO |
SRC protein affects the transport of Calcium Calcium deficiency inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of SRC protein] SRC protein affects the susceptibility to Calcium |
CTD |
PMID:17551092 PMID:19782052 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Calcium inhibits the reaction [Cyclic AMP results in increased expression of STAR protein] |
CTD |
PMID:19822634 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Calcium promotes the reaction [[Diclofenac co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:26609140 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stim1 |
stromal interaction molecule 1 |
affects abundance increases uptake multiple interactions |
ISO EXP |
STIM1 protein affects the abundance of Calcium STIM1 protein results in increased uptake of Calcium [Calcium affects the activity of and affects the localization of STIM1 protein] which affects the activity of ORAI1 protein; STIM1 protein promotes the reaction [Taurodeoxycholic Acid results in increased abundance of Calcium] |
CTD |
PMID:18342630 PMID:18439569 PMID:23212906 PMID:24990931 |
|
NCBI chr 1:156,656,246...156,818,777
Ensembl chr 1:156,656,013...156,818,363
|
|
G |
Stmn1 |
stathmin 1 |
affects expression |
EXP |
Calcium affects the expression of STMN1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
multiple interactions |
ISO |
Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Syn2 |
synapsin II |
multiple interactions decreases abundance |
ISO |
SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium] SYN2 mutant form results in decreased abundance of Calcium |
CTD |
PMID:18701217 |
|
NCBI chr 4:148,178,846...148,347,010
Ensembl chr 4:148,186,270...148,344,192
|
|
G |
Syt1 |
synaptotagmin 1 |
affects binding |
EXP |
Calcium binds to SYT1 protein |
CTD |
PMID:16262243 |
|
NCBI chr 7:43,813,204...44,358,020
Ensembl chr 7:43,815,785...44,357,803
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases transport |
ISO |
TAC1 protein modified form results in increased transport of Calcium |
CTD |
PMID:30116771 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Taok1 |
TAO kinase 1 |
affects expression |
EXP |
Calcium affects the expression of TAOK1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:62,373,072...62,465,295
Ensembl chr10:62,381,404...62,465,766
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions increases transport |
ISO |
rosiglitazone inhibits the reaction [TBXA2R protein results in increased transport of Calcium]; troglitazone inhibits the reaction [TBXA2R protein results in increased transport of Calcium] |
CTD |
PMID:16499875 |
|
NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176
|
|
G |
Tgfa |
transforming growth factor alpha |
increases abundance |
ISO |
TGFA protein results in increased abundance of Calcium |
CTD |
PMID:11527950 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases abundance increases uptake |
ISO EXP |
TGFB1 protein results in increased abundance of Calcium TGFB1 protein results in increased uptake of Calcium |
CTD |
PMID:15703175 PMID:17090780 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgm1 |
transglutaminase 1 |
increases expression multiple interactions |
ISO |
Calcium results in increased expression of TGM1 mRNA NPS R-467 promotes the reaction [Calcium results in increased expression of TGM1 mRNA] |
CTD |
PMID:10469331 |
|
NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17A |
affects expression |
EXP |
Calcium affects the expression of TIMM17A mRNA |
CTD |
PMID:15913539 |
|
NCBI chr13:46,731,117...46,742,604
Ensembl chr13:46,730,660...46,742,655
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
Calcium deficiency inhibits the reaction [TJP1 protein binds to OCLN protein] |
CTD |
PMID:11054866 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
KL protein inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]] [IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]; [TNF protein co-treated with IFNG protein] promotes the reaction [Diclofenac affects the abundance of Calcium]; Calcium affects the reaction [Morphine inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]] |
CTD |
PMID:23747339 PMID:24068670 PMID:26609140 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
Calcium promotes the reaction [ITIH1 protein binds to TNFAIP6 protein]; Calcium promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
TNFRSF11B protein inhibits the reaction [IL11 protein results in increased abundance of Calcium]; TNFRSF11B protein inhibits the reaction [TNFSF11 protein results in increased abundance of Calcium] |
CTD |
PMID:12110441 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions increases abundance |
ISO |
TNFRSF11B protein inhibits the reaction [TNFSF11 protein results in increased abundance of Calcium] |
CTD |
PMID:12110441 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnc1 |
troponin C1, slow skeletal and cardiac type |
affects binding |
ISO |
TNNC1 protein binds to Calcium |
CTD |
PMID:18212018 |
|
NCBI chr16:6,400,801...6,405,634
Ensembl chr16:6,402,171...6,405,634
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression affects localization |
ISO |
Calcium results in decreased expression of TP53 protein TP53 protein affects the localization of Calcium |
CTD |
PMID:15059885 PMID:16043423 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp73 |
tumor protein p73 |
multiple interactions |
ISO |
[Calcium co-treated with CAPN1 protein] results in increased degradation of TP73 protein modified form |
CTD |
PMID:21516125 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
affects activity multiple interactions |
ISO EXP |
Calcium affects the activity of TRPA1 protein [allicin binds to and results in increased activity of TRPA1 protein] which results in increased transport of Calcium; [allyl isothiocyanate binds to and results in increased activity of TRPA1 protein] which results in increased transport of Calcium; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester co-treated with TRPA1 protein] results in increased uptake of Calcium; Calcium affects the reaction [Capsaicin inhibits the reaction [TRPA1 protein affects the susceptibility to mustard oil]]; TRPA1 affects the reaction [AM 1241 results in increased abundance of Calcium]; TRPA1 promotes the reaction [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone results in increased abundance of Calcium]; TRPA1 promotes the reaction [mustard oil results in increased abundance of Calcium] 4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime inhibits the reaction [[2-chloroethyl ethyl sulfide results in increased activity of TRPA1 protein] which results in increased uptake of Calcium]; 4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime inhibits the reaction [[Mustard Gas results in increased activity of TRPA1 protein] which results in increased uptake of Calcium]; [2-chloroethyl ethyl sulfide results in increased activity of TRPA1 protein] which results in increased uptake of Calcium; [allyl isothiocyanate results in increased activity of TRPA1 protein] which results in increased uptake of Calcium; [cannabidivarin results in increased activity of TRPA1 protein] which results in increased uptake of Calcium; [Cannabinol results in increased activity of TRPA1 protein] which results in increased uptake of Calcium; [cinnamaldehyde results in increased activity of TRPA1 protein] which results in increased transport of Calcium; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester co-treated with TRPA1 protein] results in increased uptake of Calcium; [hydroquinone results in increased activity of TRPA1 protein] which results in increased import of Calcium; [Mustard Gas results in increased activity of TRPA1 protein] which results in increased uptake of Calcium; [Pyruvaldehyde results in increased activity of TRPA1 protein] which results in increased transport of Calcium; [Vehicle Emissions results in increased activity of TRPA1 protein] which results in increased import of Calcium; Acetylcysteine inhibits the reaction [[allyl isothiocyanate results in increased activity of TRPA1 protein] which results in increased uptake of Calcium]; Acetylcysteine inhibits the reaction [[Mustard Gas results in increased activity of TRPA1 protein] which results in increased uptake of Calcium]; Dithiothreitol inhibits the reaction [[hydroquinone results in increased activity of TRPA1 protein] which results in increased import of Calcium]; mustard oil promotes the reaction [[hydroquinone results in increased activity of TRPA1 protein] which results in increased import of Calcium]; TRPA1 mRNA affects the reaction [Acrolein results in increased uptake of Calcium]; TRPA1 mRNA affects the reaction [allyl isothiocyanate results in increased uptake of Calcium]; TRPA1 mRNA affects the reaction [cinnamaldehyde results in increased uptake of Calcium] |
CTD |
PMID:15843607 PMID:17314320 PMID:17590514 PMID:18234885 PMID:19507004 PMID:20086034 PMID:22863862 PMID:27738742 PMID:28790335 PMID:30945539 PMID:31096838 More...
|
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpc1 |
transient receptor potential cation channel, subfamily C, member 1 |
increases transport increases import multiple interactions increases uptake decreases transport |
EXP ISO |
TRPC1 protein results in increased transport of Calcium TRPC1 protein results in increased import of Calcium LEP protein promotes the reaction [TRPC1 protein results in increased transport of Calcium] TRPC1 protein results in increased uptake of Calcium TRPC1 protein results in decreased transport of Calcium |
CTD |
PMID:17174323 PMID:18822394 PMID:20107083 PMID:22157757 PMID:24953315 |
|
NCBI chr 8:96,263,322...96,314,220
Ensembl chr 8:96,263,329...96,314,276
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions increases transport affects transport affects secretion |
ISO EXP |
1-oleoyl-2-acetylglycerol affects the reaction [TRPC3 protein affects the transport of Calcium]; 1-oleoyl-2-acetylglycerol promotes the reaction [TRPC3 protein results in increased transport of Calcium]; OXT protein promotes the reaction [TRPC3 protein results in increased transport of Calcium]; Thapsigargin promotes the reaction [TRPC3 protein results in increased transport of Calcium] TRPC3 protein affects the secretion of Calcium 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [[Phenylephrine results in increased expression of TRPC3 protein] which results in increased transport of Calcium]; [Phenylephrine results in increased expression of TRPC3 protein] which results in increased transport of Calcium; TRPC3 protein promotes the reaction [1-oleoyl-2-acetoyl-sn-glycerol results in increased transport of Calcium]; TRPC3 protein promotes the reaction [Phenylephrine results in increased transport of Calcium]; TRPC3 protein promotes the reaction [Thapsigargin results in increased transport of Calcium] |
CTD |
PMID:12700192 PMID:12736256 PMID:15672411 PMID:16484216 PMID:17351372 PMID:18822394 PMID:19244478 More...
|
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc4 |
transient receptor potential cation channel, subfamily C, member 4 |
multiple interactions increases transport |
ISO |
TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium]; TRPC4 protein affects the reaction [Carbachol results in increased transport of Calcium] TRPC4 protein results in increased transport of Calcium LEP protein promotes the reaction [TRPC4 protein results in increased transport of Calcium] |
CTD |
PMID:11830588 PMID:20107083 |
|
NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
multiple interactions increases transport affects transport |
ISO |
1-oleoyl-2-acetylglycerol affects the reaction [TRPC5 protein affects the transport of Calcium]; 2-aminoethoxydiphenyl borate promotes the reaction [resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]]; Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Ascorbic Acid inhibits the reaction [Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Calcium promotes the reaction [resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]]; Carbachol promotes the reaction [TRPC5 protein results in increased transport of Calcium]; CAT protein inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; CAT protein inhibits the reaction [Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Diethylstilbestrol inhibits the reaction [TRPC5 protein results in increased transport of Calcium]; Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]; Gallic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Gallic Acid inhibits the reaction [Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]; Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol inhibits the reaction [Carbachol promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol inhibits the reaction [Hydrogen Peroxide promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol inhibits the reaction [Lysophosphatidylcholines promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol inhibits the reaction [TRPC5 protein results in increased transport of Calcium]; resveratrol promotes the reaction [Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]] LEP protein promotes the reaction [TRPC5 protein results in increased transport of Calcium] |
CTD |
PMID:17351372 PMID:20107083 PMID:21127073 |
|
NCBI chr X:107,946,163...108,230,991
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
affects transport increases uptake multiple interactions increases transport |
ISO EXP |
TRPC6 protein affects the transport of Calcium TRPC6 protein results in increased uptake of Calcium 1,2-dioctanoylglycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; 1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1H-imidazole inhibits the reaction [Acetylcholine promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; 1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [Acetylcholine promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; 1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; 2-aminoethyl diphenylborinate inhibits the reaction [Acetylcholine promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; 2-aminoethyl diphenylborinate inhibits the reaction [Thapsigargin promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; Acetylcholine promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; Flufenamic Acid inhibits the reaction [1-oleoyl-2-acetoyl-sn-glycerol promotes the reaction [TRPC6 protein results in increased uptake of Calcium]]; Thapsigargin promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; TRPC6 protein promotes the reaction [1-oleoyl-2-acetoyl-sn-glycerol results in increased transport of Calcium]; TRPC6 protein promotes the reaction [Phenylephrine results in increased transport of Calcium] [Diglycerides results in increased activity of TRPC6 protein] which results in increased abundance of Calcium; [Flufenamic Acid results in increased activity of TRPC6 protein] which results in increased uptake of Calcium; CASR protein promotes the reaction [TRPC6 protein results in increased uptake of Calcium]; TRPC6 protein promotes the reaction [[VEGFA protein results in increased activity of KDR protein] which results in increased abundance of Calcium]; VEGFA protein promotes the reaction [[Diglycerides results in increased activity of TRPC6 protein] which results in increased abundance of Calcium] TRPC6 protein results in increased transport of Calcium |
CTD |
PMID:11179201 PMID:11535132 PMID:14551041 PMID:15672411 PMID:18209485 PMID:18822394 PMID:21562303 More...
|
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
increases transport multiple interactions |
ISO EXP |
TRPM2 protein results in increased transport of Calcium TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium]; TRPM2 protein promotes the reaction [Hydrogen Peroxide results in increased uptake of Calcium] [Clotrimazole results in decreased activity of TRPM2 protein] inhibits the reaction [Mustard Gas results in increased abundance of Calcium]; [Econazole results in decreased activity of TRPM2 protein] inhibits the reaction [Mustard Gas results in increased abundance of Calcium]; TRPM2 protein affects the reaction [Mustard Gas results in increased abundance of Calcium] Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Calcium affects the reaction [Hydrogen Peroxide promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Hydrogen Peroxide promotes the reaction [TRPM2 protein results in increased transport of Calcium] |
CTD |
PMID:12529379 PMID:20878536 PMID:21900507 PMID:22036725 |
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
multiple interactions increases activity |
EXP ISO |
Calcium binds to and results in increased activity of TRPM4 protein [Ionomycin co-treated with Calcium co-treated with CAMK2D protein] results in increased activity of TRPM4 protein Calcium results in increased activity of TRPM4 protein |
CTD |
PMID:16966582 PMID:17188667 PMID:33392831 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]]; Lanthanum inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]]; TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
G |
Trpm7 |
transient receptor potential cation channel, subfamily M, member 7 |
increases abundance decreases abundance multiple interactions |
ISO |
TRPM7 protein results in increased abundance of Calcium TRPM7 gene mutant form results in decreased abundance of Calcium Magnesium inhibits the reaction [TRPM7 protein results in increased abundance of Calcium] |
CTD |
PMID:19515901 PMID:30770447 |
|
NCBI chr 3:114,046,258...114,134,799
Ensembl chr 3:114,046,258...114,135,190
|
|
G |
Trpm8 |
transient receptor potential cation channel, subfamily M, member 8 |
affects transport multiple interactions increases transport |
EXP ISO |
TRPM8 protein affects the transport of Calcium [icilin binds to and results in increased activity of TRPM8 protein] which affects the abundance of Calcium; [Menthol binds to and results in increased activity of TRPM8 protein] which affects the abundance of Calcium TRPM8 protein results in increased transport of Calcium [icilin results in increased activity of TRPM8 protein] which results in increased transport of Calcium; [Menthol analog binds to and results in increased activity of TRPM8 protein] which results in increased transport of Calcium; [Menthol results in increased activity of TRPM8 protein] which results in increased transport of Calcium; Calcium deficiency inhibits the reaction [Praziquantel results in increased activity of TRPM8 protein]; icilin promotes the reaction [TRPM8 protein results in increased transport of Calcium]; Menthol promotes the reaction [TRPM8 protein results in increased transport of Calcium] |
CTD |
PMID:16174775 PMID:17517434 PMID:18485891 PMID:18524940 PMID:19363131 PMID:23296101 PMID:29054683 More...
|
|
NCBI chr 9:88,897,039...88,990,167
Ensembl chr 9:88,903,880...88,988,552
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
affects import multiple interactions increases import |
ISO EXP |
TRPV1 protein affects the import of Calcium 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [arachidonyl dopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [Capsaicin results in increased activity of TRPV1 protein] which results in increased transport of Calcium; [Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [Capsaicin results in increased activity of TRPV1] which results in increased uptake of Calcium; [Formaldehyde results in increased activity of TRPV1 protein] which results in increased abundance of Calcium; [Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium; Amitriptyline inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; Butyrates promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; Cadmium inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; Calcium affects the reaction [Capsaicin inhibits the reaction [TRPV1 protein affects the susceptibility to Capsaicin]]; Calcium affects the reaction [mustard oil inhibits the reaction [TRPV1 protein affects the susceptibility to Capsaicin]]; capsazepine inhibits the reaction [[Formaldehyde results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]; capsazepine inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium]; Cobalt inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; Copper inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; HTR2A protein promotes the reaction [[Freund's Adjuvant results in increased activity of TRPV1 protein] which results in increased transport of Calcium]; HTR7 protein promotes the reaction [[Freund's Adjuvant results in increased activity of TRPV1 protein] which results in increased transport of Calcium]; Indomethacin inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium]; Lidocaine promotes the reaction [TRPV1 protein results in increased abundance of Calcium]; Masoprocol inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Melitten results in increased activity of TRPV1 protein] which results in increased transport of Calcium]; Nickel inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; Ruthenium Red inhibits the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; Serotonin promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased transport of Calcium] 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [arachidonyl dopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [Protons promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [arachidonyl dopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [cannabichromene results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [cannabidiolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [cannabidivarin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [cannabigerol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [cannabigerolic acid results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [Capsaicin binds to and results in increased activity of TRPV1 protein] which results in increased abundance of Calcium; [Capsaicin binds to TRPV1 protein] which results in increased uptake of Calcium; [Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium; [Capsaicin results in increased activity of TRPV1 protein] which results in increased import of Calcium; [Capsaicin results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [Capsaicin results in increased activity of TRPV1] which results in increased uptake of Calcium; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; [nonivamide binds to and results in increased activity of TRPV1 protein] which results in increased abundance of Calcium; [resiniferatoxin binds to and results in increased activity of TRPV1 protein] which results in increased abundance of Calcium; [resiniferatoxin binds to TRPV1 protein] which results in increased uptake of Calcium; Cannabidiol inhibits the reaction [[Capsaicin binds to TRPV1 protein] which results in increased uptake of Calcium]; Cannabidiol inhibits the reaction [[resiniferatoxin binds to TRPV1 protein] which results in increased uptake of Calcium]; Capsaicin promotes the reaction [TRPV1 protein results in increased abundance of Calcium]; Capsaicin promotes the reaction [TRPV1 protein results in increased uptake of Calcium]; capsazepine inhibits the reaction [[Cannabidiol results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; capsazepine inhibits the reaction [Capsaicin promotes the reaction [TRPV1 protein results in increased abundance of Calcium]]; capsazepine inhibits the reaction [Capsaicin promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; capsazepine inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]]; Edetic Acid inhibits the reaction [Capsaicin promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [Capsaicin promotes the reaction [TRPV1 protein results in increased abundance of Calcium]]; iodoresiniferatoxin inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]]; PRKCE protein affects the reaction [F2RL1 protein promotes the reaction [[Capsaicin results in increased activity of TRPV1 protein] which results in increased abundance of Calcium]]; Ruthenium Red inhibits the reaction [Capsaicin promotes the reaction [TRPV1 protein results in increased abundance of Calcium]]; Ruthenium Red inhibits the reaction [Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]]; Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]; TRPV1 promotes the reaction [Capsaicin results in increased uptake of Calcium] Sodium affects the reaction [TRPV1 protein results in increased abundance of Calcium]; TRPV1 protein affects the reaction [Capsaicin results in increased abundance of Calcium]; TRPV1 protein affects the reaction [Capsaicin results in increased transport of Calcium] TRPV1 protein results in increased import of Calcium |
CTD |
PMID:11606325 PMID:12569099 PMID:12886029 PMID:15471852 PMID:15615864 PMID:16597917 PMID:16793902 PMID:16901936 PMID:17332266 PMID:17442041 PMID:17508023 PMID:17590514 PMID:17881535 PMID:18172555 PMID:18230619 PMID:18249134 PMID:18331834 PMID:19602228 PMID:19847360 PMID:21453681 PMID:23264033 PMID:28790335 PMID:31096838 More...
|
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv2 |
transient receptor potential cation channel, subfamily V, member 2 |
multiple interactions |
ISO |
[cannabichromene results in increased activity of TRPV2 protein] which results in increased uptake of Calcium; [Cannabidiol results in increased activity of TRPV2 protein] which results in increased uptake of Calcium; [cannabidiolic acid results in increased activity of TRPV2 protein] which results in increased uptake of Calcium; [cannabidivarin results in increased activity of TRPV2 protein] which results in increased uptake of Calcium |
CTD |
PMID:31096838 |
|
NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,272,931...47,294,260
|
|
G |
Trpv3 |
transient receptor potential cation channel, subfamily V, member 3 |
multiple interactions |
EXP ISO |
[carvacrol binds to and results in increased activity of TRPV3 protein] which results in increased transport of Calcium; [carvacrol results in increased activity of TRPV3 protein] which results in increased transport of Calcium; [Eugenol binds to and results in increased activity of TRPV3 protein] which results in increased transport of Calcium; Ruthenium Red inhibits the reaction [[carvacrol binds to and results in increased activity of TRPV3 protein] which results in increased transport of Calcium] [carvacrol results in increased activity of TRPV3 protein] which results in increased transport of Calcium; [Eugenol results in increased activity of TRPV3 protein] which results in increased transport of Calcium |
CTD |
PMID:16617338 PMID:20086034 |
|
NCBI chr10:57,883,546...57,915,865
Ensembl chr10:57,883,546...57,913,296
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
multiple interactions |
ISO |
TRPV4 protein promotes the reaction [phorbol-12,13-didecanoate results in increased import of Calcium] TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]] |
CTD |
PMID:18234883 PMID:18355916 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Trpv5 |
transient receptor potential cation channel, subfamily V, member 5 |
increases uptake multiple interactions |
ISO |
TRPV5 protein results in increased uptake of Calcium KL protein inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] inhibits the reaction [TRPV5 protein results in increased uptake of Calcium]] |
CTD |
PMID:23747339 |
|
NCBI chr 4:70,536,432...70,562,743
Ensembl chr 4:70,536,440...70,562,745
|
|
G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
increases transport multiple interactions increases uptake increases expression |
ISO |
TRPV6 protein results in increased transport of Calcium [[USP2 gene mutant form results in increased expression of NHERF4 protein] which results in increased activity of TRPV6 protein] which results in increased uptake of Calcium TRPV6 protein results in increased uptake of Calcium 4-O-methyl-12-O-tetradecanoylphorbol 13-acetate inhibits the reaction [Tamoxifen inhibits the reaction [TRPV6 protein results in increased uptake of Calcium]]; Cadmium inhibits the reaction [TRPV6 protein results in increased uptake of Calcium]; calphostin C inhibits the reaction [TRPV6 protein results in increased uptake of Calcium]; Gadolinium inhibits the reaction [TRPV6 protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [TRPV6 protein results in increased uptake of Calcium]; Tamoxifen inhibits the reaction [TRPV6 protein results in increased uptake of Calcium]; TRPV6 protein promotes the reaction [Capsaicin results in increased abundance of Calcium] Calcium deficiency results in increased expression of TRPV6 mRNA |
CTD |
PMID:12584203 PMID:17292493 PMID:18648087 PMID:19996302 PMID:21146870 PMID:26756164 More...
|
|
NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017
|
|
G |
Txn2 |
thioredoxin 2 |
decreases response to substance |
ISO |
TXN2 protein results in decreased susceptibility to Calcium |
CTD |
PMID:18550601 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Ubb |
ubiquitin B |
affects expression |
EXP |
Calcium affects the expression of UBB mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:47,247,630...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Ube2d2 |
ubiquitin-conjugating enzyme E2D 2 |
affects expression |
EXP |
Calcium affects the expression of UBE2D2 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr18:27,364,325...27,406,322
Ensembl chr18:27,364,303...27,406,181
|
|
G |
Ube2g1 |
ubiquitin-conjugating enzyme E2G 1 |
affects expression multiple interactions |
EXP |
Calcium affects the expression of UBE2G1 mRNA [Calcium co-treated with Calcitriol] affects the expression of UBE2G1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:57,225,963...57,306,748
Ensembl chr10:57,225,952...57,308,568
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
affects expression |
EXP |
Calcium affects the expression of UBE2I mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:14,277,749...14,294,681
Ensembl chr10:69,701,618...69,702,443 Ensembl chr10:69,701,618...69,702,443
|
|
G |
Ubtf |
upstream binding transcription factor |
affects expression |
EXP |
Calcium affects the expression of UBTF mRNA alternative form |
CTD |
PMID:15913539 |
|
NCBI chr10:87,258,217...87,274,291
Ensembl chr10:87,258,217...87,272,969
|
|
G |
Ucn |
urocortin |
multiple interactions |
EXP |
astressin inhibits the reaction [UCN protein inhibits the reaction [Thapsigargin results in increased uptake of Calcium]]; UCN protein inhibits the reaction [Thapsigargin results in increased uptake of Calcium] |
CTD |
PMID:17885217 |
|
NCBI chr 6:25,238,120...25,238,950
Ensembl chr 6:25,238,120...25,238,950
|
|
G |
Umod |
uromodulin |
affects binding |
ISO |
UMOD protein binds to Calcium |
CTD |
PMID:35263610 |
|
NCBI chr 1:173,816,341...173,829,681
Ensembl chr 1:173,816,339...173,830,302
|
|
G |
Usp15 |
ubiquitin specific peptidase 15 |
multiple interactions |
ISO |
Calcium affects the reaction [Morphine results in increased expression of USP15 mRNA] |
CTD |
PMID:24068670 |
|
NCBI chr 7:58,756,714...58,848,778
Ensembl chr 7:58,756,872...58,848,721
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
multiple interactions |
ISO |
[[USP2 gene mutant form results in increased expression of NHERF4 protein] which results in increased activity of TRPV6 protein] which results in increased uptake of Calcium |
CTD |
PMID:26756164 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
EXP |
[Calcium co-treated with Calcitriol] affects the expression of VDAC1 mRNA |
CTD |
PMID:15913539 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
affects metabolic processing affects abundance affects expression affects response to substance |
ISO EXP |
VDR gene polymorphism affects the metabolism of Calcium VDR protein affects the abundance of Calcium Calcium affects the expression of VDR mRNA VDR gene polymorphism affects the susceptibility to Calcium |
CTD |
PMID:11500311 PMID:15861036 PMID:15883634 PMID:15913539 PMID:16048257 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
affects expression increases abundance multiple interactions |
EXP ISO |
Calcium affects the expression of VEGFA mRNA VEGFA protein results in increased abundance of Calcium [VEGFA protein results in increased activity of KDR protein] which results in increased abundance of Calcium; TRPC6 protein promotes the reaction [[VEGFA protein results in increased activity of KDR protein] which results in increased abundance of Calcium]; VEGFA protein promotes the reaction [[Diglycerides results in increased activity of TRPC6 protein] which results in increased abundance of Calcium] |
CTD |
PMID:14551041 PMID:15913539 PMID:30524369 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Calcium affects the reaction [diphenylditelluride results in increased phosphorylation of VIM protein] |
CTD |
PMID:21879721 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vip |
vasoactive intestinal peptide |
decreases abundance |
EXP |
VIP protein results in decreased abundance of Calcium |
CTD |
PMID:21039959 |
|
NCBI chr 1:42,064,878...42,073,219
Ensembl chr 1:42,065,120...42,073,216
|
|
G |
Wnt5a |
Wnt family member 5A |
increases secretion multiple interactions increases expression |
ISO |
Calcium results in increased secretion of WNT5A protein CASR mutant form inhibits the reaction [Calcium results in increased expression of WNT5A protein]; WNT5A protein promotes the reaction [Calcium results in increased expression of KRT1 mRNA]; WNT5A protein promotes the reaction [Calcium results in increased expression of KRT1 protein]; WNT5A protein promotes the reaction [Calcium results in increased expression of LORICRIN mRNA]; WNT5A protein promotes the reaction [Calcium results in increased expression of LORICRIN protein] Calcium results in increased expression of WNT5A mRNA |
CTD |
PMID:24658506 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
affects expression |
EXP |
Calcium affects the expression of YWHAZ mRNA |
CTD |
PMID:15913539 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of BAX protein] |
CTD |
PMID:25005833 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in decreased expression of BCL2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Capsaicin results in increased cleavage of CASP3 protein]; EUK-134 inhibits the reaction [evodiamine results in increased cleavage of CASP3 protein] |
CTD |
PMID:21647434 PMID:34808100 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Capsaicin results in increased cleavage of CASP9 protein]; EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP9 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP9 protein] |
CTD |
PMID:21647434 PMID:25005833 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [diallyl trisulfide results in increased phosphorylation of and results in increased degradation of CDC25C protein] |
CTD |
PMID:16707465 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
EUK-134 affects the reaction [Vitamin K 3 results in increased expression of CDKN1A protein]; EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein] |
CTD |
PMID:25005833 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole results in increased expression of CYGB mRNA] |
CTD |
PMID:25781201 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [evodiamine results in increased expression of DDIT3 protein] |
CTD |
PMID:34808100 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [evodiamine results in decreased expression of EIF2AK3 protein] |
CTD |
PMID:34808100 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Asbestos, Amosite results in increased expression of ERN1 protein]; EUK-134 inhibits the reaction [Thapsigargin results in increased expression of ERN1 protein] |
CTD |
PMID:23885834 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in decreased activity of GSR protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in decreased activity of GSR protein]]; Acetylcysteine promotes the reaction [Zinc Sulfate inhibits the reaction [EUK-134 results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Paraquat results in decreased activity of GSR protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in decreased activity of GSR protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in decreased activity of GSR protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in decreased activity of GSR protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in decreased activity of GSR protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in decreased activity of GSR protein]] |
CTD |
PMID:25724285 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
[Acetylcysteine co-treated with EUK-134] promotes the reaction [[Zinc Sulfate co-treated with Paraquat] results in increased activity of GSTA4 protein]; [EUK-134 co-treated with Acetylcysteine] promotes the reaction [Paraquat results in increased activity of GSTA4 protein]; [EUK-134 co-treated with Acetylcysteine] promotes the reaction [Zinc Sulfate results in increased activity of GSTA4 protein] |
CTD |
PMID:25724285 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of HES1 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of HES1 protein] |
CTD |
PMID:25005833 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Iapp |
islet amyloid polypeptide |
decreases metabolic processing |
ISO |
EUK-134 results in decreased metabolism of IAPP protein |
CTD |
PMID:23528352 |
|
NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Glucose results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:20962025 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Glucose results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:20962025 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Hydrogen Peroxide results in decreased expression of MDM2 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in decreased expression of MDM2 protein] |
CTD |
PMID:25005833 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased activity of MPO protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased activity of MPO protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased activity of MPO protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased activity of MPO protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased activity of MPO protein]]; EUK-134 inhibits the reaction [Paraquat results in increased activity of MPO protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased activity of MPO protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased activity of MPO protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased activity of MPO protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased activity of MPO protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased activity of MPO protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:25724285 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
EXP |
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A protein]]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A mRNA]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT1A protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A mRNA]]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT1A protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT1A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT1A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT1A protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT1A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT1A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT1A protein]] |
CTD |
PMID:25724285 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
EXP |
Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A protein]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A mRNA]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A protein]]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]; Acetylcysteine promotes the reaction [EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A protein]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]; EUK-134 inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A protein]]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A mRNA]; EUK-134 inhibits the reaction [Paraquat results in increased expression of MT2A protein]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A mRNA]]; EUK-134 inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A protein]]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]; EUK-134 inhibits the reaction [Zinc Sulfate results in increased expression of MT2A protein]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat promotes the reaction [Zinc Sulfate results in increased expression of MT2A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT2A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Paraquat results in increased expression of MT2A protein]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A mRNA]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate promotes the reaction [Paraquat results in increased expression of MT2A protein]]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT2A mRNA]]; EUK-134 promotes the reaction [Acetylcysteine inhibits the reaction [Zinc Sulfate results in increased expression of MT2A protein]] |
CTD |
PMID:25724285 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [evodiamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:34808100 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
EUK-134 inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein]; EUK-134 inhibits the reaction [Vitamin K 3 results in increased expression of TP53 protein] |
CTD |
PMID:25005833 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
EXP |
Magnesium Chloride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]; Magnesium Chloride promotes the reaction [beryllium fluoride promotes the reaction [8-azidoadenosine 5'-triphosphate binds to ABCC6 protein]] |
CTD |
PMID:12069597 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions decreases activity |
EXP |
Magnesium Chloride inhibits the reaction [ALDH1A1 protein affects the oxidation of 9-cis-retinal]; Magnesium Chloride inhibits the reaction [ALDH1A1 protein affects the oxidation of Retinaldehyde] Magnesium Chloride results in decreased activity of ALDH1A1 protein |
CTD |
PMID:10998257 PMID:17167544 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO EXP |
Magnesium Chloride results in increased expression of BAX protein |
CTD |
PMID:17977900 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO EXP |
Magnesium Chloride results in increased activity of CASP3 protein |
CTD |
PMID:17977900 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
Magnesium Chloride promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of CD28 protein] |
CTD |
PMID:8662792 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[Magnesium Chloride co-treated with EGF protein] results in increased activity of EGFR protein |
CTD |
PMID:2354210 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
[Magnesium Chloride co-treated with EGF protein] results in increased activity of EGFR protein |
CTD |
PMID:2354210 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[2-tert-butylhydroquinone promotes the reaction [[NFE2L2 protein binds to HMOX1 promoter] which results in increased expression of HMOX1 mRNA]] which results in decreased susceptibility to Magnesium Chloride |
CTD |
PMID:21107535 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Itih1 |
inter-alpha trypsin inhibitor, heavy chain 1 |
multiple interactions |
ISO |
Magnesium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr16:6,122,246...6,136,363
Ensembl chr16:6,122,248...6,136,363
|
|
G |
Itih2 |
inter-alpha-trypsin inhibitor heavy chain 2 |
multiple interactions |
ISO |
Magnesium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr17:68,375,574...68,411,849
Ensembl chr17:68,375,567...68,411,841
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions |
ISO |
Magnesium Chloride affects the reaction [zinc chloride results in decreased activity of KIF5A protein] |
CTD |
PMID:28122263 |
|
NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases activity |
ISO |
Magnesium Chloride results in increased activity of KLK8 protein |
CTD |
PMID:16800733 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
[2-tert-butylhydroquinone promotes the reaction [[NFE2L2 protein binds to HMOX1 promoter] which results in increased expression of HMOX1 mRNA]] which results in decreased susceptibility to Magnesium Chloride |
CTD |
PMID:21107535 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nudt9 |
nudix hydrolase 9 |
multiple interactions increases activity |
ISO |
Dithiothreitol inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Magnesium Chloride results in increased activity of NUDT9 protein]]; Fluorides inhibits the reaction [Magnesium Chloride results in increased activity of NUDT9 protein]; Hydrogen Peroxide inhibits the reaction [Magnesium Chloride results in increased activity of NUDT9 protein] |
CTD |
PMID:16860484 |
|
NCBI chr14:5,675,376...5,693,332
Ensembl chr14:5,675,382...5,693,142
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
Magnesium Chloride affects the reaction [Nickel binds to SERPINE1 protein] |
CTD |
PMID:21280128 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
multiple interactions |
ISO |
[Magnesium Chloride co-treated with Phosphatidylserines] promotes the reaction [SMPD3 protein results in increased degradation of Sphingomyelins] |
CTD |
PMID:12566438 |
|
NCBI chr19:34,162,337...34,245,786
Ensembl chr19:34,162,341...34,245,749
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
multiple interactions |
ISO |
Magnesium Chloride promotes the reaction [ITIH1 protein binds to TNFAIP6 protein]; Magnesium Chloride promotes the reaction [ITIH2 protein binds to TNFAIP6 protein] |
CTD |
PMID:16768462 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tp53 |
tumor protein p53 |
affects expression |
EXP |
Magnesium Chloride affects the expression of TP53 mRNA |
CTD |
PMID:10506531 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased activity of CASP1 protein]; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] promotes the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine results in increased expression of and results in increased secretion of CASP1 protein modified form]; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] |
CTD |
PMID:18604214 PMID:22075093 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO |
Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] |
CTD |
PMID:22750351 |
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions |
ISO |
Magnesium Hydroxide inhibits the reaction [Acetylcholine results in increased activity of [CHRNA4 protein co-treated with CHRNB2 protein]] |
CTD |
PMID:22750351 |
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] inhibits the reaction [K-12 lipopolysaccharide results in increased secretion of CXCL10 protein] |
CTD |
PMID:17404311 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; CASP1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL1B protein] [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein; IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] |
CTD |
PMID:17404311 PMID:18604214 PMID:22075093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
IL1R1 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] |
CTD |
PMID:18604214 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein; N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]; TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]] |
CTD |
PMID:22075093 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] |
CTD |
PMID:18604214 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with [Aluminum Hydroxide co-treated with Magnesium Hydroxide]] results in increased cleavage of and results in increased secretion of IL1B protein] |
CTD |
PMID:18604214 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
TLR4 protein affects the reaction [N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine promotes the reaction [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] results in increased secretion of IL2 protein]]; TLR4 protein affects the susceptibility to [[Aluminum Hydroxide co-treated with Magnesium Hydroxide] co-treated with N-t-butyl-n'-tetradecyl-3-tetradecylaminopropionamidine]; TLR4 protein affects the susceptibility to [Aluminum Hydroxide co-treated with Magnesium Hydroxide] |
CTD |
PMID:22075093 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
decreases activity |
EXP |
Magnesium ion decreases activity of purified Hmbs protein |
RGD |
PMID:6732900 |
RGD:25394584 |
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of BAX mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of BAX mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in decreased expression of BCL2 mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in decreased expression of BCL2 mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in decreased expression of BIRC5 mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in decreased expression of BIRC5 mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of CASP3 mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased activity of CASP3 protein]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of CASP3 mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of CASP8 mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Magnesium Oxide analog inhibits the reaction [Diazinon results in increased activity of CASP9 protein]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of CASP9 mRNA]; Selenium analog inhibits the reaction [Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of CASP9 mRNA]] |
CTD |
PMID:27920530 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression |
EXP |
Magnesium Oxide results in decreased expression of CAT protein |
CTD |
PMID:29282847 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of CFLAR mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of CFLAR mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of CYCS mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of CYCS mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] promotes the reaction [Diazinon results in decreased expression of FADD mRNA]; Magnesium Oxide promotes the reaction [Diazinon results in decreased expression of FADD mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of FAS mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of FAS mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] promotes the reaction [Diazinon results in decreased expression of FASLG mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in decreased secretion of INS protein alternative form]; [Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in decreased secretion of INS protein]; Magnesium Oxide analog inhibits the reaction [Diazinon results in decreased secretion of INS protein alternative form]; Magnesium Oxide analog inhibits the reaction [Diazinon results in decreased secretion of INS protein] |
CTD |
PMID:27920530 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
Magnesium Oxide analog promotes the reaction [Diazinon results in decreased expression of TNFRSF10A mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of TNFRSF1A mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of TNFRSF1A mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Selenium analog co-treated with Magnesium Oxide analog] inhibits the reaction [Diazinon results in increased expression of TP53 mRNA]; Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of TP53 mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Magnesium Oxide analog inhibits the reaction [Diazinon results in increased expression of TRAF2 mRNA] |
CTD |
PMID:27920530 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
EXP |
Magnesium Sulfate promotes the reaction [Dichlorvos results in decreased activity of BCHE protein] |
CTD |
PMID:19504058 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
Magnesium Sulfate promotes the reaction [Vanadates results in decreased activity of CAT protein] Magnesium Sulfate results in decreased activity of CAT protein |
CTD |
PMID:29117755 PMID:29453945 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases activity |
EXP |
Magnesium Sulfate results in decreased activity of GPX1 protein |
CTD |
PMID:29117755 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases activity multiple interactions |
EXP |
Magnesium Sulfate results in decreased activity of GSR protein [Magnesium Sulfate co-treated with Vanadates] results in decreased activity of GSR protein |
CTD |
PMID:29453945 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Magnesium Sulfate results in decreased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnc2 |
potassium voltage-gated channel subfamily C member 2 |
decreases expression |
EXP |
Magnesium Sulfate results in decreased expression of KCNC2 mRNA; Magnesium Sulfate results in decreased expression of KCNC2 protein |
CTD |
PMID:18775767 |
|
NCBI chr 7:47,700,035...47,883,979
Ensembl chr 7:47,700,288...47,883,968
|
|
G |
Klk8 |
kallikrein related-peptidase 8 |
increases activity |
ISO |
Magnesium Sulfate results in increased activity of KLK8 protein |
CTD |
PMID:16800733 |
|
NCBI chr 1:94,251,803...94,258,646
Ensembl chr 1:94,251,803...94,258,646
|
|
G |
Ren |
renin |
increases activity |
ISO |
Magnesium Sulfate results in increased activity of REN protein |
CTD |
PMID:1874207 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity |
EXP |
Magnesium Sulfate results in decreased activity of SOD1 protein |
CTD |
PMID:29117755 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Trpm5 |
transient receptor potential cation channel, subfamily M, member 5 |
affects response to substance |
ISO |
TRPM5 protein affects the susceptibility to Magnesium Sulfate |
CTD |
PMID:19244541 |
|
NCBI chr 1:198,254,956...198,277,824
Ensembl chr 1:198,255,723...198,277,654
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ABCA1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] [Cyclosporine results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [Glyburide results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium; [troglitazone results in decreased activity of ABCB11 protein] which results in decreased secretion of Rosuvastatin Calcium |
CTD |
PMID:15901796 PMID:19853032 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects secretion increases expression |
ISO EXP |
ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the secretion of Rosuvastatin Calcium [Benzbromarone results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Probenecid results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; [Sulfasalazine results in decreased activity of ABCC2 protein] which results in decreased secretion of Rosuvastatin Calcium; ABCC2 protein binds to and results in increased uptake of Rosuvastatin Calcium analog; Rosuvastatin Calcium analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Rosuvastatin Calcium promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] Rosuvastatin Calcium results in increased expression of ABCC2 protein |
CTD |
PMID:19853032 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ABCG1 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions increases activity |
EXP ISO |
[Novobiocin results in decreased activity of ABCG2 protein] which results in decreased secretion of Rosuvastatin Calcium Rosuvastatin Calcium results in increased activity of ABCG2 protein |
CTD |
PMID:19853032 PMID:30083819 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[Piracetam co-treated with Rosuvastatin Calcium] inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein]; Rosuvastatin Calcium inhibits the reaction [[Sodium Chloride, Dietary co-treated with Cholesterol, Dietary co-treated with Coconut Oil] results in increased activity of ACHE protein] |
CTD |
PMID:28441890 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation |
EXP |
Rosuvastatin Calcium affects the phosphorylation of AKT1 protein |
CTD |
PMID:27815113 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions increases expression |
ISO |
Niacin promotes the reaction [Rosuvastatin Calcium results in increased expression of APOA1 protein] |
CTD |
PMID:12767421 PMID:15539964 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of APOB protein |
CTD |
PMID:15539964 PMID:18702965 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of BAX mRNA] |
CTD |
PMID:32007421 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of BCL2 protein |
CTD |
PMID:20852871 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C3 |
complement C3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of C3 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression |
ISO |
Rosuvastatin Calcium results in increased activity of CASP3 protein Rosuvastatin Calcium results in increased expression of CASP3 protein |
CTD |
PMID:21478229 PMID:32771489 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Rosuvastatin Calcium results in increased activity of CAT protein [Rosuvastatin Calcium co-treated with Isoproterenol] inhibits the reaction [Interleukin-6 results in increased expression of CAT protein]; Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased activity of CAT protein] |
CTD |
PMID:20146376 PMID:32007421 PMID:35130744 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of CCL2 mRNA |
CTD |
PMID:15681303 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Creb5 |
cAMP responsive element binding protein 5 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of CREB5 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3] |
CTD |
PMID:21562509 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions decreases expression |
EXP |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions decreases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [Nitroglycerin results in increased expression of CYBB mRNA] [[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:16633368 PMID:21562509 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of ESR1 protein |
CTD |
PMID:32771489 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in increased expression of GCLC mRNA [Tetradecanoylphorbol Acetate co-treated with Rosuvastatin Calcium] results in increased expression of GCLC mRNA |
CTD |
PMID:18154958 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpr183 |
G protein-coupled receptor 183 |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GPR183 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr15:99,037,764...99,050,550
Ensembl chr15:99,036,367...99,050,559
|
|
G |
Gzmk |
granzyme K |
multiple interactions increases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in increased expression of GZMK mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 2:44,840,811...44,848,829
Ensembl chr 2:44,840,811...44,848,894
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases secretion |
ISO |
HNF4A protein results in increased secretion of Rosuvastatin Calcium |
CTD |
PMID:27160211 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Il18rap |
interleukin 18 receptor accessory protein |
decreases expression multiple interactions |
ISO |
Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of IL18RAP mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 9:42,768,112...42,800,964
Ensembl chr 9:42,768,220...42,800,959
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of IL1B mRNA |
CTD |
PMID:15681303 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Rosuvastatin Calcium results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of KCNJ15 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of KDR protein] |
CTD |
PMID:27097221 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Mb |
myoglobin |
affects expression |
EXP |
Rosuvastatin Calcium affects the expression of MB protein |
CTD |
PMID:27815113 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Rosuvastatin Calcium results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Rosuvastatin Calcium results in increased expression of NOS2 mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of NOS2 mRNA] |
CTD |
PMID:21443142 PMID:32007421 PMID:35130744 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases expression affects response to substance |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [CRP protein results in decreased expression of NOS3]; Rosuvastatin Calcium results in increased phosphorylation of and results in increased activity of NOS3 protein Rosuvastatin Calcium results in increased expression of NOS3 mRNA NOS3 protein affects the susceptibility to Rosuvastatin Calcium |
CTD |
PMID:12354446 PMID:15681303 PMID:18162361 PMID:21562509 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions decreases expression |
ISO |
Lipopolysaccharides inhibits the reaction [Rosuvastatin Calcium results in decreased expression of ORM1 mRNA] |
CTD |
PMID:18192897 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of PECAM1 protein] |
CTD |
PMID:27097221 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Selp |
selectin P |
decreases expression |
EXP |
Rosuvastatin Calcium results in decreased expression of SELP mRNA |
CTD |
PMID:15681303 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpine2 |
serpin family E member 2 |
multiple interactions |
ISO |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of SERPINE2 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] |
CTD |
PMID:27097221 |
|
NCBI chr 9:81,124,746...81,188,866
Ensembl chr 9:81,124,804...81,188,826
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions increases uptake decreases expression affects transport |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1A4 protein results in increased uptake of Rosuvastatin Calcium] diosmetin inhibits the reaction [SLCO1A2 protein results in increased uptake of Rosuvastatin Calcium] Rosuvastatin Calcium results in decreased expression of SLCO1A4 protein SLCO1A4 protein affects the transport of Rosuvastatin Calcium |
CTD |
PMID:19833843 PMID:24909372 PMID:26888941 PMID:28867436 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases uptake |
EXP ISO |
Fusidic Acid inhibits the reaction [SLCO1B2 protein results in increased uptake of Rosuvastatin Calcium] Fusidic Acid inhibits the reaction [SLCO1B3 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:26888941 PMID:31299240 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
increases uptake multiple interactions |
ISO |
SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Rosuvastatin Calcium] |
CTD |
PMID:24285294 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
EXP |
[[[Rosuvastatin Calcium results in decreased expression of CYBB] co-treated with [Rosuvastatin Calcium results in decreased expression of CYBA]] co-treated with [Rosuvastatin Calcium results in increased expression of SOD1]] results in decreased abundance of Reactive Oxygen Species |
CTD |
PMID:21562509 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Tff1 |
trefoil factor 1 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of TFF1 mRNA |
CTD |
PMID:32771489 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
ISO EXP |
Rosuvastatin Calcium inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of TGFB1 protein]; Rosuvastatin Calcium inhibits the reaction [[TGFB1 protein co-treated with Serotonin] results in increased secretion of SERPINE2 protein] Rosuvastatin Calcium results in decreased expression of TGFB1 mRNA |
CTD |
PMID:15681303 PMID:27097221 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
EXP |
Rosuvastatin Calcium results in decreased expression of TNF mRNA Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNF protein] |
CTD |
PMID:15681303 PMID:32007421 PMID:35130744 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Rosuvastatin Calcium inhibits the reaction [Isoproterenol results in increased expression of TNNI3 protein] |
CTD |
PMID:32007421 PMID:35130744 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Vnn3 |
vanin 3 |
decreases expression |
ISO |
Rosuvastatin Calcium results in decreased expression of VNN3P mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 1:21,571,364...21,583,626
Ensembl chr 1:21,571,364...21,583,626
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
EXP |
Rosuvastatin Calcium results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
|
G |
Alpp |
alkaline phosphatase, placental |
affects binding |
ISO |
strontium chloride binds to ALPP protein |
CTD |
PMID:16815919 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
|
G |
Dnm1l |
dynamin 1-like |
increases expression |
ISO |
tricalcium phosphate results in increased expression of DNM1L protein |
CTD |
PMID:37678662 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of HMOX1 protein |
CTD |
PMID:37678662 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions affects localization |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate affects the localization of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein] |
CTD |
PMID:37678662 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mfn2 |
mitofusin 2 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of MFN2 protein |
CTD |
PMID:37678662 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of MLKL protein] |
CTD |
PMID:37678662 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of NFE2L2 protein |
CTD |
PMID:37678662 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of NQO1 protein |
CTD |
PMID:37678662 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased expression of PINK1 protein]; tricalcium phosphate results in increased expression of and results in increased localization of PINK1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
tricalcium phosphate results in increased phosphorylation of RIPK1 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK1 protein] |
CTD |
PMID:37678662 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein]; N-(4-(N-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein]; necrostatin-1 inhibits the reaction [tricalcium phosphate results in increased phosphorylation of RIPK3 protein] |
CTD |
PMID:37678662 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Sqstm1 |
sequestosome 1 |
decreases expression multiple interactions |
ISO |
tricalcium phosphate results in decreased expression of SQSTM1 protein Acetylcysteine inhibits the reaction [tricalcium phosphate results in decreased expression of SQSTM1 protein] |
CTD |
PMID:37678662 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Txn1 |
thioredoxin 1 |
decreases expression |
ISO |
tricalcium phosphate results in decreased expression of TXN1 protein |
CTD |
PMID:37678662 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases expression |
ISO |
tricalcium phosphate results in increased expression of TXNIP protein |
CTD |
PMID:37678662 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
|
G |
Pdxp |
pyridoxal phosphatase |
decreases activity |
ISO |
beryllium trifluoride results in decreased activity of PDXP protein |
CTD |
PMID:24338473 |
|
NCBI chr 7:110,472,515...110,477,963
Ensembl chr 7:110,472,515...110,477,963
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases activity |
ISO |
beryllium trifluoride results in decreased activity of PGP protein |
CTD |
PMID:24338473 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|